BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Valgimigli M, Bueno H, Byrne RA, Collet J, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F, Petricevic M, Roffi M, Steg PG, Windecker S, Zamorano JL, Levine GN, Badimon L, Vranckx P, Agewall S, Andreotti F, Antman E, Barbato E, Bassand J, Bugiardini R, Cikirikcioglu M, Cuisset T, De Bonis M, Delgado V, Fitzsimons D, Gaemperli O, Galiè N, Gilard M, Hamm CW, Ibanez B, Iung B, James S, Knuuti J, Landmesser U, Leclercq C, Lettino M, Lip G, Piepoli MF, Pierard L, Schwerzmann M, Sechtem U, Simpson IA, Uva MS, Stabile E, Storey RF, Tendera M, Van de Werf F, Verheugt F, Aboyans V, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, Mcdonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Windecker S, Aboyans V, Agewall S, Barbato E, Bueno H, Coca A, Collet J, Coman IM, Dean V, Delgado V, Fitzsimons D, Gaemperli O, Hindricks G, Iung B, Jüni P, Katus HA, Knuuti J, Lancellotti P, Leclercq C, Mcdonagh T, Piepoli MF, Ponikowski P, Richter DJ, Roffi M, Shlyakhto E, Simpson IA, Zamorano JL, Roithinger FX, Aliyev F, Stelmashok V, Desmet W, Postadzhiyan A, Georghiou GP, Motovska Z, Grove EL, Marandi T, Kiviniemi T, Kedev S, Gilard M, Massberg S, Alexopoulos D, Kiss RG, Gudmundsdottir IJ, Mcfadden EP, Lev E, De Luca L, Sugraliyev A, Haliti E, Mirrakhimov E, Latkovskis G, Petrauskiene B, Huijnen S, Magri CJ, Cherradi R, Ten Berg JM, Eritsland J, Budaj A, Aguiar CT, Duplyakov D, Zavatta M, Antonijevic NM, Motovska Z, Fras Z, Montoliu AT, Varenhorst C, Tsakiris D, Addad F, Aydogdu S, Parkhomenko A, Kinnaird T; ESC Scientific Document Group, ESC Committee for Practice Guidelines (CPG), ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. European Heart Journal 2018;39:213-60. [DOI: 10.1093/eurheartj/ehx419] [Cited by in Crossref: 1230] [Cited by in F6Publishing: 770] [Article Influence: 307.5] [Reference Citation Analysis]
Number Citing Articles
1 Hioki H, Kozuma K, Kinoshita Y, Nanasato M, Ito Y, Yamaguchi J, Shiode N, Hibi K, Tanabe K, Ako J, Morino Y, Hirohata A, Sonoda S, Nakagawa Y, Okada H, Nakagami T, Takamisawa I, Ando K, Abe M, Ikari Y. Ischemic/bleeding event after short dual-antiplatelet therapy in patients with high bleeding risk: Sub-analysis of the MODEL U-SES study. J Cardiol 2021;78:107-13. [PMID: 33875313 DOI: 10.1016/j.jjcc.2021.03.015] [Reference Citation Analysis]
2 Ferreiro JL, Vivas D, De La Hera JM, Marcano AL, Lugo LM, Gómez-Polo JC, Silva I, Tello-Montoliu A, Marín F, Roldán I. High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. Thromb Res 2019;175:95-101. [PMID: 30738371 DOI: 10.1016/j.thromres.2019.01.021] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
3 Sun Y, Liu X, Xu Y. The optimal duration of dual antiplatelet therapy in East Asian patients undergoing percutaneous coronary intervention with drug-eluting stents: a meta-analysis of randomized trials. Coron Artery Dis 2021;32:119-30. [PMID: 32639246 DOI: 10.1097/MCA.0000000000000921] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Chang HW, Kim HJ, Yoo JS, Kim DJ, Cho KR. Clopidogrel versus Ticagrelor for Secondary Prevention after Coronary Artery Bypass Grafting. J Clin Med 2019;8:E104. [PMID: 30658402 DOI: 10.3390/jcm8010104] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
5 Iglesias JF, Roffi M, Degrauwe S, Secco GG, Aminian A, Windecker S, Pilgrim T. Orsiro cobalt-chromium sirolimus-eluting stent: present and future perspectives. Expert Review of Medical Devices 2017;14:773-88. [DOI: 10.1080/17434440.2017.1378091] [Cited by in Crossref: 18] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
6 Swan D, Loughran N, Makris M, Thachil J. Management of bleeding and procedures in patients on antiplatelet therapy. Blood Reviews 2020;39:100619. [DOI: 10.1016/j.blre.2019.100619] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
7 Wang HY, Cai ZX, Yin D, Yang YJ, Song WH, Dou KF. Benefits and Risks of Prolonged Duration Dual Antiplatelet Therapy (Clopidogrel and Aspirin) After Percutaneous Coronary Intervention in High-Risk Patients With Diabetes Mellitus. Am J Cardiol 2021;142:14-24. [PMID: 33285091 DOI: 10.1016/j.amjcard.2020.11.043] [Reference Citation Analysis]
8 Rondano E, Bertolazzi M, Galluzzo A, Maltese L, Caccianotti P, Macciò S, Mazza S, Ruocco MVD, Favretto S, Occhetta E, Rametta F. Effectiveness and safety of antithrombotic strategies in elderly patients with acute myocardial infarction. World J Cardiol 2020;12:513-25. [PMID: 33312437 DOI: 10.4330/wjc.v12.i11.513] [Reference Citation Analysis]
9 Triantafyllou K, Gkolfakis P, Gralnek IM, Oakland K, Manes G, Radaelli F, Awadie H, Camus Duboc M, Christodoulou D, Fedorov E, Guy RJ, Hollenbach M, Ibrahim M, Neeman Z, Regge D, Rodriguez de Santiago E, Tham TC, Thelin-Schmidt P, van Hooft JE. Diagnosis and management of acute lower gastrointestinal bleeding: European Society of Gastrointestinal Endoscopy (ESGE) Guideline. Endoscopy 2021;53:850-68. [PMID: 34062566 DOI: 10.1055/a-1496-8969] [Reference Citation Analysis]
10 Ishihara T, Sotomi Y, Tsujimura T, Iida O, Kobayashi T, Hamanaka Y, Omatsu T, Sakata Y, Higuchi Y, Mano T. Impact of diabetes mellitus on the early-phase arterial healing after drug-eluting stent implantation. Cardiovasc Diabetol 2020;19:203. [PMID: 33267863 DOI: 10.1186/s12933-020-01173-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Yang C, Fan F, Sawmiller D, Tan J, Wang Q, Xiang Y. C1q/TNF‐related protein 9: A novel therapeutic target in ischemic stroke? J Neuro Res 2018;97:128-36. [DOI: 10.1002/jnr.24353] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wang YH, Kao HL, Wang CC, Lin SY, Lin FJ. Comparative Effectiveness and Safety of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome or Percutaneous Coronary Intervention. Acta Cardiol Sin 2019;35:508-21. [PMID: 31571800 DOI: 10.6515/ACS.201909_35(5).20190311A] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
13 Sambola A, Bueno H, Gordon B, Mutuberría M, Barrabés JA, Del Blanco BG, González-fernández V, Casamira N, García-dorado D. Worse 12-month prognosis in women with non-valvular atrial fibrillation undergoing percutaneous coronary intervention. Thrombosis Research 2019;178:20-5. [DOI: 10.1016/j.thromres.2019.03.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Verdoia M, Kedhi E, Suryapranata H, Frati G, Biondi-Zoccai G, De Luca G. Benefits of short-term or prolonged as compared to standard 1 year DAPT in patients with acute coronary syndrome treated with drug-eluting stents: a meta-analysis of 9 randomized trials. J Thromb Thrombolysis 2020;50:337-54. [PMID: 31919736 DOI: 10.1007/s11239-019-02033-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
15 De Luca L, Rubboli A, Bolognese L, Gonzini L, Urbinati S, Murrone A, Scotto di Uccio F, Ferrari F, Lucà F, Caldarola P, Lucci D, Gabrielli D, Di Lenarda A, Gulizia MM; MATADOR-PCI Investigators. Antithrombotic management of patients with acute coronary syndrome and atrial fibrillation undergoing coronary stenting: a prospective, observational, nationwide study. BMJ Open 2020;10:e041044. [PMID: 33371033 DOI: 10.1136/bmjopen-2020-041044] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Candela E, Marín F, Rivera-Caravaca JM, Vicente Ibarra N, Carrillo L, Esteve-Pastor MA, Lozano T, Macías MJ, Pernias V, Sandín M, Orenes-Piñero E, Quintana-Giner M, Hortelano I, Villamía B, Veliz A, Valdés M, Martínez-Martínez JG, Ruiz-Nodar JM. Conservatively managed patients with non-ST-segment elevation acute coronary syndrome are undertreated with indicated medicines. PLoS One 2018;13:e0208069. [PMID: 30485352 DOI: 10.1371/journal.pone.0208069] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
17 Verdoia M, Savonitto S, Dudek D, Kedhi E, De Luca G. Ticagrelor as compared to conventional antiplatelet agents in coronary artery disease: A comprehensive meta-analysis of 15 randomized trials. Vascular Pharmacology 2021;137:106828. [DOI: 10.1016/j.vph.2020.106828] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Rancati V, Scala E, Ltaief Z, Gunga MZ, Kirsch M, Rosner L, Marcucci C. Challenges in Patient Blood Management for Cardiac Surgery: A Narrative Review. J Clin Med 2021;10:2454. [PMID: 34205971 DOI: 10.3390/jcm10112454] [Reference Citation Analysis]
19 Brotons Cuixart C, Alemán Sánchez JJ, Banegas Banegas JR, Fondón León C, Lobos-Bejarano JM, Martín Rioboó E, Navarro Pérez J, Orozco-Beltrán D, Villar Álvarez F; Grupo de Prevención Cardiovascular del PAPPS. Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2018. Aten Primaria 2018;50 Suppl 1:4-28. [PMID: 29866357 DOI: 10.1016/S0212-6567(18)30360-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 6.5] [Reference Citation Analysis]
20 Tscharre M, Michelson AD, Gremmel T. Novel Antiplatelet Agents in Cardiovascular Disease. J Cardiovasc Pharmacol Ther 2020;25:191-200. [DOI: 10.1177/1074248419899314] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
21 Hajjar LA, Costa IBSDSD, Lopes MACQ, Hoff PMG, Diz MDPE, Fonseca SMR, Bittar CS, Rehder MHHDS, Rizk SI, Almeida DR, Fernandes GDS, Beck-da-Silva L, Campos CAHM, Montera MW, Alves SMM, Fukushima JT, Santos MVCD, Negrão CE, Silva TLFD, Ferreira SMA, Malachias MVB, Moreira MDCV, Valente Neto MMR, Fonseca VCQ, Soeiro MCFA, Alves JBS, Silva CMPDC, Sbano J, Pavanello R, Pinto IMF, Simão AF, Dracoulakis MDA, Hoff AO, Assunção BMBL, Novis Y, Testa L, Alencar Filho AC, Cruz CBBV, Pereira J, Garcia DR, Nomura CH, Rochitte CE, Macedo AVS, Marcatti PTF, Mathias Junior W, Wiermann EG, Val RD, Freitas H, Coutinho A, Mathias CMC, Vieira FMAC, Sasse AD, Rocha V, Ramires JAF, Kalil Filho R. Brazilian Cardio-oncology Guideline - 2020. Arq Bras Cardiol 2020;115:1006-43. [PMID: 33295473 DOI: 10.36660/abc.20201006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Kawashima H, Tomaniak M, Ono M, Wang R, Hara H, Gao C, Takahashi K, Sharif F, Thury A, Suryapranata H, Walsh S, Cotton J, Carrie D, Sabate M, Steinwender C, Leibundgut G, Wykrzykowska J, de Winter RJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. Safety and Efficacy of 1-Month Dual Antiplatelet Therapy (Ticagrelor + Aspirin) Followed by 23-Month Ticagrelor Monotherapy in Patients Undergoing Staged Percutaneous Coronary Intervention (A Sub-Study from GLOBAL LEADERS). The American Journal of Cardiology 2021;138:1-10. [DOI: 10.1016/j.amjcard.2020.09.057] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
23 Kinlay S, Quach L, Cormack J, Morgenstern N, Hou Y, Young M, Sherrod R, Cho K, Faxon DP, Ramadan R, Gaziano M, Gagnon D. Premature Discontinuation of Dual Antiplatelet Therapy After Coronary Stenting in Veterans: Characteristics and Long-Term Outcomes. J Am Heart Assoc 2021;10:e018481. [PMID: 33899501 DOI: 10.1161/JAHA.120.018481] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
24 Fabris E, Korjian S, Coller BS, Ten Berg JM, Granger CB, Gibson CM, van 't Hof AWJ. Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. Thromb Haemost 2021. [PMID: 33677829 DOI: 10.1055/a-1414-5009] [Reference Citation Analysis]
25 Hahn JY, Song YB, Oh JH, Chun WJ, Park YH, Jang WJ, Im ES, Jeong JO, Cho BR, Oh SK, Yun KH, Cho DK, Lee JY, Koh YY, Bae JW, Choi JW, Lee WS, Yoon HJ, Lee SU, Cho JH, Choi WG, Rha SW, Lee JM, Park TK, Yang JH, Choi JH, Choi SH, Lee SH, Gwon HC; SMART-CHOICE Investigators. Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention: The SMART-CHOICE Randomized Clinical Trial. JAMA 2019;321:2428-37. [PMID: 31237645 DOI: 10.1001/jama.2019.8146] [Cited by in Crossref: 202] [Cited by in F6Publishing: 133] [Article Influence: 101.0] [Reference Citation Analysis]
26 Agasthi P, Lee JZ, Pujari SH, Tseng AS, Shipman J, Almader-Douglas D, Ashraf H, Mookadam F, Fortuin FD, Beohar N, Arsanjani R, Mulpuru S. Safety and efficacy of direct oral anticoagulants compared to Vitamin K antagonists postpercutaneous coronary interventions in patients with atrial fibrillation: A systematic review and meta-analysis. J Arrhythm 2020;36:271-9. [PMID: 32256873 DOI: 10.1002/joa3.12292] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Berwanger O, Lopes RD, Moia DD, Fonseca FA, Jiang L, Goodman SG, Nicholls SJ, Parkhomenko A, Averkov O, Tajer C, Malaga G, Saraiva JF, Guimaraes HP, de Barros e Silva PG, Damiani LP, Santos RH, Paisani DM, Miranda TA, Valeis N, Piegas LS, Granger CB, White HD, Nicolau JC. Ticagrelor Versus Clopidogrel in Patients With STEMI Treated With Fibrinolysis. Journal of the American College of Cardiology 2019;73:2819-28. [DOI: 10.1016/j.jacc.2019.03.011] [Cited by in Crossref: 27] [Cited by in F6Publishing: 17] [Article Influence: 13.5] [Reference Citation Analysis]
28 Martin AC, Zlotnik D, Bonete GP, Baron E, Decouture B, Belleville-Rolland T, Le Bonniec B, Poirault-Chassac S, Alessi MC, Gaussem P, Godier A, Bachelot-Loza C. Epinephrine restores platelet functions inhibited by ticagrelor: A mechanistic approach. Eur J Pharmacol 2020;866:172798. [PMID: 31738933 DOI: 10.1016/j.ejphar.2019.172798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
29 Godino C, Scotti A, Maugeri N, Mancini N, Fominskiy E, Margonato A, Landoni G. Antithrombotic therapy in patients with COVID-19? -Rationale and Evidence. Int J Cardiol 2021;324:261-6. [PMID: 33002521 DOI: 10.1016/j.ijcard.2020.09.064] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 13.0] [Reference Citation Analysis]
30 Brouwer J, Nijenhuis VJ, Rodés-Cabau J, Stabile E, Barbanti M, Costa G, Mahmoodi BK, Ten Berg JM. Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient-Level Meta-Analysis. J Am Heart Assoc 2021;10:e019604. [PMID: 33860685 DOI: 10.1161/JAHA.120.019604] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
31 de Pommereau A, de Hemptinne Q, Varenne O, Picard F. Bioresorbable vascular scaffolds: Time to absorb past lessons or fade away? Archives of Cardiovascular Diseases 2018;111:229-32. [DOI: 10.1016/j.acvd.2018.04.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
32 Bittl JA. Does Platelet Reactivity Testing Predict Post-Operative Bleeding Risk? J Am Coll Cardiol 2021;77:1287-9. [PMID: 33706869 DOI: 10.1016/j.jacc.2021.01.016] [Reference Citation Analysis]
33 Zerah L, Bun RS, Guillo S, Collet JP, Bonnet-Zamponi D, Tubach F. A prescription support-tool for chronic management of oral antithrombotic combinations in adults based on a systematic review of international guidelines. PLoS One 2019;14:e0211695. [PMID: 30763325 DOI: 10.1371/journal.pone.0211695] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
34 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention. Intern Med 2020;59:311-21. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-19] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
35 Sinnaeve PR, Van de Werf F. Endogenous fibrinolysis in STEMI: important before and after primary PCI. Eur Heart J 2019;40:306-8. [PMID: 30496395 DOI: 10.1093/eurheartj/ehy760] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
36 Sveinsdottir A, Gudmundsdottir IJ, Hreinsson JP, Andersen K, Björnsson ES. Acute gastrointestinal bleeding among patients on antiplatelet and anticoagulant therapy after percutaneous coronary intervention. Scand J Gastroenterol 2021;56:733-9. [PMID: 33794728 DOI: 10.1080/00365521.2021.1906945] [Reference Citation Analysis]
37 Galli M, Capodanno D, Andreotti F, Crea F, Angiolillo DJ. Safety and efficacy of P2Y12 inhibitor monotherapy in patients undergoing percutaneous coronary interventions. Expert Opin Drug Saf 2021;20:9-21. [PMID: 33180563 DOI: 10.1080/14740338.2021.1850691] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
38 Mannacio VA, Mannacio L, Monaco M, Antignano A, Giordano R, Pinna GB, Musumeci A, Iannelli G. Safety of aortic aneurysm repair 8 weeks after percutaneous coronary intervention for coronary artery disease: a cohort study. Updates Surg 2020;72:1213-21. [DOI: 10.1007/s13304-020-00729-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
39 Sommer J, Seeling A, Rupprecht H. Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy. Drugs Aging 2020;37:359-72. [PMID: 32056163 DOI: 10.1007/s40266-020-00747-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
40 Ostroumova OD, Kochetkov AI, Pereverzev AP, Kravchenko EV, Kazjulin AN, Andreev DN, Pavleeva EE. [The relationship between the combined use of various proton pump inhibitors with antiplatelet drugs and the risk of cardiovascular complications]. Ter Arkh 2019;91:118-26. [PMID: 32598763 DOI: 10.26442/00403660.2019.08.000355] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
41 Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, Khan MS, Mani P, Kapadia SR, Michos ED, Stone GW, Kalra A, Bhatt DL. Dual Antiplatelet Therapy After Percutaneous Coronary Intervention and Drug-Eluting Stents: A Systematic Review and Network Meta-Analysis. Circulation 2020;142:1425-36. [PMID: 32795096 DOI: 10.1161/CIRCULATIONAHA.120.046308] [Cited by in Crossref: 27] [Cited by in F6Publishing: 9] [Article Influence: 27.0] [Reference Citation Analysis]
42 Furtado RHM, Nicolau JC, Magnani G, Im K, Bhatt DL, Storey RF, Steg PG, Spinar J, Budaj A, Kontny F, Corbalan R, Kiss RG, Abola MT, Johanson P, Jensen EC, Braunwald E, Sabatine MS, Bonaca MP. Long-term ticagrelor for secondary prevention in patients with prior myocardial infarction and no history of coronary stenting: insights from PEGASUS-TIMI 54. European Heart Journal 2020;41:1625-32. [DOI: 10.1093/eurheartj/ehz821] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 6.5] [Reference Citation Analysis]
43 Schapiro-dufour E, Tricotel A, Slama MS, Ducimetière P, Trinh-duc A, Sichel C, Le Tri T, Galmiche H, Dray-spira R, Zureik M. Major ischaemic and bleeding risks following current drug-eluting stent implantation: Are there differences across current drug-eluting stent types in real life? Archives of Cardiovascular Diseases 2019;112:469-84. [DOI: 10.1016/j.acvd.2019.04.007] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
44 Cesaro A, Taglialatela V, Gragnano F, Moscarella E, Fimiani F, Conte M, Barletta V, Monda E, Limongelli G, Severino S, Cirillo P, Calabrò P. Low-Dose Ticagrelor in Patients With High Ischemic Risk and Previous Myocardial Infarction: A Multicenter Prospective Real-World Observational Study. Journal of Cardiovascular Pharmacology 2020;76:173-80. [DOI: 10.1097/fjc.0000000000000856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
45 Mori H, Takahashi J, Sato K, Miyata S, Takagi Y, Tsunoda R, Sumiyoshi T, Matsui M, Tanabe Y, Sueda S, Momomura S, Kaikita K, Yasuda S, Ogawa H, Shimokawa H, Suzuki H; Japanese Coronary Spasm Association. The impact of antiplatelet therapy on patients with vasospastic angina: A multicenter registry study of the Japanese Coronary Spasm Association. Int J Cardiol Heart Vasc 2020;29:100561. [PMID: 32551361 DOI: 10.1016/j.ijcha.2020.100561] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
46 Massussi M, Scotti A, Lip GYH, Proietti R. Left ventricular thrombosis: new perspectives on an old problem. Eur Heart J Cardiovasc Pharmacother 2021;7:158-67. [PMID: 32569361 DOI: 10.1093/ehjcvp/pvaa066] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
47 Natsuaki M, Morimoto T, Watanabe H, Nakagawa Y, Furukawa Y, Kadota K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG registry cohort‐2, RESET and NEXT trial investigators. Ischemic and Bleeding Risk After Percutaneous Coronary Intervention in Patients With Prior Ischemic and Hemorrhagic Stroke. J Am Heart Assoc 2019;8:e013356. [PMID: 31701821 DOI: 10.1161/JAHA.119.013356] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Kalarus Z, Svendsen JH, Capodanno D, Dan GA, De Maria E, Gorenek B, Jędrzejczyk-Patej E, Mazurek M, Podolecki T, Sticherling C, Tfelt-Hansen J, Traykov V, Lip GYH, Fauchier L, Boriani G, Mansourati J, Blomström-Lundqvist C, Mairesse GH, Rubboli A, Deneke T, Dagres N, Steen T, Ahrens I, Kunadian V, Berti S. Cardiac arrhythmias in the emergency settings of acute coronary syndrome and revascularization: an European Heart Rhythm Association (EHRA) consensus document, endorsed by the European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Acute Cardiovascular Care Association (ACCA). Europace 2019;21:1603-4. [PMID: 31353412 DOI: 10.1093/europace/euz163] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 22.0] [Reference Citation Analysis]
49 Jeger RV, Farah A, Ohlow M, Mangner N, Möbius-winkler S, Leibundgut G, Weilenmann D, Wöhrle J, Richter S, Schreiber M, Mahfoud F, Linke A, Stephan F, Mueller C, Rickenbacher P, Coslovsky M, Gilgen N, Osswald S, Kaiser C, Scheller B, Buser P, Kühne M, Zellweger M, Sticherling C, Wein B, Twerenbold R, Fahrni G, Plicht B, Struck B, Önal I, Cremers B, Clever Y, Ewen S, Schirmer S, Böhm M, Wagner A, Lauer B, Stachel G, Höllriegel R, Winzer E, Rickli H, Ammann P, Haager P, Trachsel L, Joerg L, Nüssli D, Roelli H, Maeder M, Rohner F, Markovic S, Paliskyte R, Buckert D, Awad B, Erne P, Jamshidi P, Cuculi F, Kapos I, Toggweiler S, Riede F, Pörner T, Lenk K, Noutsias M, Surber R, Dannberg G, Franz M, Otto S, Zweiker R, Niederl E, Perl S, Pieske B, Schmidt A, Luha O, Von Lewinski D, Krackhardt F, Kherad B, Jerichow T, Butter C, Neuss M, Tambor G, Hölschermann F, Bruch L, Winkler S, Lenz C, Seidel M, Keweloh B, Röttgen A, Bohl S, Wolf A, Hoffmann A. Drug-coated balloons for small coronary artery disease (BASKET-SMALL 2): an open-label randomised non-inferiority trial. The Lancet 2018;392:849-56. [DOI: 10.1016/s0140-6736(18)31719-7] [Cited by in Crossref: 113] [Cited by in F6Publishing: 25] [Article Influence: 37.7] [Reference Citation Analysis]
50 Franchi F, Rollini F, Rivas Rios J, Rivas A, Agarwal M, Kureti M, Nagaraju D, Wali M, Shaikh Z, Briceno M, Nawaz A, Moon JY, Been L, Suryadevara S, Soffer D, Zenni MM, Bass TA, Angiolillo DJ. Pharmacodynamic Effects of Switching From Ticagrelor to Clopidogrel in Patients With Coronary Artery Disease: Results of the SWAP-4 Study. Circulation 2018;137:2450-62. [DOI: 10.1161/circulationaha.118.033983] [Cited by in Crossref: 30] [Cited by in F6Publishing: 12] [Article Influence: 10.0] [Reference Citation Analysis]
51 Moon JY, Franchi F, Rollini F, Angiolillo DJ. Evolution of Coronary Stent Technology and Implications for Duration of Dual Antiplatelet Therapy. Progress in Cardiovascular Diseases 2018;60:478-90. [DOI: 10.1016/j.pcad.2017.12.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 21] [Article Influence: 11.3] [Reference Citation Analysis]
52 Sibbing D, Aradi D, Alexopoulos D, ten Berg J, Bhatt DL, Bonello L, Collet J, Cuisset T, Franchi F, Gross L, Gurbel P, Jeong Y, Mehran R, Moliterno DJ, Neumann F, Pereira NL, Price MJ, Sabatine MS, So DY, Stone GW, Storey RF, Tantry U, Trenk D, Valgimigli M, Waksman R, Angiolillo DJ. Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y12 Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 2019;12:1521-37. [DOI: 10.1016/j.jcin.2019.03.034] [Cited by in Crossref: 162] [Cited by in F6Publishing: 118] [Article Influence: 81.0] [Reference Citation Analysis]
53 Lansky AJ, Kereiakes DJ, Baumbach A, Windecker S, Hussain Y, Pietras C, Dressler O, Issever O, Curtis M, Bertolet B, Zidar JP, Smits PC, Alfonso Jiménez Díaz V, McLaurin B, Hofma S, Cequier Á, Dib N, Benit E, Mathur A, Brogno D, Berland J, Wykrzykowska J, Piegari G, Brugaletta S, Saito S, Leon MB; PIONEER III Trial Investigators. Novel Supreme Drug-Eluting Stents With Early Synchronized Antiproliferative Drug Delivery to Inhibit Smooth Muscle Cell Proliferation After Drug-Eluting Stents Implantation in Coronary Artery Disease: Results of the PIONEER III Randomized Clinical Trial. Circulation 2021;143:2143-54. [PMID: 33820424 DOI: 10.1161/CIRCULATIONAHA.120.052482] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Gao M, Zhang X, Qin L, Zheng Y, Zhang Z, Tong Q, Li H. Discharge Hemoglobin Association with Long-Term Outcomes of ST-Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention. Cardiovasc Ther 2020;2020:8647837. [PMID: 32190122 DOI: 10.1155/2020/8647837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Stähli BE, Varbella F, Schwarz B, Nordbeck P, Felix SB, Lang IM, Toma A, Moccetti M, Valina C, Vercellino M, Rigopoulos AG, Rohla M, Schindler M, Wischnewsky M, Linke A, Schulze PC, Richardt G, Laugwitz K, Weidinger F, Rottbauer W, Achenbach S, Huber K, Neumann F, Kastrati A, Ford I, Ruschitzka F, Maier W. Rationale and design of the MULTISTARS AMI Trial: A randomized comparison of immediate versus staged complete revascularization in patients with ST-segment elevation myocardial infarction and multivessel disease. American Heart Journal 2020;228:98-108. [DOI: 10.1016/j.ahj.2020.07.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
56 Alhazzani A, Venkatachalapathy P, Padhilahouse S, Sellappan M, Munisamy M, Sekaran M, Kumar A. Biomarkers for Antiplatelet Therapies in Acute Ischemic Stroke: A Clinical Review. Front Neurol 2021;12:667234. [PMID: 34177775 DOI: 10.3389/fneur.2021.667234] [Reference Citation Analysis]
57 Rath D, Geisler T. Optimal antiplatelet and anticoagulation strategies in acute coronary syndromes. Herz 2020;45:528-36. [PMID: 32507904 DOI: 10.1007/s00059-020-04947-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Mamas MA. Decision making in percutaneous coronary intervention in patients with cancer: balancing ischaemic and bleeding risk. Eur Heart J 2021:ehab403. [PMID: 34254123 DOI: 10.1093/eurheartj/ehab403] [Reference Citation Analysis]
59 Liang XY, Li Y, Qiao X, Zhang WJ, Wang ZL. Clinical Outcomes of Very Short Term Dual Antiplatelet Therapy in Patients With or Without Diabetes Undergoing Second-Generation Drug-Eluting Stents: A Systematic Review and Meta-Analysis of Randomized Clinical Trials. Front Cardiovasc Med 2021;8:655718. [PMID: 34277725 DOI: 10.3389/fcvm.2021.655718] [Reference Citation Analysis]
60 Ilardi F, Gargiulo G, Paolillo R, Ferrone M, Cimino S, Giugliano G, Schiattarella GG, Verde N, Stabile E, Perrino C, Cirillo P, Coscioni E, Morisco C, Esposito G. Impact of chronic kidney disease on platelet aggregation in patients with acute coronary syndrome. J Cardiovasc Med (Hagerstown) 2020;21:660-6. [PMID: 32520854 DOI: 10.2459/JCM.0000000000000981] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
61 Kupka D, Sibbing D. De-Escalation of P2Y12 Receptor Inhibitor Therapy after Acute Coronary Syndromes in Patients Undergoing Percutaneous Coronary Intervention. Korean Circ J 2018;48:863-72. [PMID: 30238704 DOI: 10.4070/kcj.2018.0255] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
62 De Luca L. Procedural Characteristics for the Optimization of Dual Antiplatelet Therapy Duration. JACC: Cardiovascular Interventions 2018;11:2464-6. [DOI: 10.1016/j.jcin.2018.10.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
63 Cardoso R, Knijnik L, Whelton SP, Rivera M, Gluckman TJ, Metkus TS, Blumenthal RS, Mcevoy JW. Dual versus single antiplatelet therapy after coronary artery bypass graft surgery: An updated meta-analysis. International Journal of Cardiology 2018;269:80-8. [DOI: 10.1016/j.ijcard.2018.07.083] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
64 Ghafoor H, Sharma NK, Alampoondi Venkataramanan SV, Hadley M. Post PCI severe gastrointestinal bleeding in the setting of idiopathic thrombocytopenic purpura: a treatment dilemma. BMJ Case Rep 2021;14:e243706. [PMID: 34162622 DOI: 10.1136/bcr-2021-243706] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Karkouti K, Wijeysundera DN. The clinical dilemma of managing patients who are on dual antiplatelet therapy and require major non-cardiac surgery. Br J Anaesth 2019;122:162-4. [PMID: 30686300 DOI: 10.1016/j.bja.2018.10.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
66 Lugo LM, Ferreiro JL. Dual antiplatelet therapy after coronary stent implantation: Individualizing the optimal duration. Journal of Cardiology 2018;72:94-104. [DOI: 10.1016/j.jjcc.2018.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 2.7] [Reference Citation Analysis]
67 Calderone D, Capodanno D, Angiolillo DJ. An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. Expert Rev Cardiovasc Ther 2020;18:449-64. [PMID: 32662726 DOI: 10.1080/14779072.2020.1792293] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
68 Deharo P, Cuisset T. Optimal duration of dual antiplatelet therapy post percutaneous coronary intervention in acute coronary syndrome. Trends Cardiovasc Med 2020;30:198-202. [PMID: 31182263 DOI: 10.1016/j.tcm.2019.05.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Lee SJ, Lee YJ, Kim BK, Hong SJ, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Ticagrelor Monotherapy Versus Ticagrelor With Aspirin in Acute Coronary Syndrome Patients With a High Risk of Ischemic Events. Circ Cardiovasc Interv 2021;14:e010812. [PMID: 34281363 DOI: 10.1161/CIRCINTERVENTIONS.121.010812] [Reference Citation Analysis]
70 Ribeiro HB, Valim LR. DAPT: Ischemic versus bleeding risk-between Scylla and Charybdis. Int J Cardiol 2021;328:81-2. [PMID: 33358835 DOI: 10.1016/j.ijcard.2020.12.033] [Reference Citation Analysis]
71 Rivas Rios JR, Franchi F, Rollini F, Angiolillo DJ. Diabetes and antiplatelet therapy: from bench to bedside. Cardiovasc Diagn Ther 2018;8:594-609. [PMID: 30498684 DOI: 10.21037/cdt.2018.05.09] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
72 Zeb I, Krim N, Bella J. Role of CYP2C19 genotype testing in clinical use of clopidogrel: is it really useful? Expert Rev Cardiovasc Ther 2018;16:369-77. [PMID: 29589775 DOI: 10.1080/14779072.2018.1459186] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
73 Oldgren J, Steg PG, Hohnloser SH, Lip GYH, Kimura T, Nordaby M, Brueckmann M, Kleine E, Ten Berg JM, Bhatt DL, Cannon CP. Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. Eur Heart J 2019;40:1553-62. [PMID: 30793734 DOI: 10.1093/eurheartj/ehz059] [Cited by in Crossref: 41] [Cited by in F6Publishing: 32] [Article Influence: 41.0] [Reference Citation Analysis]
74 Wang R, Wu S, Gamal A, Gao C, Hara H, Kawashima H, Ono M, van Geuns RJ, Vranckx P, Windecker S, Onuma Y, Serruys PW, Garg S. Aspirin-free antiplatelet regimens after PCI: insights from the GLOBAL LEADERS trial and beyond. Eur Heart J Cardiovasc Pharmacother 2021:pvab035. [PMID: 33930107 DOI: 10.1093/ehjcvp/pvab035] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
75 Gusdon AM, Farrokh S, Grotta JC. Antithrombotic Therapy for Stroke Patients with Cardiovascular Disease. Semin Neurol 2021. [PMID: 33851394 DOI: 10.1055/s-0041-1726331] [Reference Citation Analysis]
76 Angiolillo DJ, Patti G, Chan KT, Han Y, Huang WC, Yakovlev A, Paek D, Del Aguila M, Girotra S, Sibbing D. De-escalation from ticagrelor to clopidogrel in acute coronary syndrome patients: a systematic review and meta-analysis. J Thromb Thrombolysis 2019;48:1-10. [PMID: 31004312 DOI: 10.1007/s11239-019-01860-7] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
77 Mahendiran T, Nanchen D, Gencer B, Meier D, Klingenberg R, Räber L, Carballo D, Matter CM, Lüscher TF, Windecker S, Mach F, Rodondi N, Muller O, Fournier S. Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. J of Cardiovasc Trans Res 2020;13:618-28. [DOI: 10.1007/s12265-019-09934-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
78 Ielasi A, Campo G, Cortese B, Leoncini M, Varricchio A, Brugaletta S, Favaretto E, Fineschi M, Piraino D, Calabria P, Granata F, Pisano F, Mussardo M, Latib A, Tespili M. One-Year Results Following a Pre-Specified ABSORB Implantation Strategy in ST-Elevation Myocardial Infarction (BVS STEMI STRATEGY-IT Study). Cardiovascular Revascularization Medicine 2019;20:700-4. [DOI: 10.1016/j.carrev.2018.10.003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
79 Claassens DMF, Gimbel ME, Bergmeijer TO, Vos GJA, Hermanides RS, van der Harst P, Barbato E, Morisco C, Tjon Joe Gin RM, de Vrey EA, Heestermans TACM, Jukema JW, von Birgelen C, Waalewijn RA, Hofma SH, den Hartog FR, Voskuil M, Van't Hof AWJ, Asselbergs FW, Mosterd A, Herrman JR, Dewilde W, Mahmoodi BK, Deneer VHM, Ten Berg JM. Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. Int J Cardiol 2021;334:10-7. [PMID: 33887342 DOI: 10.1016/j.ijcard.2021.04.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Bianco M, Careggio A, Destefanis P, Luciano A, Perrelli MG, Quadri G, Rossini R, Campo G, Vizzari G, D'Ascenzo F, Anselmino M, Biondi-Zoccai G, Ibáñez B, Montagna L, Varbella F, Cerrato E. P2Y12 inhibitors monotherapy after short course of dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials including 29 089 patients. Eur Heart J Cardiovasc Pharmacother 2021;7:196-205. [PMID: 32544220 DOI: 10.1093/ehjcvp/pvaa038] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
81 Youn YJ, Yoo SY, Lee JW, Ahn SG, Lee SH, Yoon J, Park JH, Choi WG, Cho S, Lim SW, Jang YS, Kwon KH, Lee NH, Doh JH, Kang WC, Jeon DW, Lee BK, Heo JH, Hong BK, Choi HH. Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World Practice. Korean Circ J 2020;50:317-27. [PMID: 31960640 DOI: 10.4070/kcj.2019.0258] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
82 Kandzari DE, Kirtane AJ, Windecker S, Latib A, Kedhi E, Mehran R, Price MJ, Abizaid A, Simon DI, Worthley SG, Zaman A, Choi JW, Caputo R, Kanitkar M, McLaurin B, Potluri S, Smith T, Spriggs D, Tolleson T, Nazif T, Parke M, Lee LC, Lung TH, Stone GW; Onyx ONE US/Japan Investigators. One-Month Dual Antiplatelet Therapy Following Percutaneous Coronary Intervention With Zotarolimus-Eluting Stents in High-Bleeding-Risk Patients. Circ Cardiovasc Interv 2020;13:e009565. [PMID: 33167705 DOI: 10.1161/CIRCINTERVENTIONS.120.009565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
83 Fu L, Zhu W, Huang L, Hu J, Ma J, Lip GYH, Hong K. Efficacy and Safety of the Use of Non-vitamin K Antagonist Oral Anticoagulants in Patients with Ischemic Heart Disease: A Meta-Analysis of Phase III Randomized Trials. Am J Cardiovasc Drugs 2019;19:37-47. [DOI: 10.1007/s40256-018-0299-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
84 Verdoia M, Pergolini P, Nardin M, Rolla R, Negro F, Kedhi E, Suryapranata H, Marcolongo M, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). Vitamin D levels and platelet reactivity in diabetic patients receiving dual antiplatelet therapy. Vascul Pharmacol 2019;120:106564. [PMID: 31176855 DOI: 10.1016/j.vph.2019.106564] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
85 Sun GL, Lei L, Liu L, Liu J, He Y, Guo Z, Dai X, He L, Chen SQ, Liang Y, Ye J, Hu Y, Chen G, Chen JY, Liu Y. Rationale and design of the Web-basEd soCial media tecHnology to improvement in Adherence to dual anTiplatelet Therapy following Drug-Eluting Stent Implantation (WECHAT): protocol for a randomised controlled study. BMJ Open 2020;10:e033017. [PMID: 31915170 DOI: 10.1136/bmjopen-2019-033017] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
86 Valgimigli M, Mehran R, Franzone A, da Costa BR, Baber U, Piccolo R, McFadden EP, Vranckx P, Angiolillo DJ, Leonardi S, Cao D, Dangas GD, Mehta SR, Serruys PW, Gibson CM, Steg GP, Sharma SK, Hamm C, Shlofmitz R, Liebetrau C, Briguori C, Janssens L, Huber K, Ferrario M, Kunadian V, Cohen DJ, Zurakowski A, Oldroyd KG, Yaling H, Dudek D, Sartori S, Kirkham B, Escaned J, Heg D, Windecker S, Pocock S, Jüni P; SIDNEY Collaboration. Ticagrelor Monotherapy Versus Dual-Antiplatelet Therapy After PCI: An Individual Patient-Level Meta-Analysis. JACC Cardiovasc Interv 2021;14:444-56. [PMID: 33602441 DOI: 10.1016/j.jcin.2020.11.046] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
87 Sato T, Taya Y, Suzuki N, Yuasa S, Kishi S, Koshikawa T, Fuse K, Fujita S, Ikeda Y, Kitazawa H, Takahashi M, Okabe M, Aizawa Y. The comparison of early healing 1-month after PCI among CoCr-everolimus-eluting stent (EES), biodegradable polymer (BP)-EES and BP-sirolimus-eluting stent: Insights from OFDI and coronary angioscopy. Int J Cardiol Heart Vasc 2018;20:40-5. [PMID: 30167453 DOI: 10.1016/j.ijcha.2018.08.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Sakamoto A, Torii S, Jinnouchi H, Virmani R, Finn AV. Histopathologic and physiologic effect of overlapping vs single coronary stents: impact of stent evolution. Expert Review of Medical Devices 2018;15:665-82. [DOI: 10.1080/17434440.2018.1515012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
89 Chichareon P, Modolo R, Kawashima H, Takahashi K, Kogame N, Chang CC, Tomaniak M, Ono M, Walsh S, Suryapranata H, Cotton J, Koning R, Akin I, Kukreja N, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Vranckx P, Valgimigli M, Windecker S, Onuma Y, Serruys PW. DAPT Score and the Impact of Ticagrelor Monotherapy During the Second Year After PCI. JACC Cardiovasc Interv 2020;13:634-46. [PMID: 32139222 DOI: 10.1016/j.jcin.2019.12.018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
90 Veron-esquivel D, Batiz-armenta F, Cazares-diazleal AC, Oviedo-moguel S, Jarvio-fernandez SM, Arce-gonzalez JM, Ivey-miranda JB. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction. Hellenic Journal of Cardiology 2019;60:296-302. [DOI: 10.1016/j.hjc.2018.05.007] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
91 Patti G, Pecen L, Lucerna M, Huber K, Rohla M, Renda G, Siller-Matula J, Schnabel RB, Cemin R, Kirchhof P, De Caterina R. Outcomes of anticoagulated patients with atrial fibrillation treated with or without antiplatelet therapy - A pooled analysis from the PREFER in AF and PREFER in AF PROLONGATON registries. Int J Cardiol 2018;270:160-6. [PMID: 30220376 DOI: 10.1016/j.ijcard.2018.06.098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 4.7] [Reference Citation Analysis]
92 Chen YC, Lin FY, Lin YW, Cheng SM, Lin RH, Chuang CL, Sheu JS, Chen SM, Chang CC, Tsai CS. DAPT Plus Cilostazol is Better Than Traditional DAPT or Aspirin Plus Ticagrelor as Elective PCI for Intermediate-to-Highly Complex Cases: Prospective, Randomized, PRU-Based Study in Taiwan. Am J Cardiovasc Drugs 2019;19:75-86. [PMID: 30467686 DOI: 10.1007/s40256-018-0302-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
93 Verheugt FWA, Ten Berg JM, Storey RF, Cuisset T, Granger CB. Antithrombotics: From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5). J Am Coll Cardiol 2019;74:699-711. [PMID: 31277840 DOI: 10.1016/j.jacc.2019.02.080] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
94 Wiebe J, Ndrepepa G, Kufner S, Lahmann AL, Xhepa E, Kuna C, Voll F, Gosetti R, Laugwitz KL, Joner M, Kastrati A, Cassese S. Early Aspirin Discontinuation After Coronary Stenting: A Systematic Review and Meta-Analysis. J Am Heart Assoc 2021;10:e018304. [PMID: 33410332 DOI: 10.1161/JAHA.120.018304] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Natsuaki M, Morimoto T, Yamamoto E, Watanabe H, Furukawa Y, Abe M, Nakao K, Ishikawa T, Kawai K, Yunoki K, Shimizu S, Akao M, Miki S, Yamamoto M, Okada H, Hoshino K, Kadota K, Morino Y, Hanaoka KI, Tanabe K, Kozuma K, Kimura T; STOPDAPT trial investigators. One-year clinical outcomes of patients with versus without acute coronary syndrome with 3-month duration of dual antiplatelet therapy after everolimus-eluting stent implantation. PLoS One 2020;15:e0227612. [PMID: 32210433 DOI: 10.1371/journal.pone.0227612] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Allencherril J, Alam M, Levine G, Jneid H, Atar D, Kloner RA, Birnbaum Y. Do We Need Potent Intravenous Antiplatelet Inhibition at the Time of Reperfusion During ST-Segment Elevation Myocardial Infarction? J Cardiovasc Pharmacol Ther 2019;24:215-24. [PMID: 30563349 DOI: 10.1177/1074248418812167] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
97 Argentiero D, Savonitto S, D’andrea P, Iacovelli F. Ticagrelor and tirofiban in pregnancy and delivery: beyond labels. J Thromb Thrombolysis 2020;49:145-8. [DOI: 10.1007/s11239-019-01939-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
98 Calnan MW, Crawford AN. A Case Report of Cangrelor Bridge Therapy for a Diagnostic Bronchoscopy With Biopsy. J Pharm Pract 2020;33:231-5. [PMID: 30139291 DOI: 10.1177/0897190018795343] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
99 Vitolo M, Javed S, Capodanno D, Rubboli A, Boriani G, Lip GYH. Antithrombotic treatment in atrial fibrillation patients undergoing percutaneous coronary interventions: focus on stent thrombosis. Expert Review of Cardiovascular Therapy 2020;18:587-600. [DOI: 10.1080/14779072.2020.1808463] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Buccheri S, Capodanno D, James S, Angiolillo DJ. Bleeding after antiplatelet therapy for the treatment of acute coronary syndromes: a review of the evidence and evolving paradigms. Expert Opinion on Drug Safety 2019;18:1171-89. [DOI: 10.1080/14740338.2019.1680637] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
101 Li P, Li Y, Chen L, Ma X, Yan X, Yan M, Qian B, Wang F, Xu J, Yin J, Xu G, Sun K. Long noncoding RNA uc003pxg.1 regulates endothelial cell proliferation and migration via miR‑25‑5p in coronary artery disease. Int J Mol Med 2021;48:160. [PMID: 34212983 DOI: 10.3892/ijmm.2021.4993] [Reference Citation Analysis]
102 Ho MY, Chen PW, Feng WH, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HW, Lin SH, Hsieh IC, Li YH. Effect of aspirin treatment duration on clinical outcomes in acute coronary syndrome patients with early aspirin discontinuation and received P2Y12 inhibitor monotherapy. PLoS One 2021;16:e0251109. [PMID: 33979377 DOI: 10.1371/journal.pone.0251109] [Reference Citation Analysis]
103 Wzorek J, Bednarek R, Watala C, Boncler M. Efficacy of a Combined Antiplatelet Therapy Is Not Affected by a Simultaneous Binding of Cangrelor and PSB 0777 to Albumin. Front Pharmacol 2021;12:638257. [PMID: 33776774 DOI: 10.3389/fphar.2021.638257] [Reference Citation Analysis]
104 Limbruno U, Goette A, De Caterina R. Commentary: Temporarily omitting oral anticoagulants early after stenting for acute coronary syndromes patients with atrial fibrillation. Int J Cardiol 2020;318:82-5. [PMID: 32389765 DOI: 10.1016/j.ijcard.2020.05.024] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
105 Tan JW, Chew DP, Abdul Kader MAS, Ako J, Bahl VK, Chan M, Park KW, Chandra P, Hsieh IC, Huan DQ, Johar S, Juzar DA, Kim BK, Lee CW, Lee MK, Li YH, Almahmeed W, Sison EO, Tan D, Wang YC, Yeh SJ, Montalescot G. 2020 Asian Pacific Society of Cardiology Consensus Recommendations on the Use of P2Y12 Receptor Antagonists in the Asia-Pacific Region. Eur Cardiol 2021;16:e02. [PMID: 33708263 DOI: 10.15420/ecr.2020.40] [Reference Citation Analysis]
106 Kanenawa K, Yamaji K, Tashiro H, Morimoto T, Hiromasa T, Hayashi M, Hiramori S, Tomoi Y, Kuramitsu S, Domei T, Hyodo M, Ando K, Kimura T. Frailty and Bleeding After Percutaneous Coronary Intervention. Am J Cardiol 2021;148:22-9. [PMID: 33667444 DOI: 10.1016/j.amjcard.2021.02.041] [Reference Citation Analysis]
107 Alaaeddine RA, AlZaim I, Hammoud SH, Arakji A, Eid AH, Abd-Elrahman KS, El-Yazbi AF. The pleiotropic effects of antithrombotic drugs in the metabolic-cardiovascular-neurodegenerative disease continuum: impact beyond reduced clotting. Clin Sci (Lond) 2021;135:1015-51. [PMID: 33881143 DOI: 10.1042/CS20201445] [Reference Citation Analysis]
108 Degli Esposti L, Perrone V, Veronesi C, Buda S, Rossini R; a LHUs Group . Long-Term Use of Antiplatelet Therapy in Real-World Patients with Acute Myocardial Infarction: Insights from the PIPER Study. TH Open 2018;2:e437-44. [PMID: 31249972 DOI: 10.1055/s-0038-1676529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Chen Z, Liu Z, Li N, Liu R, Wang M, Wang D, Li C, Li K, Luo F, He Y. Impact of Thrombocytopenia on In-Hospital Outcome in Patients Undergoing Percutaneous Coronary Intervention. Cardiovasc Ther 2021;2021:8836450. [PMID: 33519970 DOI: 10.1155/2021/8836450] [Reference Citation Analysis]
110 Kurlander JE, Rubenstein JH, Richardson CR, Krein SL, De Vries R, Zikmund-Fisher BJ, Yang YX, Laine L, Weissman A, Saini SD. Physicians' Perceptions of Proton Pump Inhibitor Risks and Recommendations to Discontinue: A National Survey. Am J Gastroenterol 2020;115:689-96. [PMID: 32091419 DOI: 10.14309/ajg.0000000000000558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
111 Santangelo G, Faggiano A, Toriello F, Carugo S, Natalini G, Bursi F, Faggiano P. Risk of cardiovascular complications during non-cardiac surgery and preoperative cardiac evaluation. Trends Cardiovasc Med 2021:S1050-1738(21)00069-4. [PMID: 34233205 DOI: 10.1016/j.tcm.2021.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
112 Gradolí J, Vidal V, Brady AJ, Facila L. Anticoagulation in Patients with Ischaemic Heart Disease and Peripheral Arterial Disease: Clinical Implications of COMPASS Study. Eur Cardiol 2018;13:115-8. [PMID: 30697356 DOI: 10.15420/ecr.2018.12.2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
113 Liao YWB, Wang TKM. Antithrombotic regimen for patients with cardiac indication for dual antiplatelet therapy and anticoagulation: a meta-analysis of randomized trials. Coronary Artery Disease 2020;31:260-5. [DOI: 10.1097/mca.0000000000000785] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
114 Zocca P, Kok MM, van der Heijden LC, Danse PW, Schotborgh CE, Scholte M, Hartmann M, Linssen GCM, Doggen CJM, von Birgelen C. High Bleeding Risk Patients Treated with Very Thin-Strut Biodegradable Polymer or Thin-Strut Durable Polymer Drug-Eluting Stents in the BIO-RESORT Trial. Cardiovasc Drugs Ther 2018;32:567-76. [PMID: 30143879 DOI: 10.1007/s10557-018-6823-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
115 Liu Z, Tian R, Wang Y, Chen Q, Li J, Xu L, Zhang S. Platelet Inhibition with Ticagrelor versus Clopidogrel in Diabetic Patients after Percutaneous Coronary Intervention for Chronic Coronary Syndromes. Thromb Haemost 2020;120:1221-9. [PMID: 32668483 DOI: 10.1055/s-0040-1713375] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
116 Du BB, Wang XT, Li XD, Li PP, Chen WW, Li SM, Yang P. Treatment of severe upper gastrointestinal bleeding caused by Mallory-Weiss syndrome after primary coronary intervention for acute inferior wall myocardial infarction: A case report. World J Clin Cases 2019;7:4407-13. [PMID: 31911925 DOI: 10.12998/wjcc.v7.i24.4407] [Reference Citation Analysis]
117 Shoji K, Yanishi K, Shiraishi J, Nakanishi N, Zen K, Nakamura T, Hyogo M, Shirayama T, Matoba S, Sawada T. In-stent Massive Thrombi Formation During Primary Percutaneous Coronary Intervention in a Patient with Acute Myocardial Infarction Complicated with Essential Thrombocythemia. Intern Med 2019;58:1287-93. [PMID: 30626836 DOI: 10.2169/internalmedicine.2083-18] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
118 Mo F, Li J, Yan Y, Wu W, Lai S. Effect and safety of antithrombotic therapies for secondary prevention after acute coronary syndrome: a network meta-analysis. Drug Des Devel Ther 2018;12:3583-94. [PMID: 30498334 DOI: 10.2147/DDDT.S166544] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
119 Burlacu A, Genovesi S, Basile C, Ortiz A, Mitra S, Kirmizis D, Kanbay M, Davenport A, van der Sande F, Covic A; EUDIAL Working Group of ERA-EDTA. Coronary artery disease in dialysis patients: evidence synthesis, controversies and proposed management strategies. J Nephrol 2021;34:39-51. [PMID: 32472526 DOI: 10.1007/s40620-020-00758-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
120 Khan SU, Lone AN, Asad ZUA, Rahman H, Khan MS, Saleem MA, Arshad A, Nawaz N, Sattur S, Kaluski E. Meta-Analysis of Efficacy and Safety of Proton Pump Inhibitors with Dual Antiplatelet Therapy for Coronary Artery Disease. Cardiovasc Revasc Med 2019;20:1125-33. [PMID: 30773427 DOI: 10.1016/j.carrev.2019.02.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
121 Torii S, Jinnouchi H, Sakamoto A, Mori H, Park J, Amoa FC, Sawan M, Sato Y, Cornelissen A, Kuntz SH, Kutyna M, Paek KH, Fernandez R, Braumann R, Mont EK, Surve D, Romero ME, Kolodgie FD, Virmani R, Finn AV. Vascular responses to coronary calcification following implantation of newer-generation drug-eluting stents in humans: impact on healing. Eur Heart J 2020;41:786-96. [PMID: 31803916 DOI: 10.1093/eurheartj/ehz850] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
122 Macaya F, Salinas P, Gonzalo N, Fernández-Ortiz A, Macaya C, Escaned J. Spontaneous coronary artery dissection: contemporary aspects of diagnosis and patient management. Open Heart 2018;5:e000884. [PMID: 30487978 DOI: 10.1136/openhrt-2018-000884] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 8.0] [Reference Citation Analysis]
123 Petzold T, Thienel M, Dannenberg L, Mourikis P, Helten C, Ayhan A, M'Pembele R, Achilles A, Trojovky K, Konsek D, Zhang Z, Regenauer R, Pircher J, Ehrlich A, Lüsebrink E, Nicolai L, Stocker TJ, Brandl R, Röschenthaler F, Strecker J, Saleh I, Spannagl M, Mayr CH, Schiller HB, Jung C, Gerdes N, Hoffmann T, Levkau B, Hohlfeld T, Zeus T, Schulz C, Kelm M, Polzin A. Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa-Driven Platelet Activation via Protease Activated Receptor-1. Circ Res 2020;126:486-500. [PMID: 31859592 DOI: 10.1161/CIRCRESAHA.119.315099] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 15.5] [Reference Citation Analysis]
124 Pereira NL, Rihal CS, So DYF, Rosenberg Y, Lennon RJ, Mathew V, Goodman SG, Weinshilboum RM, Wang L, Baudhuin LM, Lerman A, Hasan A, Iturriaga E, Fu YP, Geller N, Bailey K, Farkouh ME. Clopidogrel Pharmacogenetics. Circ Cardiovasc Interv 2019;12:e007811. [PMID: 30998396 DOI: 10.1161/CIRCINTERVENTIONS.119.007811] [Cited by in Crossref: 38] [Cited by in F6Publishing: 15] [Article Influence: 38.0] [Reference Citation Analysis]
125 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining high bleeding risk in patients undergoing percutaneous coronary intervention: a consensus document from the Academic Research Consortium for High Bleeding Risk. Eur Heart J 2019;40:2632-53. [PMID: 31116395 DOI: 10.1093/eurheartj/ehz372] [Cited by in Crossref: 128] [Cited by in F6Publishing: 74] [Article Influence: 128.0] [Reference Citation Analysis]
126 Hofer F, Kazem N, Hammer A, El-Hamid F, Koller L, Niessner A, Sulzgruber P. Long-term prognosis of de novo atrial fibrillation during acute myocardial infarction: the impact of anti-thrombotic treatment strategies. Eur Heart J Cardiovasc Pharmacother 2021;7:189-95. [PMID: 32289167 DOI: 10.1093/ehjcvp/pvaa027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
127 Bae S, Kim Y, Gogas BD, Kim MC, Sim DS, Hong YJ, Kim JH, Ahn Y, Jeong MH. Efficacy and safety of drug-eluting stents in elderly patients: A meta-analysis of randomized trials. Cardiol J 2021;28:223-34. [PMID: 31702046 DOI: 10.5603/CJ.a2019.0109] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
128 Sorrentino S, Sartori S, Baber U, Claessen BE, Giustino G, Chandrasekhar J, Chandiramani R, Cohen DJ, Henry TD, Guedeney P, Ariti C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Urban P, Mehran R. Bleeding Risk, Dual Antiplatelet Therapy Cessation, and Adverse Events After Percutaneous Coronary Intervention: The PARIS Registry. Circ: Cardiovascular Interventions 2020;13. [DOI: 10.1161/circinterventions.119.008226] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
129 Gargiulo G, Esposito G, Cirillo P, Nagler M, Minuz P, Campo G, Gragnano F, Manavifar N, Piccolo R, Avvedimento M, Tebaldi M, Wahl A, Hunziker L, Billinger M, Heg D, Windecker S, Valgimigli M. Facilitation Through Aggrastat or Cangrelor Bolus and Infusion Over PrasugreL: a MUlticenter Randomized Open-label Trial in PatientS with ST-elevation Myocardial InFarction Referred for PrimAry PercutaneouS InTERvention (FABOLUS FASTER) Trial: Design and Rationale : The FABOLUS FASTER Trial. J Cardiovasc Transl Res 2021;14:110-9. [PMID: 32096064 DOI: 10.1007/s12265-020-09969-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
130 Khalid U, Bandeali S, Jones PG, Virani SS, Hira R, Hamzeh I, Chan PS, Kleiman NS, Lakkis N, Alam M. Prescription Patterns of Clopidogrel, Prasugrel, and Ticagrelor After Percutaneous Coronary Intervention With Stent Implantation (from the NCDR PINNACLE Registry). The American Journal of Cardiology 2019;124:1807-12. [DOI: 10.1016/j.amjcard.2019.09.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
131 Yang J, Yu Q, Xu Z, Zheng N, Zhong J, Li J, Liu Y, Xu H, Su J, Ji L, Chen X. Clopidogrel Resistance Is Associated With DNA Methylation of Genes From Whole Blood of Humans. Front Genet 2020;11:583215. [PMID: 33519892 DOI: 10.3389/fgene.2020.583215] [Reference Citation Analysis]
132 Aradi D, Gross L, Trenk D, Geisler T, Merkely B, Kiss RG, Komócsi A, Dézsi CA, Ruzsa Z, Ungi I, Rizas KD, May AE, Mügge A, Zeiher AM, Holdt L, Huber K, Neumann F, Koltowski L, Huczek Z, Hadamitzky M, Massberg S, Sibbing D. Platelet reactivity and clinical outcomes in acute coronary syndrome patients treated with prasugrel and clopidogrel: a pre-specified exploratory analysis from the TROPICAL-ACS trial. European Heart Journal 2019;40:1942-51. [DOI: 10.1093/eurheartj/ehz202] [Cited by in Crossref: 25] [Cited by in F6Publishing: 13] [Article Influence: 12.5] [Reference Citation Analysis]
133 Vandiver JW, Diane Beavers K. Combining oral anticoagulation and antiplatelet therapies: appropriate patient selection. J Thromb Thrombolysis 2018;45:423-31. [DOI: 10.1007/s11239-018-1635-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
134 Piqueras-Flores J, Jurado-Román A, López-Lluva MT, Sánchez-Pérez I, Abellán-Huerta J, Lozano-Ruiz Poveda F. Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention. J Cardiovasc Pharmacol 2019;73:56-9. [PMID: 30383607 DOI: 10.1097/FJC.0000000000000632] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
135 Shima Y, Miura K, Shimada T, Ohya M, Murai R, Kubo S, Tada T, Tanaka H, Fuku Y, Kadota K. Impact of ischemic risk factors on long-term outcomes in patients with and without high bleeding risk. Int J Cardiol 2021;326:12-8. [PMID: 33152414 DOI: 10.1016/j.ijcard.2020.10.073] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
136 Guerrero C, Ariza-Solé A, Formiga F, Martínez-Sellés M, Vidán MT, Aboal J. Applicability of the PRECISE-DAPT score in elderly patients with myocardial infarction. J Geriatr Cardiol 2018;15:713-7. [PMID: 30675142 DOI: 10.11909/j.issn.1671-5411.2018.12.003] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
137 Chan Pin Yin DRPP, Vos GA, van der Sangen NMR, Walhout R, Tjon Joe Gin RM, Nicastia DM, Langerveld J, Claassens DMF, Gimbel ME, Azzahhafi J, Bor WL, Oirbans T, Dekker J, Vlachojannis GJ, van Bommel RJ, Appelman Y, Henriques JPS, Kikkert WJ, Ten Berg JM. Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards "Personalized Medicine" in Daily Clinical Practice. J Clin Med 2020;9:E3173. [PMID: 33007932 DOI: 10.3390/jcm9103173] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
138 Choi KH, Song YB, Jeong DS, Jang YH, Hong D, Lee SY, Youn T, Bak M, Min KM, Lee JM, Park TK, Yang JH, Hahn J, Choi J, Choi S, Chung SR, Cho YH, Sung K, Kim WS, Gwon H, Lee YT. Differential effects of dual antiplatelet therapy in patients presented with acute coronary syndrome vs. stable ischaemic heart disease after coronary artery bypass grafting. European Heart Journal - Cardiovascular Pharmacotherapy 2020. [DOI: 10.1093/ehjcvp/pvaa080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
139 Orme RC, Parker WAE, Thomas MR, Judge HM, Baster K, Sumaya W, Morgan KP, McMellon HC, Richardson JD, Grech ED, Wheeldon NM, Hall IR, Iqbal J, Barmby D, Gunn JP, Storey RF. Study of Two Dose Regimens of Ticagrelor Compared with Clopidogrel in Patients Undergoing Percutaneous Coronary Intervention for Stable Coronary Artery Disease (STEEL-PCI). Circulation 2018:CIRCULATIONAHA. [PMID: 29930021 DOI: 10.1161/CIRCULATIONAHA.118.034790] [Cited by in Crossref: 41] [Cited by in F6Publishing: 8] [Article Influence: 13.7] [Reference Citation Analysis]
140 Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, Gale CP, Gilard M, Jobs A, Jüni P, Lambrinou E, Lewis BS, Mehilli J, Meliga E, Merkely B, Mueller C, Roffi M, Rutten FH, Sibbing D, Siontis GCM; ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J 2021;42:1289-367. [PMID: 32860058 DOI: 10.1093/eurheartj/ehaa575] [Cited by in Crossref: 362] [Cited by in F6Publishing: 224] [Article Influence: 362.0] [Reference Citation Analysis]
141 Mohamed MO, Roddy E, Ya'qoub L, Myint PK, Al Alasnag M, Alraies C, Clarson L, Helliwell T, Mallen C, Fischman D, Al Shaibi K, Abhishek A, Mamas MA. Acute Myocardial Infarction in Autoimmune Rheumatologic Disease: A Nationwide Analysis of Clinical Outcomes and Predictors of Management Strategy. Mayo Clin Proc 2021;96:388-99. [PMID: 33248709 DOI: 10.1016/j.mayocp.2020.04.044] [Reference Citation Analysis]
142 Bonello L, Angiolillo DJ, Aradi D, Sibbing D. P2Y 12 -ADP Receptor Blockade in Chronic Kidney Disease Patients With Acute Coronary Syndromes: Review of the Current Evidence. Circulation 2018;138:1582-96. [DOI: 10.1161/circulationaha.118.032078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 7] [Article Influence: 8.7] [Reference Citation Analysis]
143 Ow KW, Parker WAE, Porter MM, Hanson J, Judge HM, Briffa NP, Thomas MR, Storey RF. Offset of ticagrelor prior to coronary artery bypass graft surgery for acute coronary syndromes: effects on platelet function and cellular adenosine uptake. Platelets 2020;31:945-51. [PMID: 31893974 DOI: 10.1080/09537104.2019.1709631] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
144 Franzone A, Mcfadden E, Leonardi S, Piccolo R, Vranckx P, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Heg D, Jüni P, Windecker S, Valgimigli M. Ticagrelor Alone Versus Dual Antiplatelet Therapy From 1 Month After Drug-Eluting Coronary Stenting. Journal of the American College of Cardiology 2019;74:2223-34. [DOI: 10.1016/j.jacc.2019.08.1038] [Cited by in Crossref: 46] [Cited by in F6Publishing: 33] [Article Influence: 23.0] [Reference Citation Analysis]
145 Klein MD, Lee CR, Stouffer GA. Clinical outcomes of CYP2C19 genotype-guided antiplatelet therapy: existing evidence and future directions. Pharmacogenomics 2018;19:1039-46. [DOI: 10.2217/pgs-2018-0072] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
146 Olivier CB, Fan J, Askari M, Mahaffey KW, Heidenreich PA, Perino AC, Leef GC, Ho PM, Harrington RA, Turakhia MP. Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention: Findings From the Veterans Health Administration. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.118.007604] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
147 Vivas D, Roldán I, Ferrandis R, Marín F, Roldán V, Tello-Montoliu A, Ruiz-Nodar JM, Gómez-Doblas JJ, Martín A, Llau JV, Ramos-Gallo MJ, Muñoz R, Arcelus JI, Leyva F, Alberca F, Oliva R, Gómez AM, Montero C, Arikan F, Ley L, Santos-Bueso E, Figuero E, Bujaldón A, Urbano J, Otero R, Hermida JF, Egocheaga I, Llisterri JL, Lobos JM, Serrano A, Madridano O, Ferreiro JL; Expert reviewers. Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT and AEU. Rev Esp Cardiol (Engl Ed) 2018;71:553-64. [PMID: 29887180 DOI: 10.1016/j.rec.2018.01.029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 9] [Article Influence: 0.3] [Reference Citation Analysis]
148 Eekels JJM, Pachler C, Krause N, Muhr T, Waltl G, Greinacher A. Ticagrelor causes false-negative functional tests for heparin-induced thrombocytopenia. Blood 2020;135:875-8. [PMID: 31914174 DOI: 10.1182/blood.2019003582] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
149 Schiele F, Aktaa S, Rossello X, Ahrens I, Claeys MJ, Collet JP, Fox KAA, Gale CP, Huber K, Iakobishvili Z, Keys A, Lambrinou E, Leonardi S, Lettino M, Masoudi FA, Price S, Quinn T, Swahn E, Thiele H, Timmis A, Tubaro M, Vrints CJM, Walker D, Bueno H, Halvorsen S, Jernberg T, Jortveit J, Blöndal M, Ibanez B, Hassager C; ESC Scientific Document Group. 2020 Update of the quality indicators for acute myocardial infarction: a position paper of the Association for Acute Cardiovascular Care: the study group for quality indicators from the ACVC and the NSTE-ACS guideline group. Eur Heart J Acute Cardiovasc Care 2021;10:224-33. [PMID: 33550362 DOI: 10.1093/ehjacc/zuaa037] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
150 Sanchez F, Boasi V, Vercellino M, Tacchi C, Cannarile P, Pingelli N, Perri D, Gomez L, Cattunar S, Mascelli G. Risk definition and outcomes with the application of the PEGASUS-TIMI 54 trial inclusion criteria to a "real world" STEMI population: results from the Italian "CARDIO-STEMI SANREMO" registry. BMC Cardiovasc Disord 2021;21:144. [PMID: 33736607 DOI: 10.1186/s12872-020-01780-y] [Reference Citation Analysis]
151 Guedeney P, Collet JP. Antithrombotic Therapy in Acute Coronary Syndromes: Current Evidence and Ongoing Issues Regarding Early and Late Management. Thromb Haemost 2021;121:854-66. [PMID: 33506483 DOI: 10.1055/s-0040-1722188] [Reference Citation Analysis]
152 D'Ascenzo F, Barbero U, Abdirashid M, Trabattoni D, Boccuzzi G, Ryan N, Quadri G, Capodanno D, Venuti G, Muscoli S, Tomassini F, Autelli M, Montabone A, Wojakowski W, Rognoni A, Gallo D, Parma R, De Luca L, Figini F, Mitomo S, Montefusco A, Mattesini A, Wańha W, Protasiewicz M, Smolka G, Huczek Z, Rolfo C, Cortese B, Chieffo A, Kuliczowki W, Nuñez-Gil I, Morbiducci U, Ugo F, Marengo G, Iannaccone M, Cerrato E, Mario CD, Moretti C, D'Amico M, Varbella F, Lüscher TF, Sheiban I, Escaned J, Romeo F, Rinaldi M, De Ferrari GM, Helft G. Incidence of Adverse Events at 3 Months Versus at 12 Months After Dual Antiplatelet Therapy Cessation in Patients Treated With Thin Stents With Unprotected Left Main or Coronary Bifurcations. Am J Cardiol 2020;125:491-9. [PMID: 31889527 DOI: 10.1016/j.amjcard.2019.10.058] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
153 Guo W, Chen X, Hao Y, Liu Q, Peng C, Zhao L, Feng Z, Wang X, Ruan H, Li L. Efficacy and safety of an antithrombotic regimen for atrial fibrillation patients with acute coronary syndrome or those undergoing percutaneous coronary intervention: a meta-analysis. Aging (Albany NY) 2020;12:12930-42. [PMID: 32611835 DOI: 10.18632/aging.103359] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
154 Selvarajah A, Tavenier AH, Bor WL, Houben V, Rasoul S, Kaplan E, Teeuwen K, Hofma SH, Lipsic E, Amoroso G, van Leeuwen MAH, Berg JMT, van 't Hof AWJ, Hermanides RS. Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry. BMC Cardiovasc Disord 2021;21:292. [PMID: 34118880 DOI: 10.1186/s12872-021-02093-4] [Reference Citation Analysis]
155 Mehran R, Vogel B, Levy P. Reducing the cost of managing patients with atrial fibrillation undergoing percutaneous coronary intervention with stenting. J Cardiol 2021;77:93-9. [PMID: 32859453 DOI: 10.1016/j.jjcc.2020.07.018] [Reference Citation Analysis]
156 Cortese B, D’ascenzo F, Fetiveau R, Balian V, Blengino S, Fineschi M, Rogacka R, Lettieri C, Pavei A, D’amico M, Poli A, Di Palma G, Latini RA, Orrego PS, Seregni R. Treatment of coronary artery disease with a new-generation drug-coated balloon: final results of the Italian Elutax SV rEgistry-DCB-RISE. Journal of Cardiovascular Medicine 2018;19:247-52. [DOI: 10.2459/jcm.0000000000000632] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
157 Petricevic M, Petricevic M, Pasalic M, Golubic Cepulic B, Raos M, Vasicek V, Goerlinger K, Rotim K, Gasparovic H, Biocina B. Bleeding risk stratification in coronary artery surgery: the should-not-bleed score. J Cardiothorac Surg 2021;16:103. [PMID: 33882969 DOI: 10.1186/s13019-021-01473-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
158 Kubica J, Adamski P, Buszko K, Barańska M, Sikora J, Marszałł MP, Sobczak P, Sikora A, Kuliczkowski W, Fabiszak T, Kubica A, Jilma B, Alexopoulos D, Navarese EP. Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. Eur Heart J Cardiovasc Pharmacother 2019;5:139-48. [PMID: 30689800 DOI: 10.1093/ehjcvp/pvz004] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 8.0] [Reference Citation Analysis]
159 Peng W, Shi X, Xu X, Lin Y. Both CYP2C19 and PON1 Q192R Genotypes Influence Platelet Response to Clopidogrel by Thrombelastography in Patients with Acute Coronary Syndrome. Cardiovasc Ther 2019;2019:3470145. [PMID: 31772608 DOI: 10.1155/2019/3470145] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
160 Uziębło-Życzkowska B, Krzesiński P, Maciorowska M, Gorczyca I, Jelonek O, Wójcik M, Błaszczyk R, Kapłon-Cieślicka A, Gawałko M, Tokarek T, Rajtar-Salwa R, Bil J, Wojewódzki M, Szpotowicz A, Krzciuk M, Bednarski J, Bakuła-Ostalska E, Tomaszuk-Kazberuk A, Szyszkowska A, Wełnicki M, Mamcarz A, Wożakowska-Kapłon B. Antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention, including compliance with current guidelines-data from the POLish Atrial Fibrillation (POL-AF) Registry. Cardiovasc Diagn Ther 2021;11:14-27. [PMID: 33708474 DOI: 10.21037/cdt-20-839] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
161 Verdoia M, Kedhi E, Suryapranata H, De Luca G. Ticagrelor in the prevention of coronary and non-coronary atherothrombotic events: A comprehensive meta-analysis of 10 randomized trials. Atherosclerosis 2019;284:136-47. [PMID: 30884417 DOI: 10.1016/j.atherosclerosis.2019.02.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
162 Sotomi Y, Hirata A, Amiya R, Kobayashi T, Hirayama A, Sakata Y, Higuchi Y. Bleeding Risk of Add-On Anti-Platelet Agents to Direct Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation (From 2216 Patients in the DIRECT Registry). The American Journal of Cardiology 2019;123:1293-300. [DOI: 10.1016/j.amjcard.2019.01.027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 4.5] [Reference Citation Analysis]
163 Choxi R, Pillai A, Ahmed S, Jovin IS. Use of Intravenous Cangrelor as Antiplatelet Bridge Therapy in a Patient Undergoing Esophageal Dilation Procedure. Cardiovasc Revasc Med 2020;21:94-5. [PMID: 31932170 DOI: 10.1016/j.carrev.2019.12.036] [Reference Citation Analysis]
164 Potter BJ, Andò G, Cimmino G, Ladeiras-Lopes R, Frikah Z, Chen XY, Virga V, Goncalves-Almeida J, Camm AJ, Fox KAA. Time trends in antithrombotic management of patients with atrial fibrillation treated with coronary stents: Results from TALENT-AF (The internAtionaL stENT - Atrial Fibrillation study) multicenter registry. Clin Cardiol 2018;41:470-5. [PMID: 29663443 DOI: 10.1002/clc.22898] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
165 Gill K, Servati N, Flahive J, Fraielli K. Safety and Efficacy of Triple Therapy With Ticagrelor or Prasugrel Versus Clopidogrel After Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. J Cardiovasc Pharmacol Ther 2021;:10742484211031436. [PMID: 34236915 DOI: 10.1177/10742484211031436] [Reference Citation Analysis]
166 Kim H, Lee SJ, Hong SJ, Shim CY, Ahn CM, Kim JS, Kim BK, Hong GR, Ko YG, Choi D, Jang Y, Hong MK. Clinical Outcomes of Transcatheter Aortic Valve Implantation for Native Aortic Valves in Patients with Low Coronary Heights. Yonsei Med J 2021;62:209-14. [PMID: 33635010 DOI: 10.3349/ymj.2021.62.3.209] [Reference Citation Analysis]
167 Gupta S, Belley-Côté EP, Rochwerg B, Bozzo A, Panchal P, Pandey A, Mbuagbaw L, Mehta S, Schwalm JD, Whitlock RP. Antiplatelet therapy and coronary artery bypass grafting: Protocol for a systematic review and network meta-analysis. Medicine (Baltimore) 2019;98:e16880. [PMID: 31441862 DOI: 10.1097/MD.0000000000016880] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
168 Natsuaki M, Morimoto T, Yamaji K, Watanabe H, Yoshikawa Y, Shiomi H, Nakagawa Y, Furukawa Y, Kadota K, Ando K, Akasaka T, Hanaoka KI, Kozuma K, Tanabe K, Morino Y, Muramatsu T, Kimura T; CREDO‐Kyoto PCI/CABG Registry Cohort 2, RESET, and NEXT trial investigators. Prediction of Thrombotic and Bleeding Events After Percutaneous Coronary Intervention: CREDO-Kyoto Thrombotic and Bleeding Risk Scores. J Am Heart Assoc 2018;7:e008708. [PMID: 29789335 DOI: 10.1161/JAHA.118.008708] [Cited by in Crossref: 55] [Cited by in F6Publishing: 8] [Article Influence: 18.3] [Reference Citation Analysis]
169 Schäfer A, Flierl U, Bauersachs J. Anti-thrombotic strategies in patients with atrial fibrillation undergoing PCI. Clin Res Cardiol 2021;110:759-74. [PMID: 32696081 DOI: 10.1007/s00392-020-01708-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
170 Cirillo P, Taglialatela V, Pellegrino G, Morello A, Conte S, Di Serafino L, Cimmino G. Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. J Thromb Thrombolysis 2020;50:468-72. [PMID: 32335777 DOI: 10.1007/s11239-020-02121-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
171 Park J, Choi EK, Han KD, Choi YJ, Lee E, Choe W, Lee SR, Cha MJ, Lim WH, Kang J, Park KW, Oh S, Lip GYH. Temporal trends in prevalence and antithrombotic treatment among Asians with atrial fibrillation undergoing percutaneous coronary intervention: A nationwide Korean population-based study. PLoS One 2019;14:e0209593. [PMID: 30645601 DOI: 10.1371/journal.pone.0209593] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
172 Lam ASM, Yan BPY, Lee VWY. Efficacy and safety comparing prasugrel/ticagrelor and clopidogrel in Hong Kong post-acute coronary syndrome patients-A 10-year cohort study. Clin Cardiol 2021;44:1072-9. [PMID: 34041774 DOI: 10.1002/clc.23653] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
173 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; STOPDAPT-2 Investigators. Effect of 1-Month Dual Antiplatelet Therapy Followed by Clopidogrel vs 12-Month Dual Antiplatelet Therapy on Cardiovascular and Bleeding Events in Patients Receiving PCI: The STOPDAPT-2 Randomized Clinical Trial. JAMA 2019;321:2414-27. [PMID: 31237644 DOI: 10.1001/jama.2019.8145] [Cited by in Crossref: 279] [Cited by in F6Publishing: 180] [Article Influence: 139.5] [Reference Citation Analysis]
174 Moriarty F, Barry A, Kenny RA, Fahey T. Aspirin prescribing for cardiovascular disease in middle-aged and older adults in Ireland: Findings from The Irish Longitudinal Study on Ageing. Prev Med 2021;147:106504. [PMID: 33667470 DOI: 10.1016/j.ypmed.2021.106504] [Reference Citation Analysis]
175 Schilling U, Dingemanse J, Dobrow M, Baumann M, Riederer MA, Juif PE, Ufer M. Insights from In Vitro and Clinical Data to Guide Transition from the Novel P2Y12 Antagonist Selatogrel to Clopidogrel, Prasugrel, and Ticagrelor. Thromb Haemost 2021;121:755-66. [PMID: 33412611 DOI: 10.1055/s-0040-1721773] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
176 NHFA CSANZ Atrial Fibrillation Guideline Working Group. Brieger D, Amerena J, Attia J, Bajorek B, Chan KH, Connell C, Freedman B, Ferguson C, Hall T, Haqqani H, Hendriks J, Hespe C, Hung J, Kalman JM, Sanders P, Worthington J, Yan TD, Zwar N. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand: Australian Clinical Guidelines for the Diagnosis and Management of Atrial Fibrillation 2018. Heart Lung Circ. 2018;27:1209-1266. [PMID: 30077228 DOI: 10.1016/j.hlc.2018.06.1043] [Cited by in Crossref: 108] [Cited by in F6Publishing: 76] [Article Influence: 54.0] [Reference Citation Analysis]
177 Steffel J, Collins R, Antz M, Cornu P, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Vanassche T, Potpara T, Camm AJ, Heidbüchel H, Lip GYH, Deneke T, Dagres N, Boriani G, Chao TF, Choi EK, Hills MT, Santos IS, Lane DA, Atar D, Joung B, Cole OM, Field M; External reviewers:. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace 2021:euab065. [PMID: 33895845 DOI: 10.1093/europace/euab065] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
178 Godier A, Fontana P, Motte S, Steib A, Bonhomme F, Schlumberger S, Lecompte T, Rosencher N, Susen S, Vincentelli A, Gruel Y, Albaladejo P, Collet JP; members of the French Working Group on perioperative haemostasis (GIHP). Management of antiplatelet therapy in patients undergoing elective invasive procedures. Proposals from the French Working Group on perioperative haemostasis (GIHP) and the French Study Group on thrombosis and haemostasis (GFHT). In collaboration with the French Society for Anaesthesia and Intensive Care Medicine (SFAR). Anaesth Crit Care Pain Med 2018;37:379-89. [PMID: 29309950 DOI: 10.1016/j.accpm.2017.12.012] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
179 Bianco M, Careggio A, Biolè CA, Quadri G, Quiros A, Raposeiras-Roubin S, Abu-Assi E, Kinnaird T, Ariza-Solè A, Liebetrau C, Manzano-Fernàndez S, Boccuzzi G, Henriques JPS, Spirito A, Templin C, Wilton SB, Velicki L, Correia L, Rognoni A, Ugo F, Nunez-Gil I, Fujii T, Durante A, Song X, Kawaji T, Alexopoulos D, Huczek Z, Gonzàlez Juanatey JR, Nie SP, Kawashiri MA, Morbiducci U, Dominguez-Rodriguez A, Destefanis P, Luciano A, De Ferrari GM, Varbella F, Montagna L, D'Ascenzo F, Cerrato E. Ticagrelor or Clopidogrel After an Acute Coronary Syndrome in the Elderly: A Propensity Score Matching Analysis from 16,653 Patients Treated with PCI Included in Two Large Multinational Registries. Cardiovasc Drugs Ther 2021. [PMID: 34224052 DOI: 10.1007/s10557-021-07213-y] [Reference Citation Analysis]
180 Long T, Peng L, Li F, Xia K, Jing R, Liu X, Xie Q, Yang T, Zhang C. Correlations of DAPT score and PRECISE-DAPT score with the extent of coronary stenosis in acute coronary syndrome. Medicine (Baltimore) 2018;97:e12531. [PMID: 30278543 DOI: 10.1097/MD.0000000000012531] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 3.7] [Reference Citation Analysis]
181 Wang X, Chen X, Sun W, Tian T, Zhou S, Zhang Z, Gao M, Qiao B, Zheng Y. Very Late Stent Thrombosis in Drug-Eluting Stents New Observations and Clinical Implications. Cardiology in Review 2019;27:279-85. [DOI: 10.1097/crd.0000000000000283] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
182 Lu W, Zhu Y, Han Z, Sun G, Qin X, Wang Z, Liu G, Xi W, Wang X, Pan L, Qiu C. Short-term outcomes from drug-coated balloon for coronary de novo lesions in large vessels. Journal of Cardiology 2019;73:151-5. [DOI: 10.1016/j.jjcc.2018.07.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
183 Fei Y, Lam CK, Cheung BMY. Efficacy and safety of newer P2Y12 inhibitors for acute coronary syndrome: a network meta-analysis. Sci Rep 2020;10:16794. [PMID: 33033323 DOI: 10.1038/s41598-020-73871-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
184 Rønning P, Helseth E, Skaansar O, Tverdal C, Andelic N, Bhatnagar R, Melberg M, Skaga NO, Aarhus M, Halvorsen S, Helseth R. Impact of Preinjury Antithrombotic Therapy on 30-Day Mortality in Older Patients Hospitalized With Traumatic Brain Injury (TBI). Front Neurol 2021;12:650695. [PMID: 34054695 DOI: 10.3389/fneur.2021.650695] [Reference Citation Analysis]
185 Janßen H, Dehne S, Giannitsis E, Weigand MA, Larmann J. Perioperative kardiovaskuläre Morbidität und Letalität bei nichtherzchirurgischen Eingriffen: Maßnahmen der optimalen anästhesiologischen Betreuung. Anaesthesist 2019;68:653-64. [DOI: 10.1007/s00101-019-0616-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
186 Tersalvi G, Biasco L, Cioffi GM, Pedrazzini G. Acute Coronary Syndrome, Antiplatelet Therapy, and Bleeding: A Clinical Perspective. J Clin Med 2020;9:E2064. [PMID: 32630233 DOI: 10.3390/jcm9072064] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
187 Barrios V, Almendro-Delia M, Facila L, Garcia-Moll X, Mazón P, Camafort M, Cepeda JM, Mediavilla Garcia JD, Pose Reino A, Suarez Fernandez C. Rivaroxaban: searching the integral vascular protection. Expert Rev Clin Pharmacol 2018;11:719-28. [PMID: 29965791 DOI: 10.1080/17512433.2018.1495559] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
188 Zhang J, Wang Z, Sang W, Wei M, Xu F, Chen Y. Omission of aspirin in patients taking oral anticoagulation after percutaneous coronary intervention: a systematic review and meta-analysis. Coron Artery Dis 2019;30:109-15. [PMID: 30629002 DOI: 10.1097/MCA.0000000000000698] [Reference Citation Analysis]
189 Chichareon P, Modolo R, Kerkmeijer L, Tomaniak M, Kogame N, Takahashi K, Chang CC, Komiyama H, Moccetti T, Talwar S, Colombo A, Maillard L, Barlis P, Wykrzykowska J, Piek JJ, Garg S, Hamm C, Steg PG, Jüni P, Valgimigli M, Windecker S, Onuma Y, Mehran R, Serruys PW. Association of Sex With Outcomes in Patients Undergoing Percutaneous Coronary Intervention: A Subgroup Analysis of the GLOBAL LEADERS Randomized Clinical Trial. JAMA Cardiol 2020;5:21-9. [PMID: 31693078 DOI: 10.1001/jamacardio.2019.4296] [Cited by in Crossref: 14] [Cited by in F6Publishing: 6] [Article Influence: 14.0] [Reference Citation Analysis]
190 Gargiulo G, Esposito G, Avvedimento M, Nagler M, Minuz P, Campo G, Gragnano F, Manavifar N, Piccolo R, Tebaldi M, Cirillo P, Hunziker L, Vranckx P, Leonardi S, Heg D, Windecker S, Valgimigli M. Cangrelor, Tirofiban, and Chewed or Standard Prasugrel Regimens in Patients With ST-Segment-Elevation Myocardial Infarction: Primary Results of the FABOLUS-FASTER Trial. Circulation 2020;142:441-54. [PMID: 32795098 DOI: 10.1161/CIRCULATIONAHA.120.046928] [Cited by in Crossref: 23] [Cited by in F6Publishing: 5] [Article Influence: 23.0] [Reference Citation Analysis]
191 López-Fernández T, Martín-García A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-Villanueva P, Escobar Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, Arrarte Esteban VI, Ayala de La Peña F, Castro Fernández A, García Pardo H, García-Sanz R, González Porras JR, López de Sá E, Lozano T, Marco Vera P, Martínez Marín V, Mesa Rubio D, Montero Á, Oristrell G, Pérez de Prado A, Velasco Del Castillo S, Virizuela Echaburu JA, Zatarain-Nicolás E, Anguita Sánchez M, Tamargo Menéndez J; Expert reviewers. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations. Rev Esp Cardiol (Engl Ed) 2019;72:749-59. [PMID: 31405794 DOI: 10.1016/j.rec.2019.03.019] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
192 Baumgartner H. The 2017 ESC/EACTS guidelines on the management of valvular heart disease : What is new and what has changed compared to the 2012 guidelines? Wien Klin Wochenschr 2018;130:168-71. [PMID: 29209824 DOI: 10.1007/s00508-017-1297-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
193 Li H, Wang Y, Li L, Dan B. Single- or dual-antiplatelet therapy after transcatheter aortic valve replacement: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e24550. [PMID: 33578550 DOI: 10.1097/MD.0000000000024550] [Reference Citation Analysis]
194 Stefanescu Schmidt AC, Steg PG, Yeh RW, Kereiakes DJ, Tanguay J, Hsieh W, Massaro JM, Mauri L, Cutlip DE. Interruption of Dual Antiplatelet Therapy Within Six Months After Coronary Stents (from the Dual Antiplatelet Therapy Study). The American Journal of Cardiology 2019;124:1813-20. [DOI: 10.1016/j.amjcard.2019.09.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
195 Bellis A, Di Gioia G, Mauro C, Mancusi C, Barbato E, Izzo R, Trimarco B, Morisco C. Reducing Cardiac Injury during ST-Elevation Myocardial Infarction: A Reasoned Approach to a Multitarget Therapeutic Strategy. J Clin Med 2021;10:2968. [PMID: 34279451 DOI: 10.3390/jcm10132968] [Reference Citation Analysis]
196 Choe JC, Cha KS, Lee JG, Kim J, Shin JY, Ahn J, Park JS, Lee HW, Oh J, Choi JH, Lee HC, Hong TJ, Jeong MH. Long-Term Outcomes of Biodegradable Versus Second-Generation Durable Polymer Drug-Eluting Stent Implantations for Myocardial Infarction. JACC: Cardiovascular Interventions 2020;13:97-111. [DOI: 10.1016/j.jcin.2019.08.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
197 Wang H, Song H, Yang Y, Wu Z, Hu R, Chen J, Guo J, Wang Y, Jia D, Cao S, Zhou Q, Guo R. Hemodynamic testing using three-dimensional printing and computational fluid dynamics preoperatively may provide more information in mitral repair than traditional image dataset. Ann Transl Med 2021;9:632. [PMID: 33987330 DOI: 10.21037/atm-20-7960] [Reference Citation Analysis]
198 Verdoia M, Pergolini P, Nardin M, Rolla R, Tonon F, Kedhi E, Suryapranata H, Carriero A, De Luca G; Novara Atherosclerosis Study Group (NAS). Impact of aging on platelet reactivity in diabetic patients receiving dual antiplatelet therapy. J Thromb Thrombolysis 2019;48:413-21. [PMID: 31065927 DOI: 10.1007/s11239-019-01873-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
199 Park YM, Park HW, Lee JM, Park J, Lee KH, Kim J, Lee YS, Joung B. 2018 Korean Heart Rhythm Society Guidelines for Non-Vitamin K Antagonist Oral Anticoagulants. Korean J Med 2019;94:57-82. [DOI: 10.3904/kjm.2019.94.1.57] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
200 Zanchin T, Temperli F, Karagiannis A, Zanchin C, Räsänen M, Koskinas KC, Stortecky S, Hunziker L, Praz F, Blöchlinger S, Moro C, Moschovitis A, Seiler C, Billinger M, Heg D, Pilgrim T, Valgimigli M, Windecker S, Räber L. Frequency, Reasons, and Impact of Premature Ticagrelor Discontinuation in Patients Undergoing Coronary Revascularization in Routine Clinical Practice: Results From the Bern Percutaneous Coronary Intervention Registry. Circ: Cardiovascular Interventions 2018;11. [DOI: 10.1161/circinterventions.117.006132] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 7.3] [Reference Citation Analysis]
201 Koh L, Kim JH, Tan SYD, Leong WQ, Syed SI, Leow KL, Wee WLE. Switching from Ticagrelor to Clopidogrel in Asian Patients with ST-Elevated Myocardial Infarction - A Time Dependent Analysis Study. Acta Cardiol Sin 2020;36:8-15. [PMID: 31903003 DOI: 10.6515/ACS.202001_36(1).20190627A] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
202 Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, Chae SC, Kim CJ, Cha KS, Park JS, Yoon JH, Chae JK, Joo SJ, Choi DJ, Hur SH, Seong IW, Cho MC, Kim DI, Oh SK, Ahn TH, Hwang JY. Dual antiplatelet therapy beyond 12 months versus for 12 months after drug-eluting stents for acute myocardial infarction. Journal of Cardiology 2020;75:66-73. [DOI: 10.1016/j.jjcc.2019.06.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
203 Dugani S, Ames JM, Manson JE, Mora S. Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. Curr Atheroscler Rep 2018;20. [DOI: 10.1007/s11883-018-0717-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
204 Cheng D, Zhao S, Hao Y. Net platelet clot strength of thromboelastography platelet mapping assay for the identification of high on-treatment platelet reactivity in post-PCI patients. Biosci Rep 2020;40:BSR20201346. [PMID: 32639536 DOI: 10.1042/BSR20201346] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
205 Williams B, Henderson RA, Reformato VS, Pham T, Taylor BS, Tanaka KA. Hemostasis Management of Patients Undergoing Emergency Cardiac Surgery After Ticagrelor Loading. Journal of Cardiothoracic and Vascular Anesthesia 2020;34:168-74. [DOI: 10.1053/j.jvca.2019.06.028] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
206 Alkhalil M. Mechanistic Insights to Target Atherosclerosis Residual Risk. Curr Probl Cardiol 2021;46:100432. [PMID: 31285037 DOI: 10.1016/j.cpcardiol.2019.06.004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 3.5] [Reference Citation Analysis]
207 Dillinger JG, Laine M, Bouajila S, Paganelli F, Henry P, Bonello L. Antithrombotic strategies in elderly patients with acute coronary syndrome. Arch Cardiovasc Dis 2021;114:232-45. [PMID: 33632631 DOI: 10.1016/j.acvd.2020.12.002] [Reference Citation Analysis]
208 Camera M, Brambilla M, Canzano P, Cavallotti L, Parolari A, Tedesco CC, Zara C, Rossetti L, Tremoli E. Association of Microvesicles With Graft Patency in Patients Undergoing CABG Surgery. J Am Coll Cardiol 2020;75:2819-32. [PMID: 32498810 DOI: 10.1016/j.jacc.2020.03.073] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
209 Spirito A, Gragnano F, Corpataux N, Vaisnora L, Galea R, Svab S, Gargiulo G, Siontis GCM, Praz F, Lanz J, Billinger M, Hunziker L, Stortecky S, Pilgrim T, Capodanno D, Urban P, Pocock S, Mehran R, Heg D, Windecker S, Räber L, Valgimigli M. Sex-Based Differences in Bleeding Risk After Percutaneous Coronary Intervention and Implications for the Academic Research Consortium High Bleeding Risk Criteria. J Am Heart Assoc 2021;10:e021965. [PMID: 34098740 DOI: 10.1161/JAHA.121.021965] [Reference Citation Analysis]
210 Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Endoscopy 2021;53:947-69. [PMID: 34359080 DOI: 10.1055/a-1547-2282] [Reference Citation Analysis]
211 Covic A, Genovesi S, Rossignol P, Kalra PA, Ortiz A, Banach M, Burlacu A. Practical issues in clinical scenarios involving CKD patients requiring antithrombotic therapy in light of the 2017 ESC guideline recommendations. BMC Med 2018;16:158. [PMID: 30227855 DOI: 10.1186/s12916-018-1145-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
212 Casadei B, Wijesurendra R. Atrial fibrillation after cardiac surgery: to screen or not to screen? Cardiovasc Res 2021;117:e21-3. [PMID: 33438019 DOI: 10.1093/cvr/cvaa352] [Reference Citation Analysis]
213 Jones DA, Wright P, Alizadeh MA, Fhadil S, Rathod KS, Guttmann O, Knight C, Timmis A, Baumbach A, Wragg A, Mathur A, Antoniou S. The use of novel oral anticoagulants compared to vitamin K antagonists (warfarin) in patients with left ventricular thrombus after acute myocardial infarction. European Heart Journal - Cardiovascular Pharmacotherapy 2021;7:398-404. [DOI: 10.1093/ehjcvp/pvaa096] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 18.0] [Reference Citation Analysis]
214 Patti G, Fattirolli F, De Luca L, Renda G, Marcucci R, Parodi G, Perna GP, Andreotti F, Ghiglieno C, Fedele F, Marchionni N. Updated antithrombotic strategies to reduce the burden of cardiovascular recurrences in patients with chronic coronary syndrome. Biomed Pharmacother 2021;140:111783. [PMID: 34102448 DOI: 10.1016/j.biopha.2021.111783] [Reference Citation Analysis]
215 Spinthakis N, Farag M, Rocca B, Gorog DA. More, More, More: Reducing Thrombosis in Acute Coronary Syndromes Beyond Dual Antiplatelet Therapy-Current Data and Future Directions. J Am Heart Assoc 2018;7:e007754. [PMID: 29374045 DOI: 10.1161/JAHA.117.007754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
216 Radmilovic J, Di Vilio A, D'Andrea A, Pastore F, Forni A, Desiderio A, Ragni M, Quaranta G, Cimmino G, Russo V, Scherillo M, Golino P. The Pharmacological Approach to Oncologic Patients with Acute Coronary Syndrome. J Clin Med 2020;9:E3926. [PMID: 33287336 DOI: 10.3390/jcm9123926] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
217 Xu K, Ye S, Zhang S, Yang M, Zhu T, Kong D, Chen J, Xu L, Li J, Zhu H, Wang F, Yang L, Zhang J, Fan Y, Ying L, Hu X, Zhang X, Chan NC, Li C. Impact of Platelet Endothelial Aggregation Receptor-1 Genotypes on Platelet Reactivity and Early Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention and Treated With Aspirin and Clopidogrel. Circ Cardiovasc Interv 2019;12:e007019. [PMID: 31018667 DOI: 10.1161/CIRCINTERVENTIONS.118.007019] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
218 Farmakis IT, Doundoulakis I, Zafeiropoulos S, Pagiantza A, Apostolidou-Kiouti F, Kourti O, Kassimis G, Haidich AB, Karvounis H, Giannakoulas G. Comparative efficacy and safety of oral P2Y12 inhibitors for patients with chronic kidney disease and acute coronary syndrome: a network meta-analysis. Hellenic J Cardiol 2021:S1109-9666(21)00144-5. [PMID: 34274518 DOI: 10.1016/j.hjc.2021.06.008] [Reference Citation Analysis]
219 Mohamed MO, Rashid M, Timmis A, Clarke S, Lawson C, Michos ED, Kwok CS, De Belder M, Valgimigli M, Mamas MA. Sex differences in distribution, management and outcomes of combined ischemic-bleeding risk following acute coronary syndrome. Int J Cardiol 2021;329:16-22. [PMID: 33388397 DOI: 10.1016/j.ijcard.2020.12.063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
220 Rozemeijer R, Stein M, Voskuil M, van den Bor R, Frambach P, Pereira B, Koudstaal S, Leenders GE, Timmers L, Rittersma SZ, Kraaijeveld AO, Agostoni P, Roes KC, Doevendans PA, Stella PR; For the ReCre8 Study Investigators. Randomized All-Comers Evaluation of a Permanent Polymer Zotarolimus-Eluting Stent Versus a Polymer-Free Amphilimus-Eluting Stent: Multicenter, Noninferiority Trial (ReCre8). Circulation 2019;139:67-77. [DOI: 10.1161/circulationaha.118.037707] [Cited by in Crossref: 17] [Cited by in F6Publishing: 2] [Article Influence: 8.5] [Reference Citation Analysis]
221 Lattuca B, Cayla G, Montalescot G. Can a stable coronary artery disease patient be at high ischaemic risk for scheduled non-cardiac surgery? Anaesth Crit Care Pain Med 2018;37:313-5. [PMID: 30055828 DOI: 10.1016/j.accpm.2018.07.003] [Reference Citation Analysis]
222 Savonitto S, Morici N, De Servi S. Antiplatelet therapy for elderly patients with Acute Coronary Syndromes. Aging (Albany NY) 2018;10:2220-1. [PMID: 30205362 DOI: 10.18632/aging.101553] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
223 Colombi D, Bodini FC, Bossalini M, Rossi B, Michieletti E. Extracranial Visceral Artery Aneurysms/Pseudoaneurysms Repaired with Flow Diverter Device Developed for Cerebral Aneurysms: Preliminary Results. Annals of Vascular Surgery 2018;53:272.e1-9. [DOI: 10.1016/j.avsg.2018.05.072] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
224 Aznaouridis K, Tselegkidi ME, Kanakakis I, Alexopoulos D. Dual Antithrombotic Therapy in Atrial Fibrillation Patients undergoing Percutaneous Coronary Angioplasty: The Impact of Bleeding Risk Score on Outcome. Thromb Haemost 2021;121:845-7. [PMID: 33378785 DOI: 10.1055/s-0040-1721777] [Reference Citation Analysis]
225 Qu J, Zhang H, Rao C, Chen S, Zhao Y, Sun H, Song Y, Liu S, Wang L, Feng W, Wang S, Hu S, Zheng Z. Dual Antiplatelet Therapy with Clopidogrel and Aspirin Versus Aspirin Monotherapy in Patients Undergoing Coronary Artery Bypass Graft Surgery. J Am Heart Assoc 2021;10:e020413. [PMID: 33998246 DOI: 10.1161/JAHA.120.020413] [Reference Citation Analysis]
226 Joung B, Lee JM, Lee KH, Kim TH, Choi EK, Lim WH, Kang KW, Shim J, Lim HE, Park J, Lee SR, Lee YS, Kim JB; KHRS Atrial Fibrillation Guideline Working Group. 2018 Korean Guideline of Atrial Fibrillation Management. Korean Circ J 2018;48:1033-80. [PMID: 30403013 DOI: 10.4070/kcj.2018.0339] [Cited by in Crossref: 60] [Cited by in F6Publishing: 38] [Article Influence: 20.0] [Reference Citation Analysis]
227 Kheiri B, Simpson TF, Stecker EC, Osman M, Rahmouni H, Zahr F, Nazer B, Cigarroa JE. Antithrombotic therapy for atrial fibrillation with stable coronary artery disease: a meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2020;50:395-8. [PMID: 31981041 DOI: 10.1007/s11239-020-02041-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
228 Laine M, Panagides V, Frère C, Cuisset T, Gouarne C, Jouve B, Lemesle G, Paganelli F, Alessi MC, Mancini J, Bonello L. On-Ticagrelor Platelet Reactivity and Clinical Outcome in Patients Undergoing Percutaneous Coronary Intervention for Acute Coronary Syndrome. Thromb Haemost 2021;121:923-30. [PMID: 33260230 DOI: 10.1055/a-1326-5110] [Reference Citation Analysis]
229 Paolisso P, Bergamaschi L, Saturi G, D'Angelo EC, Magnani I, Toniolo S, Stefanizzi A, Rinaldi A, Bartoli L, Angeli F, Donati F, Rucci P, Mattioli AV, Taglieri N, Pizzi C, Galiè N. Secondary Prevention Medical Therapy and Outcomes in Patients With Myocardial Infarction With Non-Obstructive Coronary Artery Disease. Front Pharmacol 2019;10:1606. [PMID: 32082147 DOI: 10.3389/fphar.2019.01606] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
230 Capodanno D, Huber K, Mehran R, Lip GY, Faxon DP, Granger CB, Vranckx P, Lopes RD, Montalescot G, Cannon CP, Ten Berg J, Gersh BJ, Bhatt DL, Angiolillo DJ. Management of Antithrombotic Therapy in Atrial Fibrillation Patients Undergoing PCI. Journal of the American College of Cardiology 2019;74:83-99. [DOI: 10.1016/j.jacc.2019.05.016] [Cited by in Crossref: 72] [Cited by in F6Publishing: 54] [Article Influence: 36.0] [Reference Citation Analysis]
231 Hideo-Kajita A, Rogers T, Buchanan K, Iantorno M, Gajanana D, Ozaki Y, Dan K, Kolm P, Brathwaite E, Beyene S, Melaku G, Meirovich Y, Dheendsa A, Garcia-Garcia HM, Torguson R, Waksman R. Effects of Cangrelor as Adjunct Therapy to Percutaneous Coronary Intervention. Am J Cardiol 2019;123:1228-38. [PMID: 30738570 DOI: 10.1016/j.amjcard.2019.01.031] [Reference Citation Analysis]
232 Kang J, Kim HS. The Evolving Concept of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: Focus on Unique Feature of East Asian and "Asian Paradox". Korean Circ J 2018;48:537-51. [PMID: 29968428 DOI: 10.4070/kcj.2018.0166] [Cited by in Crossref: 23] [Cited by in F6Publishing: 15] [Article Influence: 7.7] [Reference Citation Analysis]
233 Weissler EH, Aboyans V, Bauersachs R, Brodmann M, Nikol S, Debus S, Patel MR, Jones WS. The Role for Combined Antithrombotic Therapy With Platelet and Coagulation Inhibition After Lower Extremity Revascularization. JACC Cardiovasc Interv 2021;14:796-802. [PMID: 33826501 DOI: 10.1016/j.jcin.2021.01.035] [Reference Citation Analysis]
234 Casamira N, García-camarero T, Montoro-ronsano JB, Veiga G, Del Blanco BG, De La Torre JM, Gordon B, García-dorado D, Sambola A. Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. The American Journal of the Medical Sciences 2019;358:95-103. [DOI: 10.1016/j.amjms.2019.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
235 Schäfer A, Bauersachs J. Fokussiertes Update zur dualen Plättchenhemmung: ESC-Leitlinie 2017. Herz 2017;42:739-45. [DOI: 10.1007/s00059-017-4634-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
236 Godino C, Pivato CA, Rubino C, Russi A, Cera M, Margonato A. Antithrombotic Therapy After Percutaneous Coronary Intervention in Atrial Fibrillation. The American Journal of Cardiology 2020;129:122-4. [DOI: 10.1016/j.amjcard.2020.05.012] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
237 Kamel H, Hafez MS, Bastawy I. Telemedicine Improves the Short-Term Medical Care of Acute ST-Segment Elevation Myocardial Infarction After Primary Percutaneous Coronary Intervention. Front Cardiovasc Med 2021;8:693731. [PMID: 34322529 DOI: 10.3389/fcvm.2021.693731] [Reference Citation Analysis]
238 Lee CH, Franchi F, Angiolillo DJ. Clopidogrel drug interactions: a review of the evidence and clinical implications. Expert Opin Drug Metab Toxicol 2020;16:1079-96. [PMID: 32835535 DOI: 10.1080/17425255.2020.1814254] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
239 Kumsars I, Holm NR, Niemelä M, Erglis A, Kervinen K, Christiansen EH, Maeng M, Dombrovskis A, Abraitis V, Kibarskis A, Trovik T, Latkovskis G, Sondore D, Narbute I, Terkelsen CJ, Eskola M, Romppanen H, Laine M, Jensen LO, Pietila M, Gunnes P, Hebsgaard L, Frobert O, Calais F, Hartikainen J, Aarøe J, Ravkilde J, Engstrøm T, Steigen TK, Thuesen L, Lassen JF; Nordic Baltic bifurcation study group. Randomised comparison of provisional side branch stenting versus a two-stent strategy for treatment of true coronary bifurcation lesions involving a large side branch: the Nordic-Baltic Bifurcation Study IV. Open Heart 2020;7:e000947. [PMID: 32076558 DOI: 10.1136/openhrt-2018-000947] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
240 Vogel B, Claessen BE, Arnold SV, Chan D, Cohen DJ, Giannitsis E, Gibson CM, Goto S, Katus HA, Kerneis M, Kimura T, Kunadian V, Pinto DS, Shiomi H, Spertus JA, Steg PG, Mehran R. ST-segment elevation myocardial infarction. Nat Rev Dis Primers 2019;5:39. [PMID: 31171787 DOI: 10.1038/s41572-019-0090-3] [Cited by in Crossref: 50] [Cited by in F6Publishing: 40] [Article Influence: 25.0] [Reference Citation Analysis]
241 Saito Y, Kobayashi Y. Update on Antithrombotic Therapy after Percutaneous Coronary Intervention.Intern Med. 2020;59:311-321. [PMID: 31588089 DOI: 10.2169/internalmedicine.3685-3719] [Reference Citation Analysis]
242 Kawakami S, Yasuda S, Ogawa H. Antithrombotic therapy in atrial fibrillation patients with coronary artery disease: shifting paradigm to a "less is more" concept regimen. J Cardiol 2020;76:35-43. [PMID: 32389534 DOI: 10.1016/j.jjcc.2020.03.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
243 Ferlini M, Mauri S, Rossini R. Dual antiplatelet therapy after TAVR: A drop in the bucket? Int J Cardiol 2019;280:46-8. [PMID: 30700383 DOI: 10.1016/j.ijcard.2019.01.069] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
244 Yeh RW, Mihatov N. The DAPT Score Uncouples Bleeding and Ischemic Risk…Again. JACC Cardiovasc Interv 2020;13:647-50. [PMID: 32139223 DOI: 10.1016/j.jcin.2020.01.211] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
245 Shoji S, Kuno T, Fujisaki T, Takagi H, Briasoulis A, Deharo P, Cuisset T, Latib A, Kohsaka S. De-Escalation of Dual Antiplatelet Therapy in Patients With Acute Coronary Syndromes. J Am Coll Cardiol 2021;78:763-77. [PMID: 34275697 DOI: 10.1016/j.jacc.2021.06.012] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
246 Das D, Asher A, Ghosh AK. Cancer and Coronary Artery Disease: Common Associations, Diagnosis and Management Challenges. Curr Treat Options in Oncol 2019;20. [DOI: 10.1007/s11864-019-0644-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
247 Hall TS, Atar D. The Times They Are A-Changin´: Antithrombotic strategies in patients with acute coronary syndrome undergoing coronary stenting who have concomitant atrial fibrillation. Eur J Intern Med 2021;88:21-2. [PMID: 33934970 DOI: 10.1016/j.ejim.2021.04.008] [Reference Citation Analysis]
248 Gelbenegger G, Schoergenhofer C, Jilma B, Gager GM, Dizdarevic AM, Mamas MA, Parapid B, Velagapudi P, Siller-Matula JM. Efficacy and Safety of Ticagrelor Monotherapy in Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis. Clin Pharmacol Ther 2021;110:424-31. [PMID: 33668076 DOI: 10.1002/cpt.2226] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
249 Hoedemaker NPG, Damman P, Ottervanger JP, Dambrink JHE, Gosselink ATM, Kedhi E, Kolkman E, de Winter RJ, van 't Hof AWJ. Trends in cardiovascular and bleeding outcomes in acute coronary syndrome patients treated with or without proton-pump inhibitors during the introduction of novel P2Y12 inhibitors: a five-year experience from a single-centre observational registry. European Heart Journal - Cardiovascular Pharmacotherapy 2019;5:127-38. [DOI: 10.1093/ehjcvp/pvy030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
250 Cimminiello C, Dondi L, Pedrini A, Ronconi G, Calabria S, Piccinni C, Polo Friz H, Martini N, Maggioni AP. Patterns of treatment with antiplatelet therapy after an acute coronary syndrome: Data from a large database in a community setting. Eur J Prev Cardiol 2019;26:836-46. [PMID: 30477319 DOI: 10.1177/2047487318814970] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
251 Li J, Qiu H, Yan L, Guo T, Wang Y, Li Y, Zheng J, Tang Y, Xu B, Qiao S, Yang Y, Gao R. Efficacy and Safety of Ticagrelor and Clopidogrel in Patients with Stable Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. J Atheroscler Thromb 2021;28:873-82. [PMID: 32908113 DOI: 10.5551/jat.57265] [Reference Citation Analysis]
252 Zheng Y, Wu T, Yang Y, Hou X, Gao Y, Chen Y, Yang Y, Li X, Ma X, Ma Y, Xie X. Personalized antiplatelet therapy guided by a novel detection of platelet aggregation function in stable coronary artery disease patients undergoing percutaneous coronary intervention: a randomized controlled clinical trial. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:211-21. [DOI: 10.1093/ehjcvp/pvz059] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
253 Li H, Guo W, Dai W, Li L. Short-versus long-term dual antiplatelet therapy after second-generation drug-eluting stent implantation: a systematic review and meta-analysis of randomized controlled trials. Drug Des Devel Ther 2018;12:1815-25. [PMID: 29970956 DOI: 10.2147/DDDT.S165435] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
254 Genz C, Braun-Dullaeus RC. Inhibition of Platelet Aggregation After Coronary Stenting in Patients Receiving Oral Anticoagulation. Dtsch Arztebl Int 2021;118:arztebl. [PMID: 33637173 DOI: 10.3238/arztebl.m2021.0150] [Reference Citation Analysis]
255 Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, Chae SC, Kim CJ, Cha KS, Park JS, Yoon JH, Chae JK, Joo SJ, Choi DJ, Hur SH, Seong IW, Cho MC, Kim DI, Oh SK, Ahn TH, Hwang JY; KAMIR-NIH Registry Investigators. Association of potent P2Y12 blockers with ischemic and bleeding outcomes in non-ST-segment elevation myocardial infarction. J Cardiol 2019;73:142-50. [PMID: 30509351 DOI: 10.1016/j.jjcc.2018.09.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
256 Forné C, Subirana I, Blanch J, Ferrieres J, Azevedo A, Meisinger C, Farmakis D, Tavazzi L, Davoli M, Ramos R, Brosa M, Marrugat J, Dégano IR; EUROTRACS Investigators. A cost-utility analysis of increasing percutaneous coronary intervention use in elderly patients with acute coronary syndromes in six European countries. Eur J Prev Cardiol 2021;28:408-17. [PMID: 33966078 DOI: 10.1177/2047487320942644] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
257 Limeres J, Lip GY, del Blanco BG, Ferreira-gonzález I, Mutuberria M, Alfonso F, Bueno H, Cequier A, Prendergast B, Zueco J, Rodríguez-leor O, Barrabés JA, García-dorado D, Sambola A. Safety of drug-eluting stents compared to bare metal stents in patients with an indication for long-term oral anticoagulation: A propensity score matched analysis. Thrombosis Research 2019;177:180-6. [DOI: 10.1016/j.thromres.2019.02.021] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
258 Kumar A, Shariff M, Doshi R, Vaz IP. Abbreviated Dual Antiplatelet Therapy Followed by P2Y12 Inhibitor Monotherapy versus 12 Months' Dual Antiplatelet Therapy Post Percutaneous Coronary Intervention: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Cardiovasc Drugs 2020;20:355-61. [PMID: 31784888 DOI: 10.1007/s40256-019-00390-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Butler J, Khan MS, Anker SD. Novel potassium binders as enabling therapy in heart failure. Eur J Heart Fail 2019;21:550-2. [DOI: 10.1002/ejhf.1474] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
260 Iida O, Takahara M, Soga Y, Yamaoka T, Nanto S, Kuratani T, Sakata Y, Mano T. One-Year Outcomes of Heparin-Bonded Stent-Graft Therapy for Real-World Femoropopliteal Lesions and the Association of Patency With the Prothrombotic State Based on the Prospective, Observational, Multicenter V i a bahn Ste n t-Graft Placement for Femoropopliteal Diseases Re qui ring Endova s cular T h erapy (VANQUISH) Study. J Endovasc Ther 2021;28:123-31. [DOI: 10.1177/1526602820960445] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
261 Adamski P, Adamska U, Ostrowska M, Navarese EP, Kubica J. Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. Expert Opin Pharmacother 2018;19:1415-25. [PMID: 30132731 DOI: 10.1080/14656566.2018.1510487] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.7] [Reference Citation Analysis]
262 Garcia-Guimarães M, Bastante T, Antuña P, Jimenez C, de la Cuerda F, Cuesta J, Rivero F, Premawardhana D, Adlam D, Alfonso F. Spontaneous Coronary Artery Dissection: Mechanisms, Diagnosis and Management. Eur Cardiol 2020;15:1-8. [PMID: 32256714 DOI: 10.15420/ecr.2019.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 10.0] [Reference Citation Analysis]
263 Hautamäki M, Lyytikäinen LP, Eskola M, Lehtimäki T, Nikus K, Oksala N, Tynkkynen J, Hernesniemi J. Prehospital Adenosine Diphosphate Receptor Blocker Use, Culprit Artery Flow, and Mortality in STEMI: The MADDEC Study. Clin Drug Investig 2021;41:605-13. [PMID: 34101137 DOI: 10.1007/s40261-021-01045-2] [Reference Citation Analysis]
264 Gargiulo G, Valgimigli M. Antithrombotic therapy after transcatheter aortic valve implantation: a new piece of the still unresolved puzzle. J Thorac Dis 2017;9:4260-5. [PMID: 29268486 DOI: 10.21037/jtd.2017.10.28] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
265 Baldi C, Silverio A, Esposito L, Di Maio M, Tarantino F, De Angelis E, Fierro G, Attisano T, Di Muro MR, Maione A, Pierri A, Vigorito F, Vecchione C, Galasso G. Clinical outcome of patients with ST-elevation myocardial infarction and angiographic evidence of coronary artery ectasia. Catheter Cardiovasc Interv 2021. [PMID: 33949766 DOI: 10.1002/ccd.29738] [Reference Citation Analysis]
266 Yan H, Tiemuerniyazi X, Song Y, Xu F, Feng W. Comparison of dual antiplatelet therapies after coronary endarterectomy combined with coronary artery bypass grafting: a cohort study. J Cardiothorac Surg 2020;15:155. [PMID: 32600365 DOI: 10.1186/s13019-020-01205-z] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Bryniarski L, Opolski MP, Wójcik J, Lesiak M, Pawłowski T, Drozd J, Wojakowski W, Surowiec S, Dąbrowski M, Witkowski A, Dudek D, Grygier M, Bartuś S. Chronic total occlusion percutaneous coronary intervention in everyday clinical practice - an expert opinion of the Association of Cardiovascular Interventions of the Polish Cardiac Society. Postepy Kardiol Interwencyjnej 2021;17:6-20. [PMID: 33868413 DOI: 10.5114/aic.2021.104763] [Reference Citation Analysis]
268 Calabrò P, Niccoli G, Gragnano F, Grove EL, Vergallo R, Mikhailidis DP, Patti G, Spaccarotella C, Katsiki N, Masiero G, Ueshima D, Pinar E, Chieffo A, Ussia GP, Eitel I, Tarantini G; Working Group of Interventional Cardiology of the Italian Society of Cardiology. Are we ready for a gender-specific approach in interventional cardiology? Int J Cardiol 2019;286:226-33. [PMID: 30449695 DOI: 10.1016/j.ijcard.2018.11.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
269 Revol B, Jullian-desayes I, Tamisier R, Puel V, Mallaret M, Joyeux-faure M, Pépin J. Ticagrelor and Central Sleep Apnea. Journal of the American College of Cardiology 2018;71:2378-9. [DOI: 10.1016/j.jacc.2018.03.447] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 4.7] [Reference Citation Analysis]
270 Faria D, Santos M, Baptista SB, Ferreira J, Leal P, Abreu PFE, Morais C. Eligibility for extended antithrombotic therapy for secondary prevention of acute coronary syndrome. Revista Portuguesa de Cardiologia 2020;39:493-501. [DOI: 10.1016/j.repc.2020.02.012] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
271 Cordero A, Ferreiro JL, Bertomeu-González V, Rodríguez-Mañero M, Fácila L, Escribano D, Sanchez-Recalde A, Zuazola P, Ruiz-Nodar JM, González-Juanatey JR. Direct Oral Anticoagulants Versus Vitamin-K Antagonist After PCIs in Patients With AF: A Meta-analysis of Cardiac Ischemic Events. J Cardiovasc Pharmacol 2021;77:164-9. [PMID: 33351537 DOI: 10.1097/FJC.0000000000000938] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
272 Saito Y, Kobayashi Y, Tanabe K, Ikari Y. Antithrombotic therapy after percutaneous coronary intervention from the Japanese perspective. Cardiovasc Interv and Ther 2020;35:19-29. [DOI: 10.1007/s12928-019-00633-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
273 Lee SH, Cho HM, Jung SM, Choi JH, Chon MK, Hwang KW, Kim JS, Park YH, Kim JH, Chun KJ, Yeo HJ, Lee SG, Kim DH, Lee SY. Heart-lung transplantation for refractory diffuse alveolar hemorrhage supported by prolonged extracorporeal membrane oxygenation after cardiogenic shock from ST segment elevation myocardial infarction: a case report. Perfusion 2020;35:870-4. [PMID: 32308141 DOI: 10.1177/0267659120915396] [Reference Citation Analysis]
274 Verdoia M, Camaro C, Kedhi E, Marcolongo M, Suryapranata H, De Luca G. Dual Antiplatelet Therapy Duration in Acute Coronary Syndrome Patients: The State of the Art and Open Issues. Cardiovasc Ther 2020;2020:6495036. [PMID: 32328172 DOI: 10.1155/2020/6495036] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
275 Patti G. Patients with atrial fibrillation and coronary events: are we any closer to coming out from the labyrinth of the various antithrombotic strategies? Heart. 2018;104:878-879. [PMID: 29175977 DOI: 10.1136/heartjnl-2017-312576] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
276 Kedhi E, Verdoia M, Suryapranata H, Damen S, Camaro C, Benit E, Barbieri L, Rasoul S, Liew HB, Polad J, Ahmad WA, Zambahari R, Lalmand J, van der Schaaf RJ, Koh TH, Timmermans P Sr, Dilling-Boer D, Veenstra LF, Van' T Hof AW, Lee SW, Roolvink V, Ligtenberg E, Postma S, Kolkman EJ, Brouwer MA, Dudek D, De Luca G. Impact of age on the comparison between short-term vs 12-month dual antiplatelet therapy in patients with acute coronary syndrome treated with the COMBO dual therapy stent: 2-Year follow-up results of the REDUCE trial. Atherosclerosis 2021;321:39-44. [PMID: 33639478 DOI: 10.1016/j.atherosclerosis.2021.02.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
277 Mavrakanas TA, Chatzizisis YS, Gariani K, Kereiakes DJ, Gargiulo G, Helft G, Gilard M, Feres F, Costa RA, Morice MC, Georges JL, Valgimigli M, Bhatt DL, Mauri L, Charytan DM. Duration of Dual Antiplatelet Therapy in Patients with CKD and Drug-Eluting Stents: A Meta-Analysis. Clin J Am Soc Nephrol 2019;14:810-22. [PMID: 31010936 DOI: 10.2215/CJN.12901018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
278 Vivas D, Roldán I, Ferrandis R, Marín F, Roldán V, Tello-montoliu A, Ruiz-nodar JM, Gómez-doblas JJ, Martín A, Llau JV, Ramos-gallo MJ, Muñoz R, Arcelus JI, Leyva F, Alberca F, Oliva R, Gómez AM, Montero C, Arikan F, Ley L, Santos-bueso E, Figuero E, Bujaldón A, Urbano J, Otero R, Hermida JF, Egocheaga I, Llisterri JL, Lobos JM, Serrano A, Madridano O, Ferreiro JL, Cassinello C, Gómez-luque A, Hidalgo F, Sierra P, Marco Vera P, Mateo Arranz J, Palomo V, Guerrero A, Anguita M, Íñiguez A. Manejo perioperatorio y periprocedimiento del tratamiento antitrombótico: documento de consenso de SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEI, SECOT y AEU. Revista Española de Cardiología 2018;71:553-64. [DOI: 10.1016/j.recesp.2018.01.001] [Cited by in Crossref: 74] [Cited by in F6Publishing: 16] [Article Influence: 24.7] [Reference Citation Analysis]
279 Burri H, Starck C, Auricchio A, Biffi M, Burri M, D'Avila A, Deharo JC, Glikson M, Israel C, Lau CP, Leclercq C, Love CJ, Nielsen JC, Vernooy K, Dagres N, Boveda S, Butter C, Marijon E, Braunschweig F, Mairesse GH, Gleva M, Defaye P, Zanon F, Lopez-Cabanillas N, Guerra JM, Vassilikos VP, Martins Oliveira M; Reviewers:. EHRA expert consensus statement and practical guide on optimal implantation technique for conventional pacemakers and implantable cardioverter-defibrillators: endorsed by the Heart Rhythm Society (HRS), the Asia Pacific Heart Rhythm Society (APHRS), and the Latin-American Heart Rhythm Society (LAHRS). Europace 2021;23:983-1008. [PMID: 33878762 DOI: 10.1093/europace/euaa367] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 7.0] [Reference Citation Analysis]
280 Lip GY, Mauri L, Montalescot G, Ozkor M, Vardas P, Steg PG, Bhatt DL, Hohnloser SH, Miede C, Nordaby M, Brueckmann M, Kreuzer J, Kimura T, Oldgren J, ten Berg JM, Cannon CP. Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after percutaneous coronary intervention: An ancillary analysis from the RE-DUAL PCI trial. American Heart Journal 2019;212:13-22. [DOI: 10.1016/j.ahj.2019.02.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
281 Guedeney P, Sorrentino S, Claessen B, Mehran R. The link between anemia and adverse outcomes in patients with acute coronary syndrome. Expert Review of Cardiovascular Therapy 2018;17:151-9. [DOI: 10.1080/14779072.2019.1575729] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
282 Haller PM, Sulzgruber P, Kaufmann C, Geelhoed B, Tamargo J, Wassmann S, Schnabel RB, Westermann D, Huber K, Niessner A, Gremmel T. Bleeding and ischaemic outcomes in patients treated with dual or triple antithrombotic therapy: systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy 2019;5:226-36. [DOI: 10.1093/ehjcvp/pvz021] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 9.0] [Reference Citation Analysis]
283 Harris DE, Lacey A, Akbari A, Obaid DR, Smith DA, Jenkins GH, Barry JP, Gravenor MB, Halcox JP. Early Discontinuation of P2Y12 Antagonists and Adverse Clinical Events Post-Percutaneous Coronary Intervention: A Hospital and Primary Care Linked Cohort. J Am Heart Assoc 2019;8:e012812. [PMID: 31658860 DOI: 10.1161/JAHA.119.012812] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
284 Ueki Y, Vögeli B, Karagiannis A, Zanchin T, Zanchin C, Rhyner D, Otsuka T, Praz F, Siontis GCM, Moro C, Stortecky S, Billinger M, Valgimigli M, Pilgrim T, Windecker S, Suter T, Räber L. Ischemia and Bleeding in Cancer Patients Undergoing Percutaneous Coronary Intervention. JACC CardioOncol 2019;1:145-55. [PMID: 34396175 DOI: 10.1016/j.jaccao.2019.11.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
285 Zhao X, Li Q, Tu C, Zeng Y, Ye Y. High glycated albumin is an independent predictor of low response to clopidogrel in ACS patients: a cross-sectional study. Cardiovasc Diabetol 2020;19:171. [PMID: 33036613 DOI: 10.1186/s12933-020-01146-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
286 Verheugt FW, Ambrosio G, Atar D, Bassand J, Camm AJ, Costabel JP, Fitzmaurice DA, Illingworth L, Goldhaber SZ, Goto S, Haas S, Jansky P, Kayani G, Stepinska J, Turpie AG, van Eickels M, Kakkar AK. Outcomes in Newly Diagnosed Atrial Fibrillation and History of Acute Coronary Syndromes: Insights from GARFIELD-AF. The American Journal of Medicine 2019;132:1431-1440.e7. [DOI: 10.1016/j.amjmed.2019.06.008] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
287 Zhang WJ, Qiao X, Liang XY, Li Y, Yang RR, Wang ZL. Efficacy and safety of short-term 1-3 months versus standard 12 months dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: a meta-analysis of randomized clinical trials. Platelets 2021;32:582-90. [PMID: 32627616 DOI: 10.1080/09537104.2020.1786039] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
288 Vranckx P, Valgimigli M, Eckardt L, Tijssen J, Lewalter T, Gargiulo G, Batushkin V, Campo G, Lysak Z, Vakaliuk I, Milewski K, Laeis P, Reimitz P, Smolnik R, Zierhut W, Goette A. Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. The Lancet 2019;394:1335-43. [DOI: 10.1016/s0140-6736(19)31872-0] [Cited by in Crossref: 243] [Cited by in F6Publishing: 56] [Article Influence: 121.5] [Reference Citation Analysis]
289 Reiner Benaim A, Almog R, Gorelik Y, Hochberg I, Nassar L, Mashiach T, Khamaisi M, Lurie Y, Azzam ZS, Khoury J, Kurnik D, Beyar R. Analyzing Medical Research Results Based on Synthetic Data and Their Relation to Real Data Results: Systematic Comparison From Five Observational Studies. JMIR Med Inform 2020;8:e16492. [PMID: 32130148 DOI: 10.2196/16492] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 18.0] [Reference Citation Analysis]
290 Riva L, Ageno W, Di Pasquale G, Agnelli G, Rubboli A. Antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent: The case of venous thromboembolism. International Journal of Cardiology 2018;269:75-9. [DOI: 10.1016/j.ijcard.2018.07.133] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
291 Yerasi C, Case BC, Forrestal BJ, Torguson R, Weintraub WS, Garcia-garcia HM, Waksman R. Optimizing Monotherapy Selection, Aspirin Versus P2Y12 Inhibitors, Following Percutaneous Coronary Intervention. The American Journal of Cardiology 2020;135:154-65. [DOI: 10.1016/j.amjcard.2020.07.061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
292 Ten Berg J, Sibbing D, Rocca B, Van Belle E, Chevalier B, Collet JP, Dudek D, Gilard M, Gorog DA, Grapsa J, Grove EL, Lancellotti P, Petronio AS, Rubboli A, Torracca L, Vilahur G, Witkowski A, Mehilli J. Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. Eur Heart J 2021;42:2265-9. [PMID: 33822924 DOI: 10.1093/eurheartj/ehab196] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
293 Gąsecka A, Rogula S, Eyileten C, Postuła M, Jaguszewski MJ, Kochman J, Mazurek T, Nieuwland R, Filipiak KJ. Role of P2Y Receptors in Platelet Extracellular Vesicle Release. Int J Mol Sci 2020;21:E6065. [PMID: 32842470 DOI: 10.3390/ijms21176065] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
294 Caldeira D, Pereira H, Marques A, Alegria S, Calisto J, Silva PCD, Ribeiro VG, Silva JC, Seixo F, Abreu PFE, Teles RC, Fernandes R, Carvalho HC; investigators of the Portuguese Registry of Acute Coronary Syndromes (ProACS), investigators of the Portuguese Registry on Interventional Cardiology (PRIC). Adjuvant antithrombotic therapy in ST-elevation myocardial infarction: Contemporaneous Portuguese cross-sectional data. Rev Port Cardiol (Engl Ed) 2019;38:809-14. [PMID: 32007322 DOI: 10.1016/j.repc.2019.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
295 Warlo EMK, Arnesen H, Seljeflot I. A brief review on resistance to P2Y12 receptor antagonism in coronary artery disease. Thromb J 2019;17:11. [PMID: 31198410 DOI: 10.1186/s12959-019-0197-5] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 8.0] [Reference Citation Analysis]
296 Zhang ZZ, Zhang SZ, Zhou HM, Fan YQ, Liu MH, Zhong XB, Yang DY, Guo Y, Zhuang XD, Liao XX. A systematic review of guidelines for dual antiplatelet therapy in coronary artery bypass graft. Eur J Clin Invest 2021;51:e13405. [PMID: 32926588 DOI: 10.1111/eci.13405] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
297 Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, Cosín-Sales J, Gámez JM, Consuegra L, Ferreiro JL, Marín F; Revisores expertos. [Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology]. Rev Esp Cardiol 2020;73:749-57. [PMID: 32327870 DOI: 10.1016/j.recesp.2020.04.006] [Cited by in Crossref: 52] [Cited by in F6Publishing: 29] [Article Influence: 52.0] [Reference Citation Analysis]
298 Li J, Sheng Z, Tan Y, Liu C, Zhou P, Zhou J, Chen R, Chen Y, Song L, Zhao H, Yan H. Combined with ticagrelor, 50 mg aspirin daily can reduce bleeding events without increasing ischemic risk compared with 75–100 mg aspirin daily in coronary artery disease patients: insights from the TIFU (Ticagrelor in Fuwai Hospital) study. Platelets 2020;31:788-94. [DOI: 10.1080/09537104.2019.1680825] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
299 Jacobs MS, Tieleman RG. Optimal antithrombotic treatment of patients with atrial fibrillation undergoing percutaneous coronary intervention: triple therapy is too much! Neth Heart J 2018;26:334-40. [PMID: 29740755 DOI: 10.1007/s12471-018-1120-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
300 Zhu H, Xu X, Fang X, Ying F, Song L, Gao B, Tong G, Zhou L, Chen T, Huang J. Efficacy and Safety of Long-Term Antithrombotic Strategies in Patients With Chronic Coronary Syndrome: A Network Meta-analysis of Randomized Controlled Trials. J Am Heart Assoc 2021;10:e019184. [PMID: 33682435 DOI: 10.1161/JAHA.120.019184] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
301 Burlacu A, Genovesi S, Ortiz A, Combe C, Basile C, Schneditz D, van der Sande F, Popa GT, Morosanu C, Covic A. Pros and cons of antithrombotic therapy in end-stage kidney disease: a 2019 update. Nephrol Dial Transplant 2019;34:923-33. [PMID: 30879070 DOI: 10.1093/ndt/gfz040] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 13.0] [Reference Citation Analysis]
302 Schreuder MM, Badal R, Boersma E, Kavousi M, Roos-Hesselink J, Versmissen J, Visser LE, Roeters van Lennep JE. Efficacy and Safety of High Potent P2Y12 Inhibitors Prasugrel and Ticagrelor in Patients With Coronary Heart Disease Treated With Dual Antiplatelet Therapy: A Sex-Specific Systematic Review and Meta-Analysis. J Am Heart Assoc 2020;9:e014457. [PMID: 32063118 DOI: 10.1161/JAHA.119.014457] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
303 Lindholm D, Sarno G, Erlinge D, Svennblad B, Hasvold LP, Janzon M, Jernberg T, James SK. Combined association of key risk factors on ischaemic outcomes and bleeding in patients with myocardial infarction. Heart 2019;105:1175-81. [PMID: 31055499 DOI: 10.1136/heartjnl-2018-314590] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Vrkić Kirhmajer M, Macolić Šarinić V, Šimičević L, Ladić I, Putarek K, Banfić L, Božina N. Rosuvastatin-Induced Rhabdomyolysis - Possible Role of Ticagrelor and Patients' Pharmacogenetic Profile. Basic Clin Pharmacol Toxicol 2018;123:509-18. [PMID: 29734517 DOI: 10.1111/bcpt.13035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
305 Ahrens I, Averkov O, Zúñiga EC, Fong AYY, Alhabib KF, Halvorsen S, Abdul Kader MABSK, Sanz-Ruiz R, Welsh R, Yan H, Aylward P. Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox. Clin Cardiol 2019;42:1028-40. [PMID: 31317575 DOI: 10.1002/clc.23232] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
306 Cha JJ, Park JH, Joo HJ, Hong SJ, Ahn TH, Kim BK, Shin W, Ahn SG, Yoon J, Kim YH, Cho YH, Kang WC, Kim W, Lim YH, Gwon HC, Choi WG, Lim DS. Impact of genetic variants on clinical outcome after percutaneous coronary intervention in elderly patients. Aging (Albany NY) 2021;13:6506-24. [PMID: 33707344 DOI: 10.18632/aging.202799] [Reference Citation Analysis]
307 Oana Darabont R, Stoicescu C, Tiu C. Therapeutic Challenges in Patients With Noncardioembolic Acute Ischemic Stroke in Need of Double Antiplatelet Therapy for Coronary Artery Disease. American Journal of Therapeutics 2019;26:e213-21. [DOI: 10.1097/mjt.0000000000000924] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
308 Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Suzuki S, Yamamoto E, Soejimaa H, Matsushita K, Tsujita K. Hemodialysis-related low thrombogenicity measured by total thrombus-formation analysis system in patients undergoing percutaneous coronary intervention. Thromb Res 2021;200:141-8. [PMID: 33610886 DOI: 10.1016/j.thromres.2021.02.004] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
309 Loganath K, Adamson PD, Moss AJ. Ticagrelor in the management of coronary artery disease. Future Cardiol 2021;17:561-71. [PMID: 32960097 DOI: 10.2217/fca-2020-0108] [Reference Citation Analysis]
310 Kupó P, Tornyos D, Bálint A, Lukács R, Jánosi A, Komócsi A. Use of drug-eluting stents in elderly patients with acute myocardial infarction: An analysis of the Hungarian Myocardial Infarction Registry. Int J Clin Pract 2021;75:e13652. [PMID: 32851755 DOI: 10.1111/ijcp.13652] [Reference Citation Analysis]
311 Rakic M, Persic V, Kehler T, Bastiancic AL, Rosovic I, Laskarin G, Sotosek Tokmadzic V. Possible role of circulating endothelial cells in patients after acute myocardial infarction. Med Hypotheses 2018;117:42-6. [PMID: 30077195 DOI: 10.1016/j.mehy.2018.06.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
312 Cohen M, Visveswaran G. Defining and managing patients with non-ST-elevation myocardial infarction: Sorting through type 1 vs other types. Clin Cardiol 2020;43:242-50. [PMID: 31923336 DOI: 10.1002/clc.23308] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
313 Patti G, Micieli G, Cimminiello C, Bolognese L. The Role of Clopidogrel in 2020: A Reappraisal. Cardiovasc Ther 2020;2020:8703627. [PMID: 32284734 DOI: 10.1155/2020/8703627] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 14.0] [Reference Citation Analysis]
314 Storey RF, Gurbel PA, Ten Berg J, Bernaud C, Dangas GD, Frenoux JM, Gorog DA, Hmissi A, Kunadian V, James SK, Tanguay JF, Tran H, Trenk D, Ufer M, Van der Harst P, Van't Hof AWJ, Angiolillo DJ. Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. Eur Heart J 2020;41:3132-40. [PMID: 31994703 DOI: 10.1093/eurheartj/ehz807] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 19.0] [Reference Citation Analysis]
315 D'Ascenzo F, De Filippo O, Gallone G, Mittone G, Deriu MA, Iannaccone M, Ariza-Solé A, Liebetrau C, Manzano-Fernández S, Quadri G, Kinnaird T, Campo G, Simao Henriques JP, Hughes JM, Dominguez-Rodriguez A, Aldinucci M, Morbiducci U, Patti G, Raposeiras-Roubin S, Abu-Assi E, De Ferrari GM; PRAISE study group. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet 2021;397:199-207. [PMID: 33453782 DOI: 10.1016/S0140-6736(20)32519-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 3] [Article Influence: 15.0] [Reference Citation Analysis]
316 Kamran H, Jneid H, Kayani WT, Virani SS, Levine GN, Nambi V, Khalid U. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review. JAMA 2021;325:1545-55. [PMID: 33877270 DOI: 10.1001/jama.2021.0716] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
317 Fernando H, Shaw JA, Myles PS, Peter K, Stub D. The opioid-P2Y12 inhibitor interaction: Potential strategies to mitigate the interaction and consideration of alternative analgesic agents in myocardial infarction. Pharmacology & Therapeutics 2021;217:107665. [DOI: 10.1016/j.pharmthera.2020.107665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
318 Laine M, Panagides V, Frère C, Cuisset T, Gouarne C, Jouve B, Thuny F, Paganelli F, Alessi MC, Mancini J, Bonello L. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome. J Thromb Haemost 2019;17:2188-95. [PMID: 31351022 DOI: 10.1111/jth.14592] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
319 Sambola A, Rello P, Soriano T, Bhatt DL, Pasupuleti V, Cannon CP, Gibson CM, Dewilde WJM, Lip GYH, Peterson ED, Airaksinen KEJ, Kiviniemi T, Fauchier L, Räber L, Ruiz-Nodar JM, Banach M, Bueno H, Hernandez AV. Safety and efficacy of drug eluting stents vs bare metal stents in patients with atrial fibrillation: A systematic review and meta-analysis. Thromb Res 2020;195:128-35. [PMID: 32688097 DOI: 10.1016/j.thromres.2020.07.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Tea V, Bonaca M, Chamandi C, Iliou MC, Lhermusier T, Aissaoui N, Cayla G, Angoulvant D, Ferrières J, Schiele F, Simon T, Danchin N, Puymirat E; FAST-MI investigators. Appropriate secondary prevention and clinical outcomes after acute myocardial infarction according to atherothrombotic risk stratification: The FAST-MI 2010 registry. Eur J Prev Cardiol 2019;26:411-9. [PMID: 30354737 DOI: 10.1177/2047487318808638] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 2.3] [Reference Citation Analysis]
321 Koskinas KC, Zanchin T, Klingenberg R, Gencer B, Temperli F, Baumbach A, Roffi M, Moschovitis A, Muller O, Tüller D, Stortecky S, Mach F, Lüscher TF, Matter CM, Pilgrim T, Heg D, Windecker S, Räber L. Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With ST-Elevation Myocardial Infarction. J Am Heart Assoc 2018;7:e008085. [PMID: 29654204 DOI: 10.1161/JAHA.117.008085] [Cited by in Crossref: 6] [Article Influence: 2.0] [Reference Citation Analysis]
322 Ge Z, Gao XF, Kan J, Kong XQ, Zuo GF, Ye F, Tian NL, Lin S, Liu ZZ, Shao YB, He YQ, Wen SY, Yang Q, Xia Y, Wang ZZ, Xiao PX, Li F, Zeng HS, Yang S, Wang Y, Tao L, Gao DS, Qu H, Qian XS, Han YL, Chen F, Zhang JJ, Chen SL. Comparison of one-month versus twelve-month dual antiplatelet therapy after implantation of drug-eluting stents guided by either intravascular ultrasound or angiography in patients with acute coronary syndrome: rationale and design of prospective, multicenter, randomized, controlled IVUS-ACS and ULTIMATE-DAPT trial. Am Heart J 2021;236:49-58. [PMID: 33621541 DOI: 10.1016/j.ahj.2021.02.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
323 Kerneis M, Gibson CM, Chi G, Mehran R, Alkhalfan F, Talib U, Pahlavani S, Mir M, Bode C, Halperin JL, Nafee T, Peterson ED, Verheugt FW, Wildgoose P, van Eickels M, Lip GY, Fox KA, Cohen M. Effect of Procedure and Coronary Lesion Characteristics on Clinical Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions 2018;11:626-34. [DOI: 10.1016/j.jcin.2017.11.009] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
324 Januszek R, Siudak Z, Malinowski KP, Wojdyła R, Mika P, Wańha W, Kameczura T, Surdacki A, Wojakowski W, Legutko J, Bartuś S. Aspiration Thrombectomy in Patients with Acute Myocardial Infarction-5-Year Analysis Based on a Large National Registry (ORPKI). J Clin Med 2020;9:E3610. [PMID: 33182436 DOI: 10.3390/jcm9113610] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
325 Kikkert WJ, Damman P. Optimal duration of dual antiplatelet therapy for coronary artery disease. Neth Heart J 2018;26:321-33. [PMID: 29713989 DOI: 10.1007/s12471-018-1113-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
326 Bi S, Zhao Y, Peng Q, Liu W, Zhang G, Zhang C. Contradictions between DAPT and PRECISE-DAPT scores with the severity of coronary lesion in acute coronary syndrome. Medicine (Baltimore) 2020;99:e19699. [PMID: 32311950 DOI: 10.1097/MD.0000000000019699] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
327 Eitel I, Wang J, Stiermaier T, Fuernau G, Feistritzer HJ, Joost A, Jobs A, Meusel M, Blodau C, Desch S, de Waha-Thiele S, Langer H, Thiele H. Impact of Morphine Treatment on Infarct Size and Reperfusion Injury in Acute Reperfused ST-Elevation Myocardial Infarction. J Clin Med 2020;9:E735. [PMID: 32182847 DOI: 10.3390/jcm9030735] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
328 Kupka D, Sibbing D. P2Y12 receptor inhibitors: an evolution in drug design to prevent arterial thrombosis. Expert Opin Drug Metab Toxicol 2018;14:303-15. [PMID: 29338536 DOI: 10.1080/17425255.2018.1428557] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
329 Alexopoulos D, Lianos I, Vlachakis P, Sfantou D, Dragona V, Varlamos C. De-Escalation of Treatment With Oral P2Y12 Receptor Inhibitors: Current Status and Perspectives. J Cardiovasc Pharmacol Ther 2019;24:304-14. [DOI: 10.1177/1074248418823724] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
330 Buszko K, Kubica K, Hobl EL, Adamski P, Wnuk K, Jilma B, Kubica J. Pharmacokinetic Modeling of Morphine's Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. Front Physiol 2021;12:663170. [PMID: 34248659 DOI: 10.3389/fphys.2021.663170] [Reference Citation Analysis]
331 Watanabe H, Domei T, Morimoto T, Natsuaki M, Shiomi H, Toyota T, Ohya M, Suwa S, Takagi K, Nanasato M, Hata Y, Yagi M, Suematsu N, Yokomatsu T, Takamisawa I, Doi M, Noda T, Okayama H, Seino Y, Tada T, Sakamoto H, Hibi K, Abe M, Kawai K, Nakao K, Ando K, Tanabe K, Ikari Y, Hanaoka KI, Morino Y, Kozuma K, Kadota K, Furukawa Y, Nakagawa Y, Kimura T; On behalf of the STOPDAPT-2 Investigators. Very Short Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Patients With High Bleeding Risk: Insight From the STOPDAPT-2 Trial. Circulation 2019;140:1957-9. [DOI: 10.1161/circulationaha.119.043613] [Cited by in Crossref: 22] [Cited by in F6Publishing: 1] [Article Influence: 11.0] [Reference Citation Analysis]
332 Kuno T, Ueyama H, Takagi H, Bangalore S. P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials. Am Heart J 2020;227:82-90. [PMID: 32693196 DOI: 10.1016/j.ahj.2020.06.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
333 Mahla E, Tantry US, Schoerghuber M, Gurbel PA. Platelet Function Testing in Patients on Antiplatelet Therapy before Cardiac Surgery. Anesthesiology 2020;133:1263-76. [DOI: 10.1097/aln.0000000000003541] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 6.0] [Reference Citation Analysis]
334 Buccheri S, Angiolillo DJ, Capodanno D. Evolving paradigms in antithrombotic therapy for anticoagulated patients undergoing coronary stenting. Ther Adv Cardiovasc Dis 2019;13:1753944719891688. [PMID: 31814532 DOI: 10.1177/1753944719891688] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
335 Bianco M, D'ascenzo F, Raposeiras Roubin S, Kinnaird T, Peyracchia M, Ariza-solé A, Cerrato E, Manzano-fernández S, Gravinese C, Templin C, Destefanis P, Velicki L, Luciano A, Xanthopoulou I, Rinaldi M, Rognoni A, Varbella F, Boccuzzi G, Omedè P, Montabone A, Bernardi A, Taha S, Rossini R, Durante A, Gili S, Magnani G, Autelli M, Grosso A, Blanco PF, Giustetto C, Garay A, Quadri G, Queija BC, Srdanovic I, Paz RC, Fernández MC, Pousa IM, Gallo D, Morbiducci U, Dominguez-rodriguez A, Lopez-cuenca Á, Cequier A, Alexopoulos D, Iñiguez-romo A, Pozzi R, Assi EA, Valgimigli M. Comparative external validation of the PRECISE-DAPT and PARIS risk scores in 4424 acute coronary syndrome patients treated with prasugrel or ticagrelor. International Journal of Cardiology 2020;301:200-6. [DOI: 10.1016/j.ijcard.2019.11.132] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 12.0] [Reference Citation Analysis]
336 Oren O, Herrmann J. Arterial events in cancer patients-the case of acute coronary thrombosis. J Thorac Dis 2018;10:S4367-85. [PMID: 30701104 DOI: 10.21037/jtd.2018.12.79] [Cited by in Crossref: 20] [Cited by in F6Publishing: 12] [Article Influence: 6.7] [Reference Citation Analysis]
337 Kong Q, Ma X, Zhao X, Chen F, Hou C. Ticagrelor for the primary prevention of stroke in patients with coronary artery disease: a systematic review and meta-analysis of randomized controlled trials. J Thromb Thrombolysis 2020;50:942-56. [PMID: 32221808 DOI: 10.1007/s11239-020-02085-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
338 Costa IBSDS, Andrade FTA, Carter D, Seleme VB, Costa MS, Campos CM, Hajjar LA. Challenges and Management of Acute Coronary Syndrome in Cancer Patients. Front Cardiovasc Med 2021;8:590016. [PMID: 34179121 DOI: 10.3389/fcvm.2021.590016] [Reference Citation Analysis]
339 Cao D, Chandiramani R, Capodanno D, Berger JS, Levin MA, Hawn MT, Angiolillo DJ, Mehran R. Non-cardiac surgery in patients with coronary artery disease: risk evaluation and periprocedural management. Nat Rev Cardiol 2021;18:37-57. [PMID: 32759962 DOI: 10.1038/s41569-020-0410-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
340 Wadowski PP, Pultar J, Weikert C, Eichelberger B, Lang IM, Koppensteiner R, Panzer S, Gremmel T. Comparison of Light Transmission Aggregometry With Impedance Aggregometry in Patients on Potent P2Y12 Inhibitors. J Cardiovasc Pharmacol Ther 2021;26:260-8. [PMID: 33107322 DOI: 10.1177/1074248420968706] [Reference Citation Analysis]
341 Palasubramaniam J, Wang X, Peter K. Myocardial Infarction-From Atherosclerosis to Thrombosis. Arterioscler Thromb Vasc Biol 2019;39:e176-85. [PMID: 31339782 DOI: 10.1161/ATVBAHA.119.312578] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 9.5] [Reference Citation Analysis]
342 Kurdziel M, Hudzik B, Kazik A, Piegza J, Szkodziński J, Gąsior M. Idarucizumab for dabigatran reversal in cardiac tamponade complicating percutaneous intervention in ST elevation myocardial infarction. Postepy Kardiol Interwencyjnej 2021;17:129-30. [PMID: 33868433 DOI: 10.5114/aic.2021.104784] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
343 Berry NC, Mauri L, Steg PG, Bhatt DL, Hohnloser SH, Nordaby M, Miede C, Kimura T, Lip GY, Oldgren J, ten Berg JM, Cannon CP; on behalf of the REDUAL PCI Steering Committee and Investigators. Effect of Lesion Complexity and Clinical Risk Factors on the Efficacy and Safety of Dabigatran Dual Therapy Versus Warfarin Triple Therapy in Atrial Fibrillation After Percutaneous Coronary Intervention: A Subgroup Analysis From the REDUAL PCI Trial. Circ: Cardiovascular Interventions 2020;13. [DOI: 10.1161/circinterventions.119.008349] [Cited by in Crossref: 7] [Article Influence: 7.0] [Reference Citation Analysis]
344 Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, Valgimigli M. Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. Eur Heart J 2019;40:3757-67. [PMID: 31651946 DOI: 10.1093/eurheartj/ehz732] [Cited by in Crossref: 27] [Cited by in F6Publishing: 35] [Article Influence: 27.0] [Reference Citation Analysis]
345 Johnson TW, Baos S, Collett L, Hutchinson JL, Nkau M, Molina M, Aungraheeta R, Reilly-Stitt C, Bowles R, Reeves BC, Rogers CA, Mundell SJ, Baumbach A, Mumford AD. Pharmacodynamic Comparison of Ticagrelor Monotherapy Versus Ticagrelor and Aspirin in Patients After Percutaneous Coronary Intervention: The TEMPLATE (Ticagrelor Monotherapy and Platelet Reactivity) Randomized Controlled Trial. J Am Heart Assoc 2020;9:e016495. [PMID: 33305660 DOI: 10.1161/JAHA.120.016495] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
346 Ferrari R, Pavasini R, Censi S, Squeri A, Rosano G. The New ESC Guidelines for the Diagnosis and Management of Chronic Coronary Syndromes: the Good and the Not So Good. Curr Probl Cardiol 2021;46:100554. [PMID: 32173068 DOI: 10.1016/j.cpcardiol.2020.100554] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
347 Dimitroulis D, Golabkesh M, Naguib D, Knoop B, Dannenberg L, Helten C, Pöhl M, Jung C, Kelm M, Zeus T, Polzin A. Safety and Efficacy in Prasugrel- Versus Ticagrelor-Treated Patients With ST-Elevation Myocardial Infarction. Journal of Cardiovascular Pharmacology 2018;72:186-90. [DOI: 10.1097/fjc.0000000000000609] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
348 Flannery L, Liu R, Elmariah S. Dual Antiplatelet Therapy: How Long Is Long Enough? Curr Treat Options Cardiovasc Med 2019;21:17. [PMID: 30929096 DOI: 10.1007/s11936-019-0721-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
349 Ishihara T, Yamaji K, Iida O, Kohsaka S, Inohara T, Shinke T, Ando H, Amano T, Sakata Y, Mano T, Ikari Y. Impact of peripheral artery disease on short-term outcomes after percutaneous coronary intervention: A report from Japanese nationwide registry. PLoS One 2020;15:e0240095. [PMID: 33021993 DOI: 10.1371/journal.pone.0240095] [Reference Citation Analysis]
350 Hill JM, Kereiakes DJ, Shlofmitz RA, Klein AJ, Riley RF, Price MJ, Herrmann HC, Bachinsky W, Waksman R, Stone GW. Intravascular Lithotripsy for Treatment of Severely Calcified Coronary Artery Disease. Journal of the American College of Cardiology 2020;76:2635-46. [DOI: 10.1016/j.jacc.2020.09.603] [Cited by in Crossref: 34] [Cited by in F6Publishing: 18] [Article Influence: 34.0] [Reference Citation Analysis]
351 Esmonde S, Sharma D, Peace A. Antiplatelet agents in uncertain clinical scenarios-a bleeding nightmare. Cardiovasc Diagn Ther 2018;8:647-62. [PMID: 30498688 DOI: 10.21037/cdt.2018.06.09] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
352 Kim Y, Ahn Y, Cho MC, Kim CJ, Kim YJ, Jeong MH. Current status of acute myocardial infarction in Korea. Korean J Intern Med 2019;34:1-10. [PMID: 30612415 DOI: 10.3904/kjim.2018.381] [Cited by in Crossref: 37] [Cited by in F6Publishing: 13] [Article Influence: 12.3] [Reference Citation Analysis]
353 Elwany M, Palma GD, Cortese B. Treatment of coronary bifurcation lesions: current knowledge and future perspectives. Future Cardiol 2018;14:165-79. [PMID: 29372810 DOI: 10.2217/fca-2017-0068] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
354 Capodanno D, Bhatt DL, Eikelboom JW, Fox KAA, Geisler T, Michael Gibson C, Gonzalez-Juanatey JR, James S, Lopes RD, Mehran R, Montalescot G, Patel M, Steg PG, Storey RF, Vranckx P, Weitz JI, Welsh R, Zeymer U, Angiolillo DJ. Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol 2020;17:242-57. [PMID: 31953535 DOI: 10.1038/s41569-019-0314-y] [Cited by in Crossref: 37] [Cited by in F6Publishing: 23] [Article Influence: 37.0] [Reference Citation Analysis]
355 Argirò R, Raso A, Vidali S, Morosetti D. Endovascular thromboaspiration with neurointerventional devices for early hepatic artery thrombosis after split liver transplant. BMJ Case Rep 2021;14:e240583. [PMID: 33952566 DOI: 10.1136/bcr-2020-240583] [Reference Citation Analysis]
356 Terrier J, Daali Y, Fontana P, Csajka C, Reny JL. Towards Personalized Antithrombotic Treatments: Focus on P2Y12 Inhibitors and Direct Oral Anticoagulants. Clin Pharmacokinet 2019;58:1517-32. [PMID: 31250210 DOI: 10.1007/s40262-019-00792-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
357 Mazzeffi MA, Patel PA, Bolliger D, Erdoes G, Tanaka K. The Year in Coagulation: Selected Highlights From 2019. Journal of Cardiothoracic and Vascular Anesthesia 2020;34:1745-54. [DOI: 10.1053/j.jvca.2020.01.045] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
358 Shi X, Zhang Y, Zhang Y, Zhang R, Lin B, Han J, Li W, Fang Z, Yan J, Wang Y, Zheng Z, Lv Y, Lin Y. Personalized Antiplatelet Therapy Based on CYP2C19 Genotypes in Chinese ACS Patients Undergoing PCI: A Randomized Controlled Trial. Front Cardiovasc Med 2021;8:676954. [PMID: 34222372 DOI: 10.3389/fcvm.2021.676954] [Reference Citation Analysis]
359 Pultar J, Wadowski PP, Panzer S, Gremmel T. Oral antiplatelet agents in cardiovascular disease. Vasa 2019;48:291-302. [PMID: 30324870 DOI: 10.1024/0301-1526/a000753] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
360 Valgimigli M, Frigoli E, Leonardi S, Vranckx P, Rothenbühler M, Tebaldi M, Varbella F, Calabrò P, Garducci S, Rubartelli P, Briguori C, Andó G, Ferrario M, Limbruno U, Garbo R, Sganzerla P, Russo F, Nazzaro M, Lupi A, Cortese B, Ausiello A, Ierna S, Esposito G, Ferrante G, Santarelli A, Sardella G, de Cesare N, Tosi P, van 't Hof A, Omerovic E, Brugaletta S, Windecker S, Heg D, Jüni P; MATRIX Investigators. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial. Lancet 2018;392:835-48. [PMID: 30153988 DOI: 10.1016/S0140-6736(18)31714-8] [Cited by in Crossref: 108] [Cited by in F6Publishing: 27] [Article Influence: 36.0] [Reference Citation Analysis]
361 Sorrentino S, Claessen BE, Chandiramani R, Guedeney P, Vogel B, Baber U, Rau V, Wang J, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Liu Y, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann F, Hermiller J, Valgimigli M, Mehran R. Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk: A Patient-Level Stratified Analysis From Four Postapproval Studies. Circulation 2020;141:891-901. [DOI: 10.1161/circulationaha.119.041619] [Cited by in Crossref: 16] [Article Influence: 16.0] [Reference Citation Analysis]
362 Nishikawa M, Takeda Y, Isomura N, Tanigawa T, Nanasato M, Tsukahara K, Kimura K, Takayama T, Hirayama A, Kato M, Nishikawa H, Nishimura Y, Isshiki T, Yokoi H; j-CHIPS group. Association between High Platelet Reactivity Following Dual Antiplatelet Therapy and Ischemic Events in Japanese Patients with Coronary Artery Disease Undergoing Stent Implantation. J Atheroscler Thromb 2020;27:13-24. [PMID: 31092743 DOI: 10.5551/jat.48934] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 3.5] [Reference Citation Analysis]
363 Gargiulo G. To EncourAGE Individualized Dual Antiplatelet Therapy Duration After Drug-Eluting Stent Implantation. JACC: Cardiovascular Interventions 2018;11:444-7. [DOI: 10.1016/j.jcin.2017.11.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
364 Ueki Y, Karagiannis A, Zanchin C, Zanchin T, Stortecky S, Koskinas KC, Siontis GC, Praz F, Otsuka T, Hunziker L, Heg D, Moschovitis A, Seiler C, Billinger M, Pilgrim T, Valgimigli M, Windecker S, Räber L. Validation of High-Risk Features for Stent-Related Ischemic Events as Endorsed by the 2017 DAPT Guidelines. JACC: Cardiovascular Interventions 2019;12:820-30. [DOI: 10.1016/j.jcin.2018.12.005] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 10.0] [Reference Citation Analysis]
365 Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? Eur J Intern Med 2020;72:15-26. [PMID: 31796246 DOI: 10.1016/j.ejim.2019.11.017] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
366 De Luca L. Established and Emerging Pharmacological Therapies for Post-Myocardial Infarction Patients with Heart Failure: a Review of the Evidence. Cardiovasc Drugs Ther 2020;34:723-35. [PMID: 32564304 DOI: 10.1007/s10557-020-07027-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
367 Wester A, Attar R, Mohammad MA, Andell P, Hofmann R, Jensen J, Szummer K, Erlinge D, Koul S. Impact of Baseline Anemia in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: A Prespecified Analysis From the VALIDATE-SWEDEHEART Trial. J Am Heart Assoc 2019;8:e012741. [PMID: 31387441 DOI: 10.1161/JAHA.119.012741] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
368 Romero N, Lupi K, Carter D, Malloy R. The Role of Double and Triple Therapy with Direct Oral Anticoagulants in Coronary Artery Disease, Peripheral Artery Disease, and Stroke. Clinical Therapeutics 2018;40:1907-1917.e3. [DOI: 10.1016/j.clinthera.2018.09.014] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
369 Mayer K, Hein-Rothweiler R, Schüpke S, Janisch M, Bernlochner I, Ndrepepa G, Sibbing D, Gori T, Borst O, Holdenrieder S, Kupka D, Petzold T, Bradaric C, Okrojek R, Leistner DM, Trippel TD, Münzel T, Landmesser U, Pieske B, Zeiher AM, Gawaz MP, Hapfelmeier A, Laugwitz KL, Schunkert H, Kastrati A, Massberg S. Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease: The Randomized, Double-blind, Placebo-Controlled ISAR-PLASTER Phase 2 Trial. JAMA Cardiol 2021;6:753-61. [PMID: 33787834 DOI: 10.1001/jamacardio.2021.0475] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
370 Lyu SQ, Yang YM, Zhu J, Wang J, Wu S, Zhang H, Shao XH, Ren JM. The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials. Platelets 2020;31:971-80. [PMID: 32546030 DOI: 10.1080/09537104.2020.1780205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
371 Costa GF, Costa M, Gonçalves L, Teixeira R. Antiplatelet therapy after transcatheter aortic valve implantation: a systematic review and meta-analysis. Eur J Cardiothorac Surg 2021:ezab250. [PMID: 34148077 DOI: 10.1093/ejcts/ezab250] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
372 Lou B, Liang X, Wu Y, Deng Y, Zhou B, Yuan Z, She J. Meta-Analysis Comparing Dual Versus Single Antiplatelet Therapy in Combination With Antithrombotic Therapy in Patients With Atrial Fibrillation Who Underwent Percutaneous Coronary Intervention With Stent Implantation. The American Journal of Cardiology 2018;122:604-11. [DOI: 10.1016/j.amjcard.2018.04.050] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
373 Vidula MK, Secemsky EA, Yeh RW. Duration of Dual Antiplatelet Therapy for Stented Patients: An Update for the Clinician. Progress in Cardiovascular Diseases 2018;60:491-9. [DOI: 10.1016/j.pcad.2018.01.006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
374 Biancari F, Mariscalco G, Gherli R, Reichart D, Onorati F, Faggian G, Franzese I, Santarpino G, Fischlein T, Rubino AS, Maselli D, Nardella S, Salsano A, Nicolini F, Zanobini M, Saccocci M, Ruggieri VG, Bounader K, Perrotti A, Rosato S, D’errigo P, D’andrea V, De Feo M, Tauriainen T, Gatti G, Dalén M. Variation in preoperative antithrombotic strategy, severe bleeding, and use of blood products in coronary artery bypass grafting: results from the multicentre E-CABG registry. European Heart Journal - Quality of Care and Clinical Outcomes 2018;4:246-57. [DOI: 10.1093/ehjqcco/qcy027] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
375 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Haeusler KG, Oldgren J, Reinecke H, Roldan-Schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018;39:1330-93. [PMID: 29562325 DOI: 10.1093/eurheartj/ehy136] [Cited by in Crossref: 935] [Cited by in F6Publishing: 554] [Article Influence: 467.5] [Reference Citation Analysis]
376 Mach M, Watzal V, Cuhaj C, Hasan W, Poschner T, Szalkiewicz P, Strouhal A, Adlbrecht C, Delle-Karth G, Grabenwöger M, Winkler B. The impact of antiplatelet and antithrombotic regimen after TAVI: Data from the VIenna CardioThOracic Aortic Valve RegistrY (VICTORY). Eur J Clin Invest 2021;51:e13589. [PMID: 34120335 DOI: 10.1111/eci.13589] [Reference Citation Analysis]
377 Al-salama ZT, Keating GM, Keam SJ. Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events. Drugs 2017;77:2025-36. [DOI: 10.1007/s40265-017-0844-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
378 Carrillo-Estrada M, Bobrowski D, Carrasco R, Nadler MB, Kalra S, Thavendiranathan P, Abdel-Qadir H. Coronary artery disease in patients with cancer: challenges and opportunities for improvement. Curr Opin Cardiol 2021;36:597-608. [PMID: 34397466 DOI: 10.1097/HCO.0000000000000878] [Reference Citation Analysis]
379 Ma R, Fu W, Zhang J, Hu X, Yang J, Jiang H. TMAO: a potential mediator of clopidogrel resistance. Sci Rep 2021;11:6580. [PMID: 33753834 DOI: 10.1038/s41598-021-85950-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
380 Li HL, Feng Q, Tsoi MF, Fei Y, Cheung BMY. Risk of infections in patients treated with ticagrelor vs. clopidogrel: a systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother 2021;7:171-9. [PMID: 32569384 DOI: 10.1093/ehjcvp/pvaa065] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
381 Messerli AW, Ahmed T. For Prediction of "No-Reflow," How Precise is PRECISE-DAPT? Angiology 2021;:33197211018356. [PMID: 34018406 DOI: 10.1177/00033197211018356] [Reference Citation Analysis]
382 Veitch AM, Radaelli F, Alikhan R, Dumonceau JM, Eaton D, Jerrome J, Lester W, Nylander D, Thoufeeq M, Vanbiervliet G, Wilkinson JR, Van Hooft JE. Endoscopy in patients on antiplatelet or anticoagulant therapy: British Society of Gastroenterology (BSG) and European Society of Gastrointestinal Endoscopy (ESGE) guideline update. Gut 2021;70:1611-28. [PMID: 34362780 DOI: 10.1136/gutjnl-2021-325184] [Reference Citation Analysis]
383 Gremmel T, Michelson AD, Frelinger AL III, Bhatt DL. Novel aspects of antiplatelet therapy in cardiovascular disease. Res Pract Thromb Haemost 2018;2:439-49. [PMID: 30046748 DOI: 10.1002/rth2.12115] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
384 Cosentino N, Campodonico J, Faggiano P, De Metrio M, Rubino M, Milazzo V, Sbolli M, Perego C, Provini M, Bonomi A, Veglia F, Bartorelli AL, Marenzi G. A new score based on the PEGASUS-TIMI 54 criteria for risk stratification of patients with acute myocardial infarction. International Journal of Cardiology 2019;278:1-6. [DOI: 10.1016/j.ijcard.2018.11.142] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
385 Nagao K, Watanabe H, Morimoto T, Inada T, Hayashi F, Nakagawa Y, Furukawa Y, Kadota K, Akasaka T, Natsuaki M, Kozuma K, Tanabe K, Morino Y, Shiomi H, Kimura T; CREDO‐Kyoto PCI/CABG Registry Cohort‐2, RESET, and NEXT Investigators. Prognostic Impact of Baseline Hemoglobin Levels on Long-Term Thrombotic and Bleeding Events After Percutaneous Coronary Interventions. J Am Heart Assoc 2019;8:e013703. [PMID: 31701786 DOI: 10.1161/JAHA.119.013703] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
386 Qian Y, Xu B, Qian X, Cao L, Cheng Y, Liu X, Bai S, Han Z, Wang J. Incidence and Risk Factors for Antiplatelet Therapy-Related Bleeding Complications Among Elderly Patients After Coronary Stenting: A Multicenter Retrospective Observation. Front Pharmacol 2021;12:661619. [PMID: 34393770 DOI: 10.3389/fphar.2021.661619] [Reference Citation Analysis]
387 Lee S, Hong M, Palmerini T, Kim H, Valgimigli M, Feres F, Colombo A, Gilard M, Shin D, Kim J, Kim B, Ko Y, Choi D, Jang Y, Stone GW. Short-Term Versus Long-Term Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation in Elderly Patients. JACC: Cardiovascular Interventions 2018;11:435-43. [DOI: 10.1016/j.jcin.2017.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 7.3] [Reference Citation Analysis]
388 Ortega-Paz L, Capodanno D, Montalescot G, Angiolillo DJ. Coronavirus Disease 2019-Associated Thrombosis and Coagulopathy: Review of the Pathophysiological Characteristics and Implications for Antithrombotic Management. J Am Heart Assoc 2021;10:e019650. [PMID: 33228447 DOI: 10.1161/JAHA.120.019650] [Cited by in Crossref: 22] [Cited by in F6Publishing: 16] [Article Influence: 22.0] [Reference Citation Analysis]
389 Tang C, Zhu Y, Yang X, Xu B, Ye C, Yang Y, Zhong J, Zhao Q, Yu L. Upper gastrointestinal mucosal injury associated with ticagrelor plus aspirin, ticagrelor alone, or aspirin alone at 1-year after coronary artery bypass grafting. J Gastroenterol Hepatol 2020;35:1720-30. [PMID: 32154936 DOI: 10.1111/jgh.15030] [Reference Citation Analysis]
390 Sehested TSG, Carlson N, Hansen PW, Gerds TA, Charlot MG, Torp-Pedersen C, Køber L, Gislason GH, Hlatky MA, Fosbøl EL. Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction. Eur Heart J 2019;40:1963-70. [PMID: 30851041 DOI: 10.1093/eurheartj/ehz104] [Cited by in Crossref: 28] [Cited by in F6Publishing: 15] [Article Influence: 28.0] [Reference Citation Analysis]
391 Collet JP, Berti S, Cequier A, Van Belle E, Lefevre T, Leprince P, Neumann FJ, Vicaut E, Montalescot G. Oral anti-Xa anticoagulation after trans-aortic valve implantation for aortic stenosis: The randomized ATLANTIS trial. Am Heart J 2018;200:44-50. [PMID: 29898848 DOI: 10.1016/j.ahj.2018.03.008] [Cited by in Crossref: 54] [Cited by in F6Publishing: 36] [Article Influence: 18.0] [Reference Citation Analysis]
392 Pica S, Di Giovine G, Bollati M, Testa L, Bedogni F, Camporeale A, Pontone G, Andreini D, Monti L, Gasparini G, Grancini L, Secco GG, Maestroni A, Ambrogi F, Milani V, Lombardi M. Cardiac magnetic resonance for ischaemia and viability detection. Guiding patient selection to revascularization in coronary chronic total occlusions: The CARISMA_CTO study design. Int J Cardiol 2018;272:356-62. [PMID: 30173921 DOI: 10.1016/j.ijcard.2018.08.061] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
393 Kawashima H, Gao C, Takahashi K, Tomaniak M, Ono M, Hara H, Wang R, Chichareon P, Suryapranata H, Walsh S, Cotton J, Koning R, Rensing B, Wykrzykowska J, de Winter RJ, Garg S, Anderson R, Hamm C, Steg PG, Onuma Y, Serruys PW. Comparative Assessment of Predictive Performance of PRECISE-DAPT, CRUSADE, and ACUITY Scores in Risk Stratifying 30-Day Bleeding Events. Thromb Haemost 2020;120:1087-95. [PMID: 32572864 DOI: 10.1055/s-0040-1712449] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
394 Costa F, Valgimigli M, Steg PG, Bhatt DL, Hohnloser SH, Ten Berg JM, Miede C, Nordaby M, Lip GYH, Oldgren J, Cannon CP. Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. European Heart Journal - Cardiovascular Pharmacotherapy 2020. [DOI: 10.1093/ehjcvp/pvaa135] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
395 Rossini R, Masiero G, Fruttero C, Passamonti E, Calvaruso E, Cecconi M, Carlucci C, Mojoli M, Guido P, Talanas G, Pierini S, Canova P, De Cesare N, Luceri S, Barzaghi N, Melloni G, Baralis G, Locatelli A, Musumeci G, Angiolillo DJ. Antiplatelet Therapy with Cangrelor in Patients Undergoing Surgery after Coronary Stent Implantation: A Real-World Bridging Protocol Experience. TH Open 2020;4:e437-45. [PMID: 33376943 DOI: 10.1055/s-0040-1721504] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
396 De Rosa R, Piscione F, Galasso G, De Servi S, Savonitto S. Antiplatelet therapy in very elderly and comorbid patients with acute coronary syndromes. J Geriatr Cardiol 2019;16:103-13. [PMID: 30923541 DOI: 10.11909/j.issn.1671-5411.2019.02.006] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
397 Valgimigli M, Cao D, Makkar RR, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Ge J, Neumann FJ, Hermiller J, Picon H, Toelg R, Maksoud A, Chehab BM, Wang LJ, Wang J, Mehran R. Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. Am Heart J 2021;231:147-56. [PMID: 33031789 DOI: 10.1016/j.ahj.2020.09.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
398 Rozemeijer R, Voskuil M, Greving JP, Bots ML, Doevendans PA, Stella PR. Short versus long duration of dual antiplatelet therapy following drug-eluting stents: a meta-analysis of randomised trials. Neth Heart J 2018;26:242-51. [PMID: 29541996 DOI: 10.1007/s12471-018-1104-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
399 Gragnano F, Calabrò P, Valgimigli M. Is triple antithrombotic therapy, or rather its duration and composition, the true culprit for the excess of bleeding events observed in patients with atrial fibrillation undergoing coronary intervention? European Heart Journal 2019;40:216-7. [DOI: 10.1093/eurheartj/ehy675] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
400 Gragnano F, Heg D, Franzone A, McFadden EP, Leonardi S, Piccolo R, Vranckx P, Branca M, Serruys PW, Benit E, Liebetrau C, Janssens L, Ferrario M, Zurakowski A, Diletti R, Dominici M, Huber K, Slagboom T, Buszman P, Bolognese L, Tumscitz C, Bryniarski K, Aminian A, Vrolix M, Petrov I, Garg S, Naber C, Prokopczuk J, Hamm C, Steg PG, Jüni P, Windecker S, Valgimigli M; GLASSY Investigators. PRECISE-DAPT score for bleeding risk prediction in patients on dual or single antiplatelet regimens: insights from the GLOBAL LEADERS and GLASSY. Eur Heart J Cardiovasc Pharmacother 2020:pvaa106. [PMID: 32941620 DOI: 10.1093/ehjcvp/pvaa106] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
401 Montalto C, Morici N, Munafò AR, Mangieri A, Mandurino-mirizzi A, D’ascenzo F, Oreglia J, Latib A, Porto I, Colombo A, Savonitto S, De Servi S, Crimi G. Optimal P2Y12 inhibition in older adults with acute coronary syndromes: a network meta-analysis of randomized controlled trials. European Heart Journal - Cardiovascular Pharmacotherapy 2020. [DOI: 10.1093/ehjcvp/pvaa101] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
402 Bularga A, Meah MN, Doudesis D, Shah ASV, Mills NL, Newby DE, Lee KK. Duration of dual antiplatelet therapy and stability of coronary heart disease: a 60 000-patient meta-analysis of randomised controlled trials. Open Heart 2021;8:e001707. [PMID: 34341097 DOI: 10.1136/openhrt-2021-001707] [Reference Citation Analysis]
403 Rohman MS, Purnamasari Y, Ilmawan M, Mahdi BA, Tamara F, Mahendra AI, Mazen M, Heriansyah T, Yamin M, Pikir BS, Fajar JK. Comparison of major bleeding in patients with acute coronary syndrome that underwent coronary artery bypass grafting treated with clopidogrel or ticagrelor: a systematic review and meta-analysis. F1000Res 2020;9:99. [PMID: 33732438 DOI: 10.12688/f1000research.21925.2] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
404 Uskela S, Kärkkäinen JM, Eränen J, Siljander A, Mäntylä P, Mustonen J, Rissanen TT. Percutaneous coronary intervention with drug‐coated balloon‐only strategy in stable coronary artery disease and in acute coronary syndromes: An all‐comers registry study. Catheter Cardiovasc Interv 2018;93:893-900. [DOI: 10.1002/ccd.27950] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
405 Haller PM, Stojkovic S, Piackova E, Andric T, Wisgrill L, Spittler A, Wojta J, Huber K, Jäger B. The association of P2Y12 inhibitors with pro-coagulatory extracellular vesicles and microRNAs in stable coronary artery disease. Platelets 2020;31:497-504. [PMID: 31389740 DOI: 10.1080/09537104.2019.1648780] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
406 Holm M, Tornvall P, Henareh L, Jensen U, Golster N, Alström P, Santos-Pardo I, Witt N, Fedchenko N, Venetsanos D, Beck O, van der Linden J. The MOVEMENT Trial. J Am Heart Assoc 2019;8:e010152. [PMID: 30636504 DOI: 10.1161/JAHA.118.010152] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
407 Pan L, Lu W, Han Z, Pan S, Wang X, Shan Y, Wang X, Zheng X, Li R, Zhou Y, Qin P, Shi Q, Zhou S, Zhang W, Guo S, Zhang P, Qin X, Sun G, Qin Z, Huang Z, Qiu C. Clinical Outcomes of Drug-Coated Balloon in Coronary Patients with and without Diabetes Mellitus: A Multicenter, Propensity Score Study. J Diabetes Res 2021;2021:5495219. [PMID: 34368364 DOI: 10.1155/2021/5495219] [Reference Citation Analysis]
408 de Breet CPDM, Zwaveling S, Vries MJA, van Oerle RG, Henskens YMC, Van't Hof AWJ, van der Meijden PEJ, Veenstra L, Ten Cate H, Olie RH. Thrombin Generation as a Method to Identify the Risk of Bleeding in High Clinical-Risk Patients Using Dual Antiplatelet Therapy. Front Cardiovasc Med 2021;8:679934. [PMID: 34179143 DOI: 10.3389/fcvm.2021.679934] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
409 Pan L, Lu W, Han Z, Pan S, Wang X, Shan Y, Wang X, Zheng X, Li R, Zhou Y, Qin P, Shi Q, Zhou S, Zhang W, Guo S, Zhang P, Qin X, Sun G, Qin Z, Huang Z, Qiu C. Clinical outcomes of drug-coated balloon in coronary lesions: a real-world, all-comers study. Clin Res Cardiol 2021. [PMID: 34313800 DOI: 10.1007/s00392-021-01895-y] [Reference Citation Analysis]
410 Marquis-Gravel G, Roe MT, Robertson HR, Harrington RA, Pencina MJ, Berdan LG, Hammill BG, Faulkner M, Muñoz D, Fonarow GC, Nallamothu BK, Fintel DJ, Ford DE, Zhou L, Daugherty SE, Nauman E, Kraschnewski J, Ahmad FS, Benziger CP, Haynes K, Merritt JG, Metkus T, Kripalani S, Gupta K, Shah RC, McClay JC, Re RN, Geary C, Lampert BC, Bradley SM, Jain SK, Seifein H, Whittle J, Roger VL, Effron MB, Alvarado G, Goldberg YH, VanWormer JL, Girotra S, Farrehi P, McTigue KM, Rothman R, Hernandez AF, Jones WS. Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiol 2020;5:598-607. [PMID: 32186653 DOI: 10.1001/jamacardio.2020.0116] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 26.0] [Reference Citation Analysis]
411 Forrestal B, Case BC, Yerasi C, Musallam A, Chezar-Azerrad C, Waksman R. Bioresorbable Scaffolds: Current Technology and Future Perspectives. Rambam Maimonides Med J. 2020;11. [PMID: 32374257 DOI: 10.5041/rmmj.10402] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
412 Jin Y, Huang H, Shu X, Chen S, Lu L, Gao X, Wu Z. P2Y12 inhibitor monotherapy and dual antiplatelet therapy after percutaneous coronary intervention: An updated meta-analysis of randomized trials. Thromb Res 2021;198:115-21. [PMID: 33316640 DOI: 10.1016/j.thromres.2020.11.038] [Reference Citation Analysis]
413 Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, Georg Haeusler K, Oldgren J, Reinecke H, Roldan-schilling V, Rowell N, Sinnaeve P, Collins R, Camm AJ, Heidbüchel H, Lip GYH, Weitz J, Fauchier L, Lane D, Boriani G, Goette A, Keegan R, Macfadyen R, Chiang C, Joung B, Shimizu W; ESC Scientific Document Group. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary. EP Europace 2018;20:1231-42. [DOI: 10.1093/europace/euy054] [Cited by in Crossref: 122] [Cited by in F6Publishing: 85] [Article Influence: 40.7] [Reference Citation Analysis]
414 Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, Oldgren J, Ten Berg JM, Kimura T, Hohnloser SH, Lip GYH, Bhatt DL. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2018;39:1726-1735a. [PMID: 29668889 DOI: 10.1093/eurheartj/ehy162] [Cited by in Crossref: 102] [Cited by in F6Publishing: 69] [Article Influence: 51.0] [Reference Citation Analysis]
415 Raccah PharmD PhD BH, Erlichman Y, Pollak A, Matok I, Muszkat M. Prescribing Errors With Direct Oral Anticoagulants and Their Impact on the Risk of Bleeding in Patients With Atrial Fibrillation. J Cardiovasc Pharmacol Ther 2021;:10742484211019657. [PMID: 34060932 DOI: 10.1177/10742484211019657] [Reference Citation Analysis]
416 Chung J, Bae J, Kwon Y, Yoon H, Yoo S, Lee H, Park S, Kim J, Kim WH. Neutrophil/Lymphocyte Ratio in Patients Undergoing Noncardiac Surgery After Coronary Stent Implantation. Journal of Cardiothoracic and Vascular Anesthesia 2020;34:1516-25. [DOI: 10.1053/j.jvca.2019.10.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
417 Wongsalap Y, Ungsriwong S, Kumtep W, Saokaew S, Senthong V, Kengkla K. Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis. Cardiovasc Drugs Ther 2021. [PMID: 34169380 DOI: 10.1007/s10557-021-07202-1] [Reference Citation Analysis]
418 Vranckx P, Valgimigli M, Jüni P, Hamm C, Steg PG, Heg D, van Es GA, Mcfadden EP, Onuma Y, van Meijeren C, Chichareon P, Benit E, Möllmann H, Janssens L, Ferrario M, Moschovitis A, Zurakowski A, Dominici M, Van Geuns RJ, Huber K, Slagboom T, Serruys PW, Windecker S, Abdellaoui M, Adlam D, Akin I, Albarran Gonzalez-trevilla A, Almeida M, Alves Lemos Neto P, Aminian A, Anderson R, Andreae R, Angioi M, Asano T, Barbato E, Barlis P, Barraud P, Benit E, Bertrand O, Beygui F, Bolognese L, Botelho R, Bouwman C, Bressers M, Brunel P, Buszman P, Buysschaert I, Canas da Silva P, Carrie D, Cequier A, Chichareon P, Chin Chang C, Chowdhary S, Collet C, Colombo A, Cotton J, Cruz Ferreira R, Curello S, Curzen N, de Bot J, de Vreede T, Delle Karth G, Dijksma L, Dominici M, Édes I, Eeckhout E, Eitel I, Faluközy J, Fath-ordoubadi F, Ferrario M, Fontos G, Francisco Diaz J, Freitas Quintella E, Frey B, Friedrich G, Galasko G, Galuszka G, Gama Ribeiro V, Garg S, Gargiulo G, Geisler T, Gelev V, Ghandilyan A, Goicolea J, Gori T, Gragnano F, Guimarães A, Hamm C, Haude M, Heg D, Heijke P, Hernández Antolin RA, Hildick-smith D, Hillen D, Hoekman I, Hofma S, Holmvang L, Hoole S, Horváth I, Huber K, Hugense A, Ibrahim K, Iñiguez A, Isaaz K, Jambrik Z, Janssens L, Jasionowicz P, Jonk J, Jung W, Jüni P, Katagiri Y, Kogame N, Koh TH, Koning R, Konteva M, Kőszegi Z, Krackhardt F, Kreuger Y, Kukreja N, Ladan B, Lantelme P, Leandro S, Leibundgut G, Liebetrau C, Lindeboom W, Macaya Miguel C, Mach F, Magro M, Maillard L, Manavifar N, Mauri L, Mcfadden E, Merkely B, Miyazaki Y, Młodziankowski A, Moccetti T, Modolo R, Möllman H, Morelle J, Moschovitis A, Munndt Ottesen M, Muurling M, Naber CK, Neumann F, Oldroyd K, Ong P, Onuma Y, Palsrok S, Petrov I, Plante S, Prokopczuk J, Rademaker-havinga T, Raffel C, Rensing B, Roffi M, Royaards K, Sabate M, Schächinger V, Seidler T, Serra Peñaranda A, Serruys P, Sikarulidze L, Slagboom T, Soliman OI, Sousa A, Spitzer E, Stables R, Steg G, Steinwender C, Subkovas E, Suryapranata H, Takahashi K, Talwar S, Teiger E, ter Weele A, Teurlings E, Thury A, Tijssen J, Tonev G, Trendafilova-lazarova D, Tumscitz C, Umans V, Ungi I, Valkov V, van der Harst P, van Geuns RJ, van Meijeren C, Vassilev D, Velchev V, Velthuizen E, Verheugt F, Vlcek N, vom Dahl J, Vrolix M, Walsh S, Werner N, Windecker S, Witsenburg M, Zaman A, Żmudka K, Zrenner B, Zurakowski A, Zweiker R. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. The Lancet 2018;392:940-9. [DOI: 10.1016/s0140-6736(18)31858-0] [Cited by in Crossref: 306] [Cited by in F6Publishing: 66] [Article Influence: 102.0] [Reference Citation Analysis]
419 Gajanana D, Rogers T, Weintraub WS, Kolm P, Iantorno M, Khalid N, Chen Y, Shlofmitz E, Khan JM, Musallam A, Ben-dor I, Satler LF, Zhang C, Torguson R, Waksman R. Ischemic Versus Bleeding Outcomes After Percutaneous Coronary Interventions in Patients With High Bleeding Risk. The American Journal of Cardiology 2020;125:1631-7. [DOI: 10.1016/j.amjcard.2020.02.032] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
420 Gasecka A, Nieuwland R, Budnik M, Dignat-George F, Eyileten C, Harrison P, Lacroix R, Leroyer A, Opolski G, Pluta K, van der Pol E, Postuła M, Siljander P, Siller-Matula JM, Filipiak KJ. Ticagrelor attenuates the increase of extracellular vesicle concentrations in plasma after acute myocardial infarction compared to clopidogrel. J Thromb Haemost 2020;18:609-23. [PMID: 31833175 DOI: 10.1111/jth.14689] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 19.0] [Reference Citation Analysis]
421 Rossini R, Tarantini G, Musumeci G, Masiero G, Barbato E, Calabrò P, Capodanno D, Leonardi S, Lettino M, Limbruno U, Menozzi A, Marchese UOA, Saia F, Valgimigli M, Ageno W, Falanga A, Corcione A, Locatelli A, Montorsi M, Piazza D, Stella A, Bozzani A, Parolari A, Carone R, Angiolillo DJ; Italian Society of Interventional Cardiology (SICI-GISE)., Italian Society for the Study of Haemostasis and Thrombosis (SISET)., Italian Society of Anesthesia and Intensive Care Medicine (SIAARTI)., Italian Society of Surgery (SIC)., Italian Society for Cardiac Surgery (SICCH)., Italian Society of Vascular and Endovascular Surgery (SICVE)., Italian Society of Urology (SIU)., Italian Orthopaedic Society (SIOT)., Italian Society of Thoracic Surgeons (SICT)., Italian Federation of Scientific Societies of Digestive System Diseases (FISMAD)., Italian Society of Digestive Endoscopy (SIED)., Italian Association of Hospital Gastroenterology and Digestive Endoscopy (AIGO)., Italian Association of Gastroenterology and Digestive Endoscopy (SIGE)., Italian Society of Maxillofacial Surgery (SICMF)., Italian Society of Reconstructive Plastic Surgery and Aesthetics (SICPRE)., Italian Society of Gynecology and Obstetrics (SIGO)., Italian Society of Neurosurgery (SINch)., Italian Association of Hospital Pulmonologist (AIPO)., Italian Society of Periodontology (SIdP)., Italian Society of Ophthalmology (SOI)., Italian Association of Hospital Otorhinolaryngologist (AOOI)., Italian Association of Hospital Surgeons (ACOI)., Association of Obstetricians Gynecologists Italian Hospital (AOGOI). A Multidisciplinary Approach on the Perioperative Antithrombotic Management of Patients With Coronary Stents Undergoing Surgery: Surgery After Stenting 2. JACC Cardiovasc Interv 2018;11:417-34. [PMID: 29519377 DOI: 10.1016/j.jcin.2017.10.051] [Cited by in Crossref: 43] [Cited by in F6Publishing: 25] [Article Influence: 21.5] [Reference Citation Analysis]
422 Armario P, Brotons C, Elosua R, Alonso de Leciñana M, Castro A, Clarà A, Cortés O, Díaz Rodriguez Á, Herranz M, Justo S, Lahoz C, Pedro-Botet J, Pérez Pérez A, Santamaria R, Tresserras R, Aznar Lain S, Royo-Bordonada MÁ. [Statement of the Spanish Interdisciplinary Vascular Prevention Committee on the updated European Cardiovascular Prevention Guidelines]. Hipertens Riesgo Vasc 2021;38:21-43. [PMID: 33069629 DOI: 10.1016/j.hipert.2020.07.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
423 Shimamatsu J, Sasaki KI, Katsuki Y, Kawasaki T, Murasato Y, Ajisaka H, Yokoi H, Tashiro H, Harada A, Hirakawa Y, Ishizaki Y, Ishimatsu T, Kagiyama K, Fukumoto Y, Kakuma T, Ueno T. Prasugrel effectively reduces the platelet reactivity units in patients with genetically metabolic dysfunction of cytochrome P450 2C19 who are treated with long-term dual antiplatelet therapy after undergoing drug-eluting stent implantation. Heart Vessels 2020;35:312-22. [PMID: 31549178 DOI: 10.1007/s00380-019-01499-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
424 Ishida M, Takahashi F, Goto I, Niiyama M, Saitoh H, Sakamoto T, Maegawa Y, Osaki T, Nishiyama O, Endo H, Sakamoto R, Kojima T, Koeda Y, Kimura T, Itoh T, Morino Y; REIWA investigators. Clinical outcomes of patients treated using very short duration dual antiplatelet therapy after implantation of biodegradable-polymer drug-eluting stents: rationale and design of a prospective multicenter REIWA registry. Cardiovasc Interv Ther 2020;35:398-404. [PMID: 32776221 DOI: 10.1007/s12928-020-00694-y] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
425 Tomaniak M, Chichareon P, Takahashi K, Kogame N, Modolo R, Chang CC, Spitzer E, Neumann F, Plante S, Hernández Antolin R, Jambrik Z, Gelev V, Brunel P, Konteva M, Beygui F, Morelle J, Filipiak KJ, van Geuns R, Soliman O, Tijssen J, Rademaker-havinga T, Storey RF, Hamm C, Steg PG, Windecker S, Onuma Y, Valgimigli M, Serruys PW; for the GLOBAL LEADERS Study Investigators. Impact of chronic obstructive pulmonary disease and dyspnoea on clinical outcomes in ticagrelor treated patients undergoing percutaneous coronary intervention in the randomized GLOBAL LEADERS trial. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:222-30. [DOI: 10.1093/ehjcvp/pvz052] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
426 Montalto C, Crimi G, Morici N, Piatti L, Grosseto D, Sganzerla P, Tortorella G, De Rosa R, De Luca L, De Luca G, Palmerini T, Valgimigli M, Savonitto S, De Servi S. Bleeding risk prediction in elderly patients managed invasively for acute coronary syndromes: External validation of the PRECISE-DAPT and PARIS scores. Int J Cardiol 2021;328:22-8. [PMID: 33279593 DOI: 10.1016/j.ijcard.2020.11.065] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
427 Mahé G, Boge G, Bura-rivière A, Chakfé N, Constans J, Goueffic Y, Lacroix P, Le Hello C, Pernod G, Perez-martin A, Picquet J, Sprynger M, Behar T, Bérard X, Breteau C, Brisot D, Chleir F, Choquenet C, Coscas R, Detriché G, Elias M, Ezzaki K, Fiori S, Gaertner S, Gaillard C, Gaudout C, Gauthier C, Georg Y, Hertault A, Jean-baptiste E, Joly M, Kaladji A, Laffont J, Laneelle D, Laroche J, Lejay A, Long A, Loric T, Madika A, Magnou B, Maillard J, Malloizel J, Miserey G, Moukarzel A, Mounier-vehier C, Nasr B, Nelzy M, Nicolini P, Phelipot J, Sabatier J, Schaumann G, Soudet S, Tissot A, Tribout L, Wautrecht J, Zarca C, Zuber A. Disparities Between International Guidelines (AHA/ESC/ESVS/ESVM/SVS) Concerning Lower Extremity Arterial Disease: Consensus of the French Society of Vascular Medicine (SFMV) and the French Society for Vascular and Endovascular Surgery (SCVE). Annals of Vascular Surgery 2021;72:1-56. [DOI: 10.1016/j.avsg.2020.11.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
428 Porta Bonete G, Godier A, Gaussem P, Belleville-Rolland T, Leuci A, Poirault-Chassac S, Bachelot-Loza C, Martin AC. Comparative In Vitro Study of Various α2-Adrenoreceptor Agonist Drugs for Ticagrelor Reversal. J Clin Med 2020;9:E809. [PMID: 32188130 DOI: 10.3390/jcm9030809] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
429 Mahla E, Tantry US, Prüller F, Gurbel PA. Is There a Role for Preoperative Platelet Function Testing in Patients Undergoing Cardiac Surgery During Antiplatelet Therapy? Circulation 2018;138:2145-59. [DOI: 10.1161/circulationaha.118.035160] [Cited by in Crossref: 19] [Cited by in F6Publishing: 4] [Article Influence: 6.3] [Reference Citation Analysis]
430 Kim HK, Kim HB, Lee JM, Kim SS, Bae IH, Park DS, Park JK, Shim JW, Na JY, Lee MY, Kim JS, Sim DS, Hong YJ, Nam CW, Doh JH, Park J, Koo BK, Kim SU, Lim KS, Jeong MH. Influence of Local Myocardial Infarction on Endothelial Function, Neointimal Progression, and Inflammation in Target and Non-Target Vascular Territories in a Porcine Model of Acute Myocardial Infarction. J Korean Med Sci 2019;34:e145. [PMID: 31099195 DOI: 10.3346/jkms.2019.34.e145] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
431 Agarwal N, Mahmoud AN, Mojadidi MK, Golwala H, Elgendy IY. Dual versus triple antithrombotic therapy in patients undergoing percutaneous coronary intervention-meta-analysis and meta-regression. Cardiovascular Revascularization Medicine 2019;20:1134-9. [DOI: 10.1016/j.carrev.2019.02.022] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
432 Gurbel PA, Tantry US, Bliden KP, Fisher R, Sukavaneshvar S, Dahlen J, Speros PC. Clinical validation of AggreGuide A-100 ADP, a novel assay for assessing the antiplatelet effect of oral P2Y12 antagonists. J Thromb Thrombolysis 2021;52:272-80. [PMID: 34143384 DOI: 10.1007/s11239-021-02498-0] [Reference Citation Analysis]
433 Cervo A, Ferrari F, Barchetti G, Quilici L, Piano M, Boccardi E, Pero G. Use of Cangrelor in Cervical and Intracranial Stenting for the Treatment of Acute Ischemic Stroke: A "Real Life" Single-Center Experience. AJNR Am J Neuroradiol 2020;41:2094-9. [PMID: 33033047 DOI: 10.3174/ajnr.A6785] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 9.0] [Reference Citation Analysis]
434 Kereiakes DJ, Hill JM, Ben-yehuda O, Maehara A, Alexander B, Stone GW. Evaluation of safety and efficacy of coronary intravascular lithotripsy for treatment of severely calcified coronary stenoses: Design and rationale for the Disrupt CAD III trial. American Heart Journal 2020;225:10-8. [DOI: 10.1016/j.ahj.2020.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
435 Cho JY, Lee SY, Yun KH, Kim BK, Hong SJ, Ko JS, Rhee SJ, Oh SK, Shin DH, Ahn CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y. Factors Related to Major Bleeding After Ticagrelor Therapy: Results from the TICO Trial. J Am Heart Assoc 2021;10:e019630. [PMID: 33739127 DOI: 10.1161/JAHA.120.019630] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
436 Chen PW, Feng WH, Ho MY, Su CH, Huang SW, Cheng CW, Yeh HI, Chen CP, Huang WC, Fang CC, Lin HLS, Hsieh IC, Li YH. P2Y12 Inhibitor Monotherapy with Clopidogrel Versus Ticagrelor in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. J Clin Med 2020;9:E1657. [PMID: 32492818 DOI: 10.3390/jcm9061657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
437 van der Sangen NMR, Rozemeijer R, Chan Pin Yin DRPP, Valgimigli M, Windecker S, James SK, Buccheri S, Ten Berg JM, Henriques JPS, Voskuil M, Kikkert WJ. Patient-tailored antithrombotic therapy following percutaneous coronary intervention. Eur Heart J 2021;42:1038-46. [PMID: 33515031 DOI: 10.1093/eurheartj/ehaa1097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
438 Pavasini R, Maietti E, Tonet E, Bugani G, Tebaldi M, Biscaglia S, Cimaglia P, Serenelli M, Ruggiero R, Vitali F, Galvani M, Minarelli M, Rubboli A, Bernucci D, Volpato S, Campo G. Bleeding Risk Scores and Scales of Frailty for the Prediction of Haemorrhagic Events in Older Adults with Acute Coronary Syndrome: Insights from the FRASER study. Cardiovasc Drugs Ther 2019;33:523-32. [PMID: 31549262 DOI: 10.1007/s10557-019-06911-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 7.0] [Reference Citation Analysis]
439 Wang Y, Liu B, Chen L, Wang Y, Wang Z, Zhang X, Suo M, Mintz GS, Wu X. Safety and efficacy of low-dose ticagrelor in Chinese patients with acute coronary syndrome undergoing percutaneous coronary intervention. Platelets 2021;:1-8. [PMID: 33813995 DOI: 10.1080/09537104.2021.1909717] [Reference Citation Analysis]
440 Cavallari LH, Franchi F, Rollini F, Been L, Rivas A, Agarwal M, Smith DM, Newsom K, Gong Y, Elsey AR, Starostik P, Johnson JA, Angiolillo DJ. Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention. J Transl Med 2018;16:92. [PMID: 29642909 DOI: 10.1186/s12967-018-1469-8] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 7.7] [Reference Citation Analysis]
441 Schiele F, Puymirat E, Ferrières J, Simon T, Fox KA, Eikelboom J, Danchin N. The FAST-MI 2005-2010-2015 registries in the light of the COMPASS trial: The COMPASS criteria applied to a post-MI population. International Journal of Cardiology 2019;278:7-13. [DOI: 10.1016/j.ijcard.2018.11.138] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 5.5] [Reference Citation Analysis]
442 Leidi F, Schiavon R; Gruppo di Autoformazione Metodologica (GrAM). Drug-eluting stents vs. bare metal stents in elderly patients. Intern Emerg Med 2018;13:773-4. [PMID: 29594816 DOI: 10.1007/s11739-018-1839-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
443 Urban P, Mehran R, Colleran R, Angiolillo DJ, Byrne RA, Capodanno D, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim HS, Kimura T, Konishi A, Laschinger J, Leon MB, Magee PFA, Mitsutake Y, Mylotte D, Pocock S, Price MJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhoevel U, Yeh RW, Krucoff MW, Morice MC. Defining High Bleeding Risk in Patients Undergoing Percutaneous Coronary Intervention. Circulation 2019;140:240-61. [PMID: 31116032 DOI: 10.1161/CIRCULATIONAHA.119.040167] [Cited by in Crossref: 162] [Cited by in F6Publishing: 30] [Article Influence: 81.0] [Reference Citation Analysis]
444 Jeger RV, Pfisterer M, Vogt DR, Galatius S, Abildgaard U, Naber C, Alber H, Eberli F, Kurz DJ, Pedrazzini G, Vuilliomenet A, Weilenmann D, Rickli H, Hansen KW, Rickenbacher P, Conen D, Müller C, Osswald S, Gilgen N, Kaiser C. Competing risks of major bleeding and thrombotic events with prasugrel-based dual antiplatelet therapy after stent implantation - An observational analysis from BASKET-PROVE II. PLoS One 2019;14:e0210821. [PMID: 30645635 DOI: 10.1371/journal.pone.0210821] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
445 Witberg G, Zusman O, Bental T, Plakht I, Gabbay H, Gerber Y, Kornowski R. Validation of the DAPT score in real-world patients undergoing coronary stent implantation. International Journal of Cardiology 2020;300:99-105. [DOI: 10.1016/j.ijcard.2019.08.044] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
446 Lordkipanidzé M, Marquis-Gravel G, Tanguay JF, Mehta SR, So DYF. Implications of the Antiplatelet Therapy Gap Left With Discontinuation of Prasugrel in Canada. CJC Open 2021;3:814-21. [PMID: 34169260 DOI: 10.1016/j.cjco.2020.11.021] [Reference Citation Analysis]
447 Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ. ACC/AHA Versus ESC Guidelines on Dual Antiplatelet Therapy. Journal of the American College of Cardiology 2018;72:2915-31. [DOI: 10.1016/j.jacc.2018.09.057] [Cited by in Crossref: 138] [Cited by in F6Publishing: 86] [Article Influence: 46.0] [Reference Citation Analysis]
448 De Luca L, Temporelli PL, Riccio C, Gonzini L, Marinacci L, Tartaglione SN, Costa P, Scherillo M, Senni M, Colivicchi F, Gulizia MM; START Investigators. Clinical outcomes, pharmacological treatment, and quality of life of patients with stable coronary artery diseases managed by cardiologists: 1-year results of the START study. Eur Heart J Qual Care Clin Outcomes 2019;5:334-42. [PMID: 30649303 DOI: 10.1093/ehjqcco/qcz002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 7.0] [Reference Citation Analysis]
449 Valgimigli M, Costa F. Chronic Thrombocytopenia and Percutaneous Coronary Intervention: The Virtue of Prudence. JACC Cardiovasc Interv 2018;11:1869-71. [PMID: 30172793 DOI: 10.1016/j.jcin.2018.06.051] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
450 Shi J, He M, Wang W, Liu G, Zhang H, Sun D, Li J, Mu H, Xu M, Zhao C, Wang J, Zhang C, Cang H, Zhao S, Zhang Z, Li Y. Efficacy and safety of different ticagrelor regimens versus clopidogrel in patients with coronary artery disease: a retrospective multicenter study (SUPERIOR). Platelets 2021;32:120-9. [PMID: 32090650 DOI: 10.1080/09537104.2020.1732328] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
451 Podda G, Scavone M, Femia EA, Cattaneo M. Aggregometry in the settings of thrombocytopenia, thrombocytosis and antiplatelet therapy. Platelets 2018;29:644-9. [DOI: 10.1080/09537104.2018.1445843] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
452 Montalto C, Ferlini M, Casula M, Mandurino-Mirizzi A, Costa F, Leonardi S, Oltrona Visconti L. DAPT Score to Stratify Ischemic and Bleeding Risk after Percutaneous Coronary Intervention: An Updated Systematic Review, Meta-Analysis, and Meta-Regression of 100,211 Patients. Thromb Haemost 2021;121:687-9. [PMID: 33212543 DOI: 10.1055/s-0040-1721145] [Reference Citation Analysis]
453 Repossini A, Di Bacco L, Nicoli F, Passaretti B, Stara A, Jonida B, Muneretto C. Minimally invasive coronary artery bypass: Twenty-year experience. The Journal of Thoracic and Cardiovascular Surgery 2019;158:127-138.e1. [DOI: 10.1016/j.jtcvs.2018.11.149] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 7.0] [Reference Citation Analysis]
454 Brunetti ND, Tarantino N, De Gennaro L, Correale M, Santoro F, Di Biase M. Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis. Open Heart 2018;5:e000785. [PMID: 30018775 DOI: 10.1136/openhrt-2018-000785] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
455 Kedhi E, Latib A, Abizaid A, Kandzari D, Kirtane AJ, Mehran R, Price MJ, Simon D, Worthley S, Zaman A, Brar S, Liu M, Stone GW, Windecker S. Rationale and design of the Onyx ONE global randomized trial: A randomized controlled trial of high-bleeding risk patients after stent placement with 1 month of dual antiplatelet therapy. Am Heart J 2019;214:134-41. [PMID: 31203158 DOI: 10.1016/j.ahj.2019.04.017] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 10.5] [Reference Citation Analysis]
456 Wang HY, Gao RL, Xu B, Yang YJ, Yin D, Wang Y, Dou KF. Benefit-risk profile of extended dual antiplatelet therapy beyond 1 year in patients with high risk of ischemic or bleeding events after PCI. Platelets 2021;32:533-41. [PMID: 32498587 DOI: 10.1080/09537104.2020.1774052] [Reference Citation Analysis]
457 Ziviello F, Pilgrim T, Kroon H, Ooms JF, van Wiechen MP, El Azzouzi I, Stortecky S, Asami M, Daemen J, de Jaegere PP, Windecker S, van Mieghem NM. HAS-BLED score and actual bleeding in elderly patients undergoing transcatheter aortic valve implantation. Minerva Med 2020;111. [DOI: 10.23736/s0026-4806.19.06154-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
458 Kamada T, Satoh K, Itoh T, Ito M, Iwamoto J, Okimoto T, Kanno T, Sugimoto M, Chiba T, Nomura S, Mieda M, Hiraishi H, Yoshino J, Takagi A, Watanabe S, Koike K. Evidence-based clinical practice guidelines for peptic ulcer disease 2020. J Gastroenterol 2021;56:303-22. [PMID: 33620586 DOI: 10.1007/s00535-021-01769-0] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
459 Cassese S, Ndrepepa G, Byrne RA, Laugwitz K, Schunkert H, Fusaro M, Alfonso F, Kastrati A. Ticagrelor-based antiplatelet regimens in patients with atherosclerotic artery disease—A meta-analysis of randomized clinical trials. American Heart Journal 2020;219:109-16. [DOI: 10.1016/j.ahj.2019.08.020] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
460 Weintraub WS, Taggart DP, Mancini GBJ, Brown DL, Boden WE. Historical Milestones in the Management of Stable Coronary Artery Disease over the Last Half Century. Am J Med 2018;131:1285-92. [PMID: 29959899 DOI: 10.1016/j.amjmed.2018.05.039] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
461 Kanenawa K, Yamaji K, Tashiro H, Domei T, Ando K, Watanabe H, Kimura T. Patient Selection and Clinical Outcomes in the STOPDAPT-2 Trial: An All-Comer Single-Center Registry During the Enrollment Period of the STOPDAPT-2 Randomized Controlled Trial. Circ Cardiovasc Interv 2021;14:e010007. [PMID: 33541100 DOI: 10.1161/CIRCINTERVENTIONS.120.010007] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
462 González-Juanatey JR, Almendro-Delia M, Cosín-Sales J, Bellmunt-Montoya S, Gómez-Doblas JJ, Riambau V, García-Moll X, García-Alegría J, Hernández JL, Lozano FS, Suarez Fernández C. Residual risk reduction opportunities in patients with chronic coronary syndrome. Role of dual pathway inhibition. Expert Rev Clin Pharmacol 2020;13:695-706. [PMID: 32434452 DOI: 10.1080/17512433.2020.1772056] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
463 Crea F. Management of ischaemic stroke, prognostic impact of procedural myocardial injury, and antiplatelet treatment: the many facets of interventional cardiology. Eur Heart J 2021;42:289-91. [PMID: 33625517 DOI: 10.1093/eurheartj/ehab001] [Reference Citation Analysis]
464 Verdoia M, Khedi E, Suryapranata H, De Luca G. Very short dual antiplatelet therapy after PCI and new DES: a meta-analysis of 5 randomized trials. Rev Esp Cardiol (Engl Ed) 2021;74:140-8. [PMID: 32482558 DOI: 10.1016/j.rec.2020.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
465 Cervino G, Fiorillo L, Monte IP, De Stefano R, Laino L, Crimi S, Bianchi A, Herford AS, Biondi A, Cicciù M. Advances in Antiplatelet Therapy for Dentofacial Surgery Patients: Focus on Past and Present Strategies. Materials (Basel) 2019;12:E1524. [PMID: 31075947 DOI: 10.3390/ma12091524] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 10.0] [Reference Citation Analysis]
466 Bunmark W, Jinatongthai P, Vathesatogkit P, Thakkinstian A, Reid CM, Wongcharoen W, Chaiyakunapruk N, Nathisuwan S. Antithrombotic Regimens in Patients With Percutaneous Coronary Intervention Whom an Anticoagulant Is Indicated: A Systematic Review and Network Meta-Analysis. Front Pharmacol 2018;9:1322. [PMID: 30510510 DOI: 10.3389/fphar.2018.01322] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
467 Serrano CV Jr, Soeiro AM, Leal TCAT, Godoy LC, Biselli B, Hata LA, Martins EB, Abud-Manta ICK, Tavares CAM, Cardozo FAM, Oliveira MT Jr. Statement on Antiplatelet Agents and Anticoagulants in Cardiology - 2019. Arq Bras Cardiol 2019;113:111-34. [PMID: 31411300 DOI: 10.5935/abc.20190128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
468 Stys TP, Gedela M, Gowda SN, Bares V, Fanta L, Petrasko M, Hajek C, Larson E, Stys AT. CYP2C19 genotype-directed P2Y12 inhibitor antiplatelet therapy normalizes risk for major adverse cardiovascular events after percutaneous coronary intervention. Indian Heart J 2021;73:281-8. [PMID: 34154743 DOI: 10.1016/j.ihj.2021.03.004] [Reference Citation Analysis]
469 Schäfer A, Flierl U, Berliner D, Bauersachs J. Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients. Cardiovasc Drugs Ther 2020;34:555-68. [PMID: 32350792 DOI: 10.1007/s10557-020-06981-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 6.0] [Reference Citation Analysis]
470 Gupta S, Belley-cote EP, Panchal P, Pandey A, Basha A, Pallo L, Rochwerg B, Mehta S, Schwalm J-, Whitlock RP. Antiplatelet therapy and coronary artery bypass grafting: a systematic review and network meta-analysis. Interactive CardioVascular and Thoracic Surgery 2020;31:354-63. [DOI: 10.1093/icvts/ivaa115] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
471 Hong SJ, Kim JS, Hong SJ, Lim DS, Lee SY, Yun KH, Park JK, Kang WC, Kim YH, Yoon HJ, Won H, Nam CM, Ahn CM, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; One-Month DAPT Investigators. 1-Month Dual-Antiplatelet Therapy Followed by Aspirin Monotherapy After Polymer-Free Drug-Coated Stent Implantation: One-Month DAPT Trial. JACC Cardiovasc Interv 2021;14:1801-11. [PMID: 34332946 DOI: 10.1016/j.jcin.2021.06.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
472 Piepoli MF, Abreu A, Albus C, Ambrosetti M, Brotons C, Catapano AL, Corra U, Cosyns B, Deaton C, Graham I, Hoes A, Lochen ML, Matrone B, Redon J, Sattar N, Smulders Y, Tiberi M. Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology. Eur J Prev Cardiol 2020;27:181-205. [PMID: 31826679 DOI: 10.1177/2047487319893035] [Cited by in Crossref: 69] [Cited by in F6Publishing: 42] [Article Influence: 34.5] [Reference Citation Analysis]
473 Gimbel ME, Ten Berg JM. Safety considerations with the use of platelet inhibitors for elderly patients with non-ST- elevation acute coronary syndrome. Expert Opin Drug Saf 2021;:1-8. [PMID: 34106029 DOI: 10.1080/14740338.2021.1936498] [Reference Citation Analysis]
474 Mehran R, Cao D, Baber U. Ticagrelor Monotherapy After Coronary Stenting. Journal of the American College of Cardiology 2019;74:2235-7. [DOI: 10.1016/j.jacc.2019.08.1037] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
475 Hahn J, Song YB, Oh J, Cho D, Lee JB, Doh J, Kim S, Jeong J, Bae J, Kim B, Cho JH, Suh I, Kim D, Park H, Park J, Choi WG, Lee WS, Kim J, Choi KH, Park TK, Lee JM, Yang JH, Choi J, Choi S, Gwon H, Gwon H, Hahn J, Song YB, Park TK, Lee JM, Yang JH, Choi J, Choi S, Lee J, Choi WG, Bae J, Park HS, Hwang J, Hur S, Rha S, Cho D, Cho SC, Kang WY, Lim S, Lee JB, Kim MH, Cha KS, Choi RK, Chae I, Oh J, Jang WJ, Park YH, Chun WJ, Kim S, Cho JH, Suh I, Park J, Choi JW, Kim B, Doh J, Kim D, Jeong MH, Kang SH, Lee WS, Park H, Jeong J, Ahn K. 6-month versus 12-month or longer dual antiplatelet therapy after percutaneous coronary intervention in patients with acute coronary syndrome (SMART-DATE): a randomised, open-label, non-inferiority trial. The Lancet 2018;391:1274-84. [DOI: 10.1016/s0140-6736(18)30493-8] [Cited by in Crossref: 135] [Cited by in F6Publishing: 40] [Article Influence: 45.0] [Reference Citation Analysis]
476 Teng M, Zhao YJ, Khoo AL, Ananthakrishna R, Yeo TC, Lim BP, Chan MY, Loh JP. Cost-effectiveness analysis of biodegradable polymer versus durable polymer drug-eluting stents incorporating real-world evidence. Cardiovasc Ther 2018;36:e12442. [PMID: 29873191 DOI: 10.1111/1755-5922.12442] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
477 Shi W, Yan L, Yang J, Yu M. Ethnic variance on long term clinical outcomes of concomitant use of proton pump inhibitors and clopidogrel in patients with stent implantation: A PRISMA-complaint systematic review with meta-analysis. Medicine (Baltimore) 2021;100:e24366. [PMID: 33578533 DOI: 10.1097/MD.0000000000024366] [Reference Citation Analysis]
478 Lesén E, Hewitt C, Giannitsis E, Hedberg J, Jernberg T, Lambrelli D, Maggioni AP, Simeone JC, Ariza-Solé A, Storey RF, Ten Berg J, Bonaca M; ALETHEIA study team. Extended dual antiplatelet therapy with ticagrelor 60 mg in patients with prior myocardial infarction: The design of ALETHEIA, a multi-country observational study. Clin Cardiol 2021. [PMID: 34365644 DOI: 10.1002/clc.23702] [Reference Citation Analysis]
479 Đukanović N, Obradović S, Zdravković M, Đurašević S, Stojković M, Tosti T, Jasnić N, Đorđević J, Todorović Z. Lipids and Antiplatelet Therapy: Important Considerations and Future Perspectives. Int J Mol Sci 2021;22:3180. [PMID: 33804754 DOI: 10.3390/ijms22063180] [Reference Citation Analysis]
480 Windecker S, Lopes RD, Massaro T, Jones-Burton C, Granger CB, Aronson R, Heizer G, Goodman SG, Darius H, Jones WS, Aschermann M, Brieger D, Cura F, Engstrøm T, Fridrich V, Halvorsen S, Huber K, Kang HJ, Leiva-Pons JL, Lewis BS, Malaga G, Meneveau N, Merkely B, Milicic D, Morais J, Potpara TS, Raev D, Sabaté M, de Waha-Thiele S, Welsh RC, Xavier D, Mehran R, Alexander JH; AUGUSTUS Investigators. Antithrombotic Therapy in Patients With Atrial Fibrillation and Acute Coronary Syndrome Treated Medically or With Percutaneous Coronary Intervention or Undergoing Elective Percutaneous Coronary Intervention: Insights From the AUGUSTUS Trial. Circulation 2019;140:1921-32. [PMID: 31557056 DOI: 10.1161/CIRCULATIONAHA.119.043308] [Cited by in Crossref: 35] [Cited by in F6Publishing: 6] [Article Influence: 17.5] [Reference Citation Analysis]
481 Zhao G, Zhou M, Ma C, Huo Y, Smith SC Jr, Fonarow GC, Ge J, Han Y, Liu J, Hao Y, Liu J, Wang X, Taubert KA, Morgan L, Zhao D, Nie S; CCC‐ACS Investigators. In-Hospital Outcomes of Dual Loading Antiplatelet Therapy in Patients 75 Years and Older With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: Findings From the CCC-ACS (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) Project. J Am Heart Assoc 2018;7:e008100. [PMID: 29602767 DOI: 10.1161/JAHA.117.008100] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
482 Nakanishi N, Kaikita K, Ishii M, Kuyama N, Tabata N, Ito M, Yamanaga K, Fujisue K, Hoshiyama T, Kanazawa H, Hanatani S, Sueta D, Takashio S, Arima Y, Araki S, Usuku H, Nakamura T, Suzuki S, Yamamoto E, Soejima H, Matsushita K, Tsujita K. Development and assessment of total thrombus-formation analysis system-based bleeding risk model in patients undergoing percutaneous coronary intervention. Int J Cardiol 2021;325:121-6. [PMID: 33053391 DOI: 10.1016/j.ijcard.2020.10.015] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
483 Li J, He K, Ge J, Li C, Jing Z. Short-term vs long-term dual antiplatelet therapy after drug-eluting stent implantation in patients undergoing percutaneous coronary intervention: A systematic review and meta-analysis. Int J Clin Pract 2021;75:e13938. [PMID: 33341109 DOI: 10.1111/ijcp.13938] [Reference Citation Analysis]
484 Gimbel M, Qaderdan K, Willemsen L, Hermanides R, Bergmeijer T, de Vrey E, Heestermans T, Tjon Joe Gin M, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg J. Clopidogrel versus ticagrelor or prasugrel in patients aged 70 years or older with non-ST-elevation acute coronary syndrome (POPular AGE): the randomised, open-label, non-inferiority trial. Lancet 2020;395:1374-81. [PMID: 32334703 DOI: 10.1016/S0140-6736(20)30325-1] [Cited by in Crossref: 65] [Cited by in F6Publishing: 11] [Article Influence: 65.0] [Reference Citation Analysis]
485 De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ. Cangrelor: Clinical Data, Contemporary Use, and Future Perspectives. J Am Heart Assoc 2021;10:e022125. [PMID: 34212768 DOI: 10.1161/JAHA.121.022125] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
486 Godier A, Garrigue D, Lasne D, Fontana P, Bonhomme F, Collet J, de Maistre E, Ickx B, Gruel Y, Mazighi M, Nguyen P, Vincentelli A, Albaladejo P, Lecompte T. Management of antiplatelet therapy for non-elective invasive procedures or bleeding complications: Proposals from the French Working Group on Perioperative Haemostasis (GIHP) and the French Study Group on Thrombosis and Haemostasis (GFHT), in collaboration with the French Society for Anaesthesia and Intensive Care (SFAR). Archives of Cardiovascular Diseases 2019;112:199-216. [DOI: 10.1016/j.acvd.2018.10.004] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
487 Shoji K, Zen K, Ookura T, Yanishi K, Matoba S. Early stent thrombosis confirmed in a cancer patient receiving regorafenib, despite triple antithrombotic therapy: a case report. BMC Cardiovasc Disord 2021;21:60. [PMID: 33516171 DOI: 10.1186/s12872-021-01888-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
488 Lupu L, Shepshelovich D, Banai S, Hershkoviz R, Isakov O. Effect of Ticagrelor on Reducing the Risk of Gram-Positive Infections in Patients With Acute Coronary Syndrome. The American Journal of Cardiology 2020;130:56-63. [DOI: 10.1016/j.amjcard.2020.06.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
489 Sibbing D, Cassese S. Ticagrelor Monotherapy After Coronary Stenting: Like a Twilight Through the Looking Glass. JACC Cardiovasc Interv 2021;14:457-60. [PMID: 33602442 DOI: 10.1016/j.jcin.2020.12.039] [Reference Citation Analysis]
490 Gamal AS, Hara H, Tomaniak M, Lunardi M, Gao C, Ono M, Kawashima H, Jüni P, Vranckx P, Windecker S, Hamm C, Steg PG, Onuma Y, Serruys PW. 'Ticagrelor alone vs. dual antiplatelet therapy from 1 month after drug-eluting coronary stenting among patients with STEMI': a post hoc analysis of the randomized GLOBAL LEADERS trial. Eur Heart J Acute Cardiovasc Care 2021:zuab033. [PMID: 34212187 DOI: 10.1093/ehjacc/zuab033] [Reference Citation Analysis]
491 Chieffo A, Dudek D, Hassager C, Combes A, Gramegna M, Halvorsen S, Huber K, Kunadian V, Maly J, Møller JE, Pappalardo F, Tarantini G, Tavazzi G, Thiele H, Vandenbriele C, van Mieghem N, Vranckx P, Werner N, Price S. Joint EAPCI/ACVC expert consensus document on percutaneous ventricular assist devices. Eur Heart J Acute Cardiovasc Care 2021;10:570-83. [PMID: 34057173 DOI: 10.1093/ehjacc/zuab015] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
492 Floyd CN. Dual Antiplatelet Therapy in Coronary Artery Disease: Comparison Between ACC/AHA 2016 and ESC 2017 Guidelines. Eur Cardiol 2020;15:1-3. [PMID: 32180836 DOI: 10.15420/ecr.2019.09] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
493 Mirzaev KB, Rytkin E, Ryzhikova KA, Grishina EA, Sozaeva ZA, Fedorinov DS, Konova OD, Giliarov MI, Belyakova GA, Andreev DA, Sychev DA. The ABCB1, CYP2C19, CYP3A5 and CYP4F2 genetic polymorphisms and platelet reactivity in the early phases of acute coronary syndromes. Drug Metabolism and Personalized Therapy 2018;33:109-18. [DOI: 10.1515/dmpt-2018-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
494 Honda S, Nishihira K, Kojima S, Takegami M, Asaumi Y, Suzuki M, Kosuge M, Takahashi J, Sakata Y, Takayama M, Sumiyoshi T, Ogawa H, Kimura K, Yasuda S; JAMIR Investigators. Characteristics and clinical outcomes of patients with de-escalation from prasugrel to clopidogrel after acute myocardial infarction - Insights from the prospective Japan Acute Myocardial Infarction Registry (JAMIR). J Cardiol 2021;78:99-106. [PMID: 33745775 DOI: 10.1016/j.jjcc.2021.03.001] [Reference Citation Analysis]
495 Mauler-Wittwer S, Garot P. The Biolimus A9-coated BioFreedom stent: from clinical efficacy to real-world evidence. Future Cardiol 2021;17:239-55. [PMID: 32893680 DOI: 10.2217/fca-2020-0069] [Reference Citation Analysis]
496 Ariotti S, Ortega-Paz L, van Leeuwen M, Brugaletta S, Leonardi S, Akkerhuis KM, Rimoldi SF, Janssens G, Gianni U, van den Berge JC, Karagiannis A, Windecker S, Valgimigli M; HI-TECH Investigators. Effects of Ticagrelor, Prasugrel, or Clopidogrel on Endothelial Function and Other Vascular Biomarkers: A Randomized Crossover Study. JACC Cardiovasc Interv 2018;11:1576-86. [PMID: 29805112 DOI: 10.1016/j.jcin.2018.04.022] [Cited by in Crossref: 26] [Cited by in F6Publishing: 19] [Article Influence: 8.7] [Reference Citation Analysis]
497 Luo L, Fu M, Li Y, Chen Z, Yu J, Luo J, Hu S, Tu L, Xu X. The efficacy and safety of P2Y12 inhibitor monotherapy in patients after percutaneous coronary intervention. Clin Cardiol 2020;43:235-41. [PMID: 31777973 DOI: 10.1002/clc.23305] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
498 Lattuca B, Kerneis M, Zeitouni M, Cayla G, Guedeney P, Collet J, Montalescot G, Silvain J. Elderly Patients with ST-Segment Elevation Myocardial Infarction: A Patient-Centered Approach. Drugs Aging 2019;36:531-9. [DOI: 10.1007/s40266-019-00663-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
499 Terlouw LG, Moelker A, Abrahamsen J, Acosta S, Bakker OJ, Baumgartner I, Boyer L, Corcos O, van Dijk LJ, Duran M, Geelkerken RH, Illuminati G, Jackson RW, Kärkkäinen JM, Kolkman JJ, Lönn L, Mazzei MA, Nuzzo A, Pecoraro F, Raupach J, Verhagen HJ, Zech CJ, van Noord D, Bruno MJ. European guidelines on chronic mesenteric ischaemia - joint United European Gastroenterology, European Association for Gastroenterology, Endoscopy and Nutrition, European Society of Gastrointestinal and Abdominal Radiology, Netherlands Association of Hepatogastroenterologists, Hellenic Society of Gastroenterology, Cardiovascular and Interventional Radiological Society of Europe, and Dutch Mesenteric Ischemia Study group clinical guidelines on the diagnosis and treatment of patients with chronic mesenteric ischaemia. United European Gastroenterol J 2020;8:371-95. [PMID: 32297566 DOI: 10.1177/2050640620916681] [Cited by in Crossref: 23] [Cited by in F6Publishing: 13] [Article Influence: 23.0] [Reference Citation Analysis]
500 Chaturvedula S, Diver D, Vashist A. Antiplatelet Therapy in Coronary Artery Disease: A Daunting Dilemma. J Clin Med 2018;7:E74. [PMID: 29642547 DOI: 10.3390/jcm7040074] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
501 Wang HY, Wang Y, Yin D, Gao RL, Yang YJ, Xu B, Dou KF. Percutaneous Coronary Intervention Complexity and Risk of Adverse Events in relation to High Bleeding Risk among Patients Receiving Drug-Eluting Stents: Insights from a Large Single-Center Cohort Study. J Interv Cardiol 2020;2020:2985435. [PMID: 32405273 DOI: 10.1155/2020/2985435] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
502 Kheiri B, Osman M, Abdalla A, Haykal T, Chahine A, Gwinn M, Ahmed S, Hassan M, Bachuwa G, Bhatt DL. Drug-Eluting Versus Bare-Metal Stents in Older Patients: A Meta-Analysis of Randomized Controlled Trials. Cardiovasc Revasc Med 2019;20:744-51. [PMID: 30446398 DOI: 10.1016/j.carrev.2018.11.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
503 Wolska N, Kassassir H, Luzak B, Watala C, Rozalski M. Adenosine Receptor Agonists Increase the Inhibition of Platelet Function by P2Y12 Antagonists in a cAMP- and Calcium-Dependent Manner. Pharmaceuticals (Basel) 2020;13:E177. [PMID: 32752089 DOI: 10.3390/ph13080177] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
504 Lin Y, Chen Y, Yuan J, Qin H, Dong S, Chen Q. Impact of aspirin use on clinical outcomes in patients with vasospastic angina: a systematic review and meta-analysis. BMJ Open 2021;11:e048719. [PMID: 34326051 DOI: 10.1136/bmjopen-2021-048719] [Reference Citation Analysis]
505 Sinha N, Balayla G, Braghiroli J. Coronary artery disease in lung transplant patients. Clin Transplant 2020;34:e14078. [PMID: 32940380 DOI: 10.1111/ctr.14078] [Reference Citation Analysis]
506 He J, Ge H, Dong JX, Zhang W, Kong LC, Qiao ZQ, Zheng Y, Ding S, Wan F, Shen L, Wang W, Gu ZC, Yang F, Li Z, Pu J. Rationale and design of a prospective multi-center randomized trial of EARLY treatment by rivaroxaban versus warfarin in ST-segment elevation MYOcardial infarction with Left Ventricular Thrombus (EARLY-MYO-LVT trial). Ann Transl Med 2020;8:392. [PMID: 32355836 DOI: 10.21037/atm.2020.02.117] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
507 Koyama S, Yamashita A, Matsuura Y, Saito Y, Maekawa K, Gi T, Kitamura K, Asada Y. Intracellular glutamine level determines vascular smooth muscle cell-derived thrombogenicity. Atherosclerosis 2021;328:62-73. [PMID: 34102425 DOI: 10.1016/j.atherosclerosis.2021.05.012] [Reference Citation Analysis]
508 Chi G, Kerneis M, Kalayci A, Liu Y, Mehran R, Bode C, Halperin JL, Verheugt FW, Wildgoose P, van Eickels M, Lip GY, Cohen M, Peterson ED, Fox KA, Gibson CM. Safety and efficacy of non–vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. American Heart Journal 2018;203:17-24. [DOI: 10.1016/j.ahj.2018.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
509 Katsi V, Georgiopoulos G, Skafida A, Oikonomou D, Klettas D, Vemmos K, Tousoulis D. Noncardioembolic Stroke in Patients with Atrial Fibrillation. Angiology 2019;70:299-304. [DOI: 10.1177/0003319718791711] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 4.3] [Reference Citation Analysis]
510 Pelliccia F, Pasceri V, Marazzi G, Cacciotti L, Placanica A, Gragnano F, Niccoli G, Palmerini T, Tanzilli G, Speciale G, Granatelli A, Calabrò P, Crea F, Gaudio C. Predictive ability of longitudinal changes in PRECISE-DAPT score in patients on dual antiplatelet therapy: The RE-SCORE multicentre prospective registry. Eur J Prev Cardiol 2020;:2047487320937846. [PMID: 32623903 DOI: 10.1177/2047487320937846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
511 Wu XT, He RR, Liang SZ, Ye GY, Ding SB. Effect of P2Y12 inhibitor monotherapy versus dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: systematic review and meta-analysis. Minerva Med 2020;111:173-80. [PMID: 32338843 DOI: 10.23736/S0026-4806.19.06281-5] [Reference Citation Analysis]
512 Schiele F, Lemesle G, Angoulvant D, Krempf M, Kownator S, Cheggour S, Belle L, Ferrières J, Bauters C, Bergerot C, Beygui F, Boccara F, Bonnefoy E, Bruckert E, Cayla G, Collet J, Coste P, Descotes-genon V, Ducrocq G, Elbaz M, Farnier M, Ferrari E, Guedj D, Levai L, Mansourati J, Mansencal N, Meneveau N, Meune C, Morel O, Ohlmann P, Paillard F, Piot C, Puymirat E, Rioufol G, Roubille F, Sabouret P, Teiger E. Proposal for a standardized discharge letter after hospital stay for acute myocardial infarction. European Heart Journal. Acute Cardiovascular Care 2020;9:788-801. [DOI: 10.1177/2048872619844444] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
513 Serruys PW, Takahashi K, Chichareon P, Onuma Y. Twilight, the Dawn of a New Era of Aspirin-Free PCI? Journal of the American College of Cardiology 2020;75:2425-9. [DOI: 10.1016/j.jacc.2020.03.071] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
514 Ortega-Paz L, Brugaletta S, Sabaté M. Impact of PSP Technique on Clinical Outcomes Following Bioresorbable Scaffolds Implantation. J Clin Med 2018;7:E27. [PMID: 29415486 DOI: 10.3390/jcm7020027] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
515 Shi W, Ni L, Yang J, Fan X, Yu M, Yang H, Yu M, Yang Y; China Acute Myocardial Infarction (CAMI) Registry study group. Appropriateness of gastrointestinal prophylaxis use during hospitalization in patients with acute myocardial infarction: Analysis from the China Acute Myocardial Infarction Registry. Clin Cardiol 2021;44:43-50. [PMID: 33211327 DOI: 10.1002/clc.23449] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
516 Holm M, Biancari F, Khodabandeh S, Gherli R, Airaksinen J, Mariscalco G, Gatti G, Reichart D, Onorati F, De Feo M, Santarpino G, Rubino AS, Maselli D, Santini F, Nicolini F, Zanobini M, Kinnunen E, Ruggieri VG, Perrotti A, Rosato S, Dalén M. Bleeding in Patients Treated With Ticagrelor or Clopidogrel Before Coronary Artery Bypass Grafting. The Annals of Thoracic Surgery 2019;107:1690-8. [DOI: 10.1016/j.athoracsur.2019.01.086] [Cited by in Crossref: 22] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
517 Kubica J, Jaguszewski M. ISAR-REACT 5 - What have we learned? Cardiol J 2019;26:427-8. [PMID: 31536136 DOI: 10.5603/CJ.a2019.0090] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
518 Gimbel ME, Minderhoud SCS, Ten Berg JM. A practical guide on how to handle patients with bleeding events while on oral antithrombotic treatment. Neth Heart J 2018;26:341-51. [PMID: 29740754 DOI: 10.1007/s12471-018-1117-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
519 Mangieri A, Gallo F, Sticchi A, Khokhar AA, Laricchia A, Giannini F, Colombo A. Dual antiplatelet therapy in coronary artery disease: from the past to the future prospective. Cardiovasc Interv and Ther 2020;35:117-29. [DOI: 10.1007/s12928-020-00642-w] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 13.0] [Reference Citation Analysis]
520 Costa F, Valgimigli M. The optimal duration of dual antiplatelet therapy after coronary stent implantation: to go too far is as bad as to fall short. Cardiovasc Diagn Ther 2018;8:630-46. [PMID: 30498687 DOI: 10.21037/cdt.2018.10.01] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
521 López-fernández T, Martín-garcía A, Roldán Rabadán I, Mitroi C, Mazón Ramos P, Díez-villanueva P, Escobar Cervantes C, Alonso Martín C, Alonso Salinas GL, Arenas M, Arrarte Esteban VI, Ayala de La Peña F, Castro Fernández A, García Pardo H, García-sanz R, González Porras JR, López de Sá E, Lozano T, Marco Vera P, Martínez Marín V, Mesa Rubio D, Montero Á, Oristrell G, Pérez de Prado A, Velasco del Castillo S, Virizuela Echaburu JA, Zatarain-nicolás E, Anguita Sánchez M, Tamargo Menéndez J, Marín F, López-sendón JL, Zamorano JL. Abordaje de la fibrilación auricular en pacientes con cáncer activo. Documento de consenso de expertos y recomendaciones. Revista Española de Cardiología 2019;72:749-59. [DOI: 10.1016/j.recesp.2019.03.017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
522 Villecourt A, Faroux L, Muneaux A, Tassan-mangina S, Heroguelle V, Poncet A, Nazeyrollas P, Ruggieri VG, Metz D. Comparison of clinical outcomes after transcarotid and transsubclavian versus transfemoral transcatheter aortic valve implantation: A propensity-matched analysis. Archives of Cardiovascular Diseases 2020;113:189-98. [DOI: 10.1016/j.acvd.2020.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
523 Sim DS, Jeong MH, Kim HS, Gwon HC, Seung KB, Rha SW, Chae SC, Kim CJ, Cha KS, Park JS, Yoon JH, Chae JK, Joo SJ, Choi DJ, Hur SH, Seong IW, Cho MC, Kim DI, Oh SK, Ahn TH, Hwang JY; KAMIR-NIH registry investigators. Clopidogrel versus Aspirin after Dual Antiplatelet Therapy in Acute Myocardial Infarction Patients Undergoing Drug-Eluting Stenting. Korean Circ J 2020;50:120-9. [PMID: 31845550 DOI: 10.4070/kcj.2019.0166] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
524 Chyrchel B, Drożdż A, Długosz D, Stępień EŁ, Surdacki A. Platelet Reactivity And Circulating Platelet-Derived Microvesicles Are Differently Affected By P2Y12 Receptor Antagonists. Int J Med Sci 2019;16:264-75. [PMID: 30745807 DOI: 10.7150/ijms.28580] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
525 Kurlander JE, Barnes GD, Sukul D, Helminski D, Kokaly AN, Platt K, Gurm H, Saini SD. Trials of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention Lack Strategies to Ensure Appropriate Gastroprotection. Am J Gastroenterol 2021;116:821-4. [PMID: 33982954 DOI: 10.14309/ajg.0000000000001134] [Reference Citation Analysis]
526 Moja L, Polo Friz H, Capobussi M, Kwag K, Banzi R, Ruggiero F, González-Lorenzo M, Liberati EG, Mangia M, Nyberg P, Kunnamo I, Cimminiello C, Vighi G, Grimshaw JM, Delgrossi G, Bonovas S. Effectiveness of a Hospital-Based Computerized Decision Support System on Clinician Recommendations and Patient Outcomes: A Randomized Clinical Trial. JAMA Netw Open 2019;2:e1917094. [PMID: 31825499 DOI: 10.1001/jamanetworkopen.2019.17094] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
527 Chen C, Liu H, Duan R, Wang F, Duan L. The efficacy and safety of acid suppressants for gastrointestinal bleeding prophylaxis in cardiac care unit patients. J Gastroenterol Hepatol 2021;36:2131-40. [PMID: 33586808 DOI: 10.1111/jgh.15432] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
528 Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, Agewall S, Dickstein K, Edvardsen T, Escaned J, Gersh BJ, Svitil P, Gilard M, Hasdai D, Hatala R, Mahfoud F, Masip J, Muneretto C, Valgimigli M, Achenbach S, Bax JJ;  ESC Scientific Document Group. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41:407-477. [PMID: 31504439 DOI: 10.1093/eurheartj/ehz425] [Cited by in Crossref: 1201] [Cited by in F6Publishing: 728] [Article Influence: 1201.0] [Reference Citation Analysis]
529 Zocca P, Kok MM, van der Heijden LC, van Houwelingen KG, Hartmann M, de Man FH, Stoel MG, Louwerenburg JW, Knottnerus IL, Linssen GC, Doggen CJ, von Birgelen C. High bleeding risk patients with acute coronary syndromes treated with contemporary drug-eluting stents and Clopidogrel or Ticagrelor: Insights from CHANGE DAPT. International Journal of Cardiology 2018;268:11-7. [DOI: 10.1016/j.ijcard.2018.03.116] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
530 Liang LR, Ma Q, Feng L, Qiu Q, Zheng W, Xie WX. Long-term effect of clopidogrel in patients with and without diabetes: A systematic review and meta-analysis of randomized controlled trials. World J Diabetes 2020;11:137-49. [PMID: 32313612 DOI: 10.4239/wjd.v11.i4.137] [Reference Citation Analysis]
531 Krucoff MW, Urban P, Tanguay JF, McAndrew T, Zhang Y, Rao SV, Morice MC, Price MJ, Cohen DJ, Abdel-Wahab M, Mehta SR, Faurie B, McLaurin B, Diaz C, Stoll HP, Pocock S, Leon MB. Global Approach to High Bleeding Risk Patients With Polymer-Free Drug-Coated Coronary Stents: The LF II Study. Circ Cardiovasc Interv 2020;13:e008603. [PMID: 32279567 DOI: 10.1161/CIRCINTERVENTIONS.119.008603] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 12.0] [Reference Citation Analysis]
532 Fontana P, Roffi M, Reny JL. Platelet Function Test Use for Patients with Coronary Artery Disease in the Early 2020s. J Clin Med 2020;9:E194. [PMID: 31936845 DOI: 10.3390/jcm9010194] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
533 Sinnaeve P, Fahrni G, Schelfaut D, Spirito A, Mueller C, Frenoux J, Hmissi A, Bernaud C, Ufer M, Moccetti T, Atar S, Valgimigli M. Subcutaneous Selatogrel Inhibits Platelet Aggregation in Patients With Acute Myocardial Infarction. Journal of the American College of Cardiology 2020;75:2588-97. [DOI: 10.1016/j.jacc.2020.03.059] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 23.0] [Reference Citation Analysis]
534 Danielak D, Karaźniewicz-Łada M, Główka F. Assessment of the Risk of Rhabdomyolysis and Myopathy During Concomitant Treatment with Ticagrelor and Statins. Drugs 2018;78:1105-12. [PMID: 30003466 DOI: 10.1007/s40265-018-0947-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 5.5] [Reference Citation Analysis]
535 Krackhardt F, Waliszewski M, Kočka V, Toušek P, Janek B, Hudec M, Lozano F, Roman KG, Del Blanco BG, Mauri J, Heang TM, Ahn TH, Jeong MH, Herberger D, Tomulic V, Levy G, Sebagh L, Rischner J, Pansieri M. Real-World Dual Antiplatelet Therapy Following Polymer-Free Sirolimus-Eluting Stent Implantations to Treat Coronary Artery Disease. Cardiovasc Drugs Ther 2020;34:335-44. [PMID: 32212061 DOI: 10.1007/s10557-020-06963-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
536 Zerah L, Bonnet-Zamponi D, Dechartres A, Frappé P, Hauguel-Moreau M, Collet JP, Rycke Y, Tubach F. Impact of a Prescription Support Tool to Improve Adherence to the Guidelines for the Prescription of Oral Antithrombotics: The Combi-AT Randomized Controlled Trial Using Clinical Vignettes. J Clin Med 2019;8:E1919. [PMID: 31717418 DOI: 10.3390/jcm8111919] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
537 Lee S, Rhee T, Kang D, Choi E, Oh S, Lip GY. Meta-Analysis of Oral Anticoagulant Monotherapy as an Antithrombotic Strategy in Patients With Stable Coronary Artery Disease and Nonvalvular Atrial Fibrillation. The American Journal of Cardiology 2019;124:879-85. [DOI: 10.1016/j.amjcard.2019.05.072] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
538 Kirtane AJ, Stoler R, Feldman R, Neumann FJ, Boutis L, Tahirkheli N, Toelg R, Othman I, Stein B, Choi JW, Windecker S, Yeh RW, Dauerman HL, Price MJ, Underwood P, Allocco D, Meredith I, Kereiakes DJ. Primary Results of the EVOLVE Short DAPT Study: Evaluation of 3-Month Dual Antiplatelet Therapy in High Bleeding Risk Patients Treated With a Bioabsorbable Polymer-Coated Everolimus-Eluting Stent. Circ Cardiovasc Interv 2021;14:e010144. [PMID: 33641374 DOI: 10.1161/CIRCINTERVENTIONS.120.010144] [Cited by in Crossref: 6] [Article Influence: 6.0] [Reference Citation Analysis]
539 Halbach M, Baldus S. [Platelet inhibition in patients with coronary, cerebral and peripheral macroangiopathy : What, when and how long?]. Internist (Berl) 2018;59:288-303. [PMID: 29340741 DOI: 10.1007/s00108-017-0362-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
540 Shakhmatova OO, Komarov AL, Korobkova VV, Yarovaya EB, Andreevskaya MV, Shuleshova AG, Panchenko EP. [Upper gastrointestinal bleeding in patients with stable coronary artery disease (registry of antithrombotic therapy "REGATТA" results)]. Ter Arkh 2020;92:30-8. [PMID: 33346428 DOI: 10.26442/00403660.2020.09.000699] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
541 Lane DA, Dagres N, Dan GA, García Seara J, Iliodromitis K, Lenarczyk R, Lip GYH, Mansourati J, Marín F, Scherr D, Potpara TS. Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. Europace 2019;21:1116-25. [PMID: 30874724 DOI: 10.1093/europace/euz033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
542 Tian L, Gao X, Yang J, Yao Y, Ji H. Association of Adenosine Diphosphate-Induced Platelet Maximum Amplitude With Postoperative Bleeding and Blood Transfusions in Patients Undergoing Coronary Artery Bypass Grafting. J Cardiothorac Vasc Anesth 2021;35:421-8. [PMID: 32758409 DOI: 10.1053/j.jvca.2020.07.009] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
543 Kebernik J, Borlich M, Tölg R, El-Mawardy M, Abdel-Wahab M, Richardt G. Dual Antithrombotic Therapy with Clopidogrel and Novel Oral Anticoagulants in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Real-world Study. Cardiol Ther 2018;7:79-87. [PMID: 29633088 DOI: 10.1007/s40119-018-0108-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
544 Meloche C, Seth M, Madder RD, Kurlander JE, Yaser J, Chattahi J, Collins J, Lingam N, Arora D, Gurm HS, Sukul D. Percutaneous Coronary Intervention in Patients With a History of Gastrointestinal Bleeding (From the Blue Cross Blue Shield of Michigan Cardiovascular Consortium). Am J Cardiol 2021;155:9-15. [PMID: 34325106 DOI: 10.1016/j.amjcard.2021.06.013] [Reference Citation Analysis]
545 Bhattad VB, Gaddam S, Lassiter MA, Jagadish PS, Ardeshna D, Cave B, Khouzam RN. Intravenous cangrelor as a peri-procedural bridge with applied uses in ischemic events. Ann Transl Med 2019;7:408. [PMID: 31660307 DOI: 10.21037/atm.2019.07.64] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
546 Kubica A, Kosobucka A, Niezgoda P, Adamski P, Buszko K, Lesiak M, Wojakowski W, Gasior M, Gorący J, Kleinrok A, Nadolny K, Navarese E, Kubica J. ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. BMJ Open 2021;11:e043330. [PMID: 33649058 DOI: 10.1136/bmjopen-2020-043330] [Reference Citation Analysis]
547 Alfredsson J, Swahn E, Gustafsson KM, Janzon M, Jonasson L, Logander E, Nilsson L, Lindahl TL. Individual long-term variation of platelet reactivity in patients with dual antiplatelet therapy after myocardial infarction: Results from Assessing Platelet Activity in Coronary Heart Disease (APACHE). Platelets 2019;30:572-8. [DOI: 10.1080/09537104.2018.1479519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
548 Reid C, Alturki A, Yan A, So D, Ko D, Tanguay JF, Bessissow A, Mehta S, Goodman S, Huynh T. Meta-analysis Comparing Outcomes of Type 2 Myocardial Infarction and Type 1 Myocardial Infarction With a Focus on Dual Antiplatelet Therapy. CJC Open 2020;2:118-28. [PMID: 32462125 DOI: 10.1016/j.cjco.2020.02.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
549 Bálint A, Kupó P, Tornyos D, El Alaoui El Abdallaoui O, Jánosi A, Komócsi A. Oral anticoagulation and outcomes in patients with acute myocardial infarction: Insights from the Hungarian Myocardial Infarction Registry. Int J Clin Pract 2021;75:e14179. [PMID: 33759332 DOI: 10.1111/ijcp.14179] [Reference Citation Analysis]
550 Mauri L, Kirtane AJ, Windecker S, Yeh RW, Dauerman HL, Price MJ, Christen T, Allocco DJ, Meredith IT, Kereiakes DJ. Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention. American Heart Journal 2018;205:110-7. [DOI: 10.1016/j.ahj.2018.08.004] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 5.0] [Reference Citation Analysis]
551 Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA, Storey RF. Impaired Fibrinolysis Predicts Adverse Outcome in Acute Coronary Syndrome Patients with Diabetes: A PLATO Sub-Study. Thromb Haemost 2020;120:412-22. [PMID: 31975352 DOI: 10.1055/s-0039-1701011] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
552 Kim BK, Hong SJ, Cho YH, Yun KH, Kim YH, Suh Y, Cho JY, Her AY, Cho S, Jeon DW, Yoo SY, Cho DK, Hong BK, Kwon H, Ahn CM, Shin DH, Nam CM, Kim JS, Ko YG, Choi D, Hong MK, Jang Y; TICO Investigators. Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary Syndrome: The TICO Randomized Clinical Trial. JAMA 2020;323:2407-16. [PMID: 32543684 DOI: 10.1001/jama.2020.7580] [Cited by in Crossref: 98] [Cited by in F6Publishing: 71] [Article Influence: 98.0] [Reference Citation Analysis]
553 Wadowski PP, Pultar J, Weikert C, Eichelberger B, Panzer B, Huber K, Lang IM, Koppensteiner R, Panzer S, Gremmel T. Protease-activated receptor-mediated platelet aggregation in acute coronary syndrome patients on potent P2Y12 inhibitors. Res Pract Thromb Haemost 2019;3:383-90. [PMID: 31294325 DOI: 10.1002/rth2.12213] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
554 Garg A, Rout A, Sharma A, Sargsyan D, Beavers T, Tantry U, Gurbel P, Rao SV, Kostis JB, Cohen M. Safety and efficacy of antiplatelet regimens after percutaneous coronary intervention using drug eluting stents: A network meta-analysis of randomized controlled trials. Progress in Cardiovascular Diseases 2020;63:243-8. [DOI: 10.1016/j.pcad.2020.03.018] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
555 Chandrasekhar J, Sartori S, Aquino MB, Baber U, Hájek P, Atzev B, Hudec M, Ong TK, Mates M, Borisov B, Warda HM, den Heijer P, Wojcik J, Iniguez A, Coufal Z, Khashaba A, Schee A, Munawar M, Gerber RT, Yan BP, Tejedor P, Kala P, Liew HB, Lee M, Kalkman DN, Dangas GD, de Winter RJ, Colombo A, Mehran R; MASCOT investigators (Appendix I). Comparison of One-Year Outcomes in Patients >75 Versus ≤75 Years With Coronary Artery Disease Treated With COMBO Stents (From The MASCOT Registry).Am J Cardiol. 2020;127:1-8. [PMID: 32418717 DOI: 10.1016/j.amjcard.2020.04.014] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
556 Capranzano P, Capodanno D. Switching between P2Y12 inhibitors: Rationale, methods, and expected consequences. Vascul Pharmacol 2019;116:4-7. [PMID: 30876967 DOI: 10.1016/j.vph.2019.03.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
557 Natsuaki M, Morimoto T, Shiomi H, Yamaji K, Watanabe H, Shizuta S, Kato T, Ando K, Nakagawa Y, Furukawa Y, Tada T, Nagao K, Kadota K, Toyofuku M, Kimura T; on behalf of the CREDO-Kyoto PCI/CABG Registry Cohort-2 Investigators. Application of the Academic Research Consortium High Bleeding Risk Criteria in an All-Comers Registry of Percutaneous Coronary Intervention. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.119.008307] [Cited by in Crossref: 51] [Cited by in F6Publishing: 5] [Article Influence: 25.5] [Reference Citation Analysis]
558 Giacoppo D, Matsuda Y, Fovino LN, D'Amico G, Gargiulo G, Byrne RA, Capodanno D, Valgimigli M, Mehran R, Tarantini G. Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J 2021;42:308-19. [PMID: 33284979 DOI: 10.1093/eurheartj/ehaa739] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
559 Zeymer U, Cully M, Hochadel M. Adherence to dual antiplatelet therapy with ticagrelor in patients with acute coronary syndromes treated with percutaneous coronary intervention in real life. Results of the REAL-TICA registry. European Heart Journal - Cardiovascular Pharmacotherapy 2018;4:205-10. [DOI: 10.1093/ehjcvp/pvy018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
560 Li J, Qiu H, Yan L, Guo T, Wang Y, Li Y, Zheng J, Tang Y, Xu B, Qiao S, Yang Y, Gao R. Efficacy and safety of ticagrelor and clopidogrel in East Asian patients with coronary artery disease undergoing percutaneous coronary intervention. Curr Med Res Opin 2020;36:1739-45. [PMID: 32945695 DOI: 10.1080/03007995.2020.1825364] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
561 Ahn JH, Ahn Y, Jeong MH, Kim JH, Hong YJ, Sim DS, Kim MC, Hwang JY, Yoon JH, Seong IW, Hur S, Oh SK. Ticagrelor versus clopidogrel in acute myocardial infarction patients with multivessel disease; From Korea Acute Myocardial Infarction Registry-National Institute of Health. Journal of Cardiology 2020;75:478-84. [DOI: 10.1016/j.jjcc.2019.11.003] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
562 Carrillo-Aleman L, Marín F, Rivera-Caravaca JM, Vicente-Ibarra N, Candela-Sanchez E, Esteve-Pastor MA, Lozano T, Sandín-Rollan M, Pernias-Escrig V, Macías M, Quintana-Giner M, Veliz A, Orenes-Piñero E, Martínez-Martínez JG, Ruiz-Nodar JM. Switching of Oral P2Y12 Inhibitor Treatment in Patients with Acute Coronary Syndrome: Prevalence, Predictors, and Prognosis. Clin Drug Investig 2019;39:275-83. [PMID: 30623372 DOI: 10.1007/s40261-018-0736-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
563 Jang JY, Shin DH, Kim JS, Hong SJ, Ahn CM, Kim BK, Ko YG, Choi D, Hong MK, Park KW, Gwon HC, Kim HS, Jang Y. Optimal duration of DAPT after second-generation drug-eluting stent in acute coronary syndrome. PLoS One 2018;13:e0207386. [PMID: 30475845 DOI: 10.1371/journal.pone.0207386] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
564 Buccheri S, James S, Lindholm D, Fröbert O, Olivecrona GK, Persson J, Hambraeus K, Witt N, Erlinge D, Angerås O, Lagerqvist B, Sarno G. Clinical and angiographic outcomes of bioabsorbable vs. permanent polymer drug-eluting stents in Sweden: a report from the Swedish Coronary and Angioplasty Registry (SCAAR). European Heart Journal 2019;40:2607-15. [DOI: 10.1093/eurheartj/ehz244] [Cited by in Crossref: 12] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
565 Andò G, Costa F. Double or triple antithrombotic therapy after coronary stenting and atrial fibrillation: A systematic review and meta-analysis of randomized clinical trials. International Journal of Cardiology 2020;302:95-102. [DOI: 10.1016/j.ijcard.2019.12.054] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 16.0] [Reference Citation Analysis]
566 Kang DO, An H, Park GU, Yum Y, Park EJ, Park Y, Jang WY, Kim W, Choi JY, Roh SY, Na JO, Kim JW, Kim EJ, Rha SW, Park CG, Seo HS, Choi CU. Cardiovascular and Bleeding Risks Associated With Nonsteroidal Anti-Inflammatory Drugs After Myocardial Infarction. J Am Coll Cardiol 2020;76:518-29. [PMID: 32731930 DOI: 10.1016/j.jacc.2020.06.017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 8.0] [Reference Citation Analysis]
567 Matsumura-nakano Y, Shizuta S, Komasa A, Morimoto T, Masuda H, Shiomi H, Goto K, Nakai K, Ogawa H, Kobori A, Kono Y, Kaitani K, Suwa S, Aoyama T, Takahashi M, Sasaki Y, Onishi Y, Mano T, Matsuda M, Motooka M, Tomita H, Inoko M, Wakeyama T, Hagiwara N, Tanabe K, Akao M, Miyauchi K, Yajima J, Hanaoka K, Morino Y, Ando K, Furukawa Y, Nakagawa Y, Nakao K, Kozuma K, Kadota K, Kimura K, Kawai K, Ueno T, Okumura K, Kimura T; On behalf of the OAC-ALONE Study Investigators. Open-Label Randomized Trial Comparing Oral Anticoagulation With and Without Single Antiplatelet Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease Beyond 1 Year After Coronary Stent Implantation: OAC-ALONE Study. Circulation 2019;139:604-16. [DOI: 10.1161/circulationaha.118.036768] [Cited by in Crossref: 65] [Cited by in F6Publishing: 16] [Article Influence: 32.5] [Reference Citation Analysis]
568 Vivas D, Roldán V, Esteve-Pastor MA, Roldán I, Tello-Montoliu A, Ruiz-Nodar JM, Cosín-Sales J, Gámez JM, Consuegra L, Ferreiro JL, Marín F; Expert reviewers. Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed) 2020;73:749-57. [PMID: 32694078 DOI: 10.1016/j.rec.2020.04.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
569 Jędrychowska M, Siudak Z, Malinowski KP, Zandecki Ł, Zabojszcz M, Kameczura T, Mika P, Bartuś K, Wańha W, Wojakowski W, Legutko J, Bartuś S, Januszek R. ST-segment elevation myocardial infarction with non-obstructive coronary arteries: Score derivation for prediction based on a large national registry. PLoS One 2021;16:e0254427. [PMID: 34351919 DOI: 10.1371/journal.pone.0254427] [Reference Citation Analysis]
570 Wang C, Zhao G, Wang X, Nie S. Effect of Potent P2Y12 Inhibitors on Ventricular Arrhythmias and Cardiac Dysfunction in Coronary Artery Disease: A Systematic Review and Meta-Analysis. Biomed Res Int 2018;2018:8572740. [PMID: 30648108 DOI: 10.1155/2018/8572740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
571 Corballis NH, Wickramarachchi U, Vassiliou VS, Eccleshall SC. Duration of dual antiplatelet therapy in elective drug-coated balloon angioplasty. Catheter Cardiovasc Interv 2020;96:1016-20. [PMID: 31797532 DOI: 10.1002/ccd.28632] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
572 Yin SH, Xu P, Wang B, Lu Y, Wu QY, Zhou ML, Wu JR, Cai JJ, Sun X, Yuan H. Duration of dual antiplatelet therapy after percutaneous coronary intervention with drug-eluting stent: systematic review and network meta-analysis. BMJ 2019;365:l2222. [PMID: 31253632 DOI: 10.1136/bmj.l2222] [Cited by in Crossref: 41] [Cited by in F6Publishing: 23] [Article Influence: 20.5] [Reference Citation Analysis]
573 Watanabe H, Morimoto T, Ogita M, Suwa S, Natsuaki M, Suematsu N, Koeda Y, Morino Y, Nikaido A, Hata Y, Doi M, Hibi K, Kimura K, Yoda S, Kaneko T, Nishida K, Kawai K, Yamaguchi K, Wakatsuki T, Tonoike N, Yamamoto M, Shimizu S, Shimohama T, Ako J, Kimura T; STOPDAPT-2 Investigators. Influence of CYP2C19 genotypes for the effect of 1-month dual antiplatelet therapy followed by clopidogrel monotherapy relative to 12-month dual antiplatelet therapy on clinical outcomes after percutaneous coronary intervention: a genetic substudy from the STOPDAPT-2. Cardiovasc Interv Ther 2021;36:403-15. [PMID: 33184726 DOI: 10.1007/s12928-020-00719-6] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
574 Galimzhanov AM, Azizov BS. Ticagrelor for Asian patients with acute coronary syndrome in real-world practice: A systematic review and meta-analysis of observational studies. Indian Heart J 2019;71:15-24. [PMID: 31000178 DOI: 10.1016/j.ihj.2019.01.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
575 Liu J, Qin L, Wang Z, Peng L, Liu J, Wang X, Du R, Zou Y, Wu Y, Yin T. Platelet-derived miRNAs as determinants of the antiplatelet response in clopidogrel-treated patients with ACS. Thromb Res 2020;186:71-4. [PMID: 31891827 DOI: 10.1016/j.thromres.2019.12.016] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
576 Niederseer D, Ghadri JR, Manka R, Templin C. Case report of a 66-year-old woman with atypical takotsubo syndrome and concomitant coronary artery disease. BMJ Case Rep 2020;13:e230164. [PMID: 32060106 DOI: 10.1136/bcr-2019-230164] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
577 Li YS, Wang SH, Hwang SJ, Yang YH, Hsieh KP. Comparison of effectiveness and safety between ticagrelor and clopidogrel in patients with acute coronary syndrome and on dialysis in Taiwan. Br J Clin Pharmacol 2021. [PMID: 34080719 DOI: 10.1111/bcp.14935] [Reference Citation Analysis]
578 Cormican D, Jayaraman AL, Sheu R, Peterson C, Narasimhan S, Shaefi S, Núñez-Gil IJ, Ramakrishna H. Coronary Artery Bypass Grafting Versus Percutaneous Transcatheter Coronary Interventions: Analysis of Outcomes in Myocardial Revascularization. J Cardiothorac Vasc Anesth 2019;33:2569-88. [PMID: 30340948 DOI: 10.1053/j.jvca.2018.09.019] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
579 Kerneis M, Yee MK, Mehran R, Nafee T, Bode C, Halperin JL, Peterson ED, Verheugt FW, Wildgoose P, van Eickels M, Lip GY, Cohen M, Fox KA, Gibson CM. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention: Insights From the PIONEER AF-PCI Trial. Circ: Cardiovascular Interventions 2019;12. [DOI: 10.1161/circinterventions.118.007124] [Cited by in Crossref: 5] [Article Influence: 2.5] [Reference Citation Analysis]
580 Frigoli E, Smits P, Vranckx P, Ozaki Y, Tijssen J, Jüni P, Morice MC, Onuma Y, Windecker S, Frenk A, Spaulding C, Chevalier B, Barbato E, Tonino P, Hildick-Smith D, Roffi M, Kornowski R, Schultz C, Lesiak M, Iñiguez A, Colombo A, Alasnag M, Mullasari A, James S, Stankovic G, Ong PJL, Rodriguez AE, Mahfoud F, Bartunek J, Moschovitis A, Laanmets P, Leonardi S, Heg D, Sunnåker M, Valgimigli M. Design and rationale of the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Standard DAPT Regimen (MASTER DAPT) Study. Am Heart J 2019;209:97-105. [PMID: 30703644 DOI: 10.1016/j.ahj.2018.10.009] [Cited by in Crossref: 29] [Cited by in F6Publishing: 16] [Article Influence: 9.7] [Reference Citation Analysis]
581 Fox KAA, Metra M, Morais J, Atar D. The myth of ‘stable’ coronary artery disease. Nat Rev Cardiol 2020;17:9-21. [DOI: 10.1038/s41569-019-0233-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 15.5] [Reference Citation Analysis]
582 Crea F, Binder RK, Lüscher TF. The year in cardiology 2017: acute coronary syndromes. European Heart Journal 2018;39:1054-64. [DOI: 10.1093/eurheartj/ehx781] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
583 Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology. Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs. Nat Rev Cardiol 2019;16:113-30. [PMID: 30250166 DOI: 10.1038/s41569-018-0080-2] [Cited by in Crossref: 30] [Cited by in F6Publishing: 25] [Article Influence: 30.0] [Reference Citation Analysis]
584 Han YL. De-escalation of anti-platelet therapy in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a narrative review. Chin Med J (Engl) 2019;132:197-210. [PMID: 30614864 DOI: 10.1097/CM9.0000000000000047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 2.5] [Reference Citation Analysis]
585 Mihalj M, Carrel T, Urman RD, Stueber F, Luedi MM. Recommendations for Preoperative Assessment and Shared Decision-Making in Cardiac Surgery. Curr Anesthesiol Rep 2020;10:185-95. [PMID: 32431570 DOI: 10.1007/s40140-020-00377-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 7.0] [Reference Citation Analysis]
586 Kubica J, Adamski P, Niezgoda P, Kubica A, Podhajski P, Barańska M, Umińska JM, Pietrzykowski Ł, Ostrowska M, Siller-Matula JM, Badarienė J, Bartuś S, Budaj A, Dobrzycki S, Fidor Ł, Gąsior M, Gessek J, Gierlotka M, Gil R, Gorący J, Grzelakowski P, Hajdukiewicz T, Jaguszewski M, Janion M, Kasprzak J, Kern A, Klecha A, Kleinrok A, Kochman W, Krakowiak B, Legutko J, Lesiak M, Nosal M, Piotrowski G, Przybylski A, Roleder T, Skonieczny G, Sobieszek G, Tycińska A, Wojciechowski D, Wojakowski W, Wójcik J, Zielińska M, Żurakowski A, Specchia G, Gorog DA, Navarese EP. A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. Cardiol J 2021;28:607-14. [PMID: 34096012 DOI: 10.5603/CJ.a2021.0056] [Reference Citation Analysis]
587 Bijak M, Sut A, Kosiorek A, Saluk-Bijak J, Golanski J. Dual Anticoagulant/Antiplatelet Activity of Polyphenolic Grape Seeds Extract. Nutrients 2019;11:E93. [PMID: 30621248 DOI: 10.3390/nu11010093] [Cited by in Crossref: 17] [Cited by in F6Publishing: 10] [Article Influence: 8.5] [Reference Citation Analysis]
588 Kim DY, Cho SW, Park KT, Ahn JH, Park TK, Jang YH, Choi KH, Lee JM, Yang JH, Song YB, Choi JH, Choi SH, Gwon HC, Lee SH, Hahn JY. Long-term Outcomes of Clopidogrel Monotherapy versus Prolonged Dual Antiplatelet Therapy beyond 12 Months after Percutaneous Coronary Intervention in High-risk Patients. J Korean Med Sci 2021;36:e106. [PMID: 33904262 DOI: 10.3346/jkms.2021.36.e106] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
589 Jortveit J, Pripp AH, Langørgen J, Halvorsen S. Poor adherence to guideline recommendations among patients with atrial fibrillation and acute myocardial infarction. Eur J Prev Cardiolog 2019;26:1373-82. [DOI: 10.1177/2047487319841940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
590 Feng KY, Mahaffey KW. Cangrelor in clinical use. Future Cardiol 2020;16:89-102. [PMID: 32067479 DOI: 10.2217/fca-2019-0095] [Reference Citation Analysis]
591 Savonitto S, Pelizzoli S, Selva AM. Rivaroxaban in patients with ischaemic chronic cardiomyopathy and obstructive peripheral arterial disease: rationale for treatment and results. Eur Heart J Suppl 2020;22:E137-41. [PMID: 32523458 DOI: 10.1093/eurheartj/suaa079] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
592 Galli M, Andreotti F, D’amario D, Vergallo R, Vescovo GM, Giraldi L, Migliaro S, Ameri P, Porto I, Crea F. Antithrombotic therapy in the early phase of non-ST-elevation acute coronary syndromes: a systematic review and meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy 2020;6:43-56. [DOI: 10.1093/ehjcvp/pvz031] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
593 Di Mario C, Mugelli A, Perrone Filardi P, Rosano G, Rossi F. Long-term dual antiplatelet therapy: pharmacological and clinical implications. J Cardiovasc Med (Hagerstown) 2018;19:399-410. [PMID: 29894353 DOI: 10.2459/JCM.0000000000000677] [Reference Citation Analysis]
594 Benenati S, Galli M, De Marzo V, Pescetelli F, Toma M, Andreotti F, Della Bona R, Canepa M, Ameri P, Crea F, Porto I. Very short vs. long dual antiplatelet therapy after second generation drug-eluting stents in 35 785 patients undergoing percutaneous coronary interventions: a meta-analysis of randomized controlled trials. Eur Heart J Cardiovasc Pharmacother 2021;7:86-93. [PMID: 31942965 DOI: 10.1093/ehjcvp/pvaa001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
595 Ziada KM, Moliterno DJ. Dual Antiplatelet Therapy: Is It Time to Cut the Cord With Aspirin? JAMA 2019;321:2409. [DOI: 10.1001/jama.2019.7025] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
596 Lattuca B, Silvain J, Yan Y, Pouillot C, Cuisset T, Cayla G, Henry P, Diallo A, Elhadad S, Rangé G, Lhermusier T, Boueri Z, Motreff P, Carrié D, Vicaut E, Montalescot G, Collet JP. Reasons for the Failure of Platelet Function Testing to Adjust Antiplatelet Therapy: Pharmacodynamic Insights From the ARCTIC Study. Circ Cardiovasc Interv 2019;12:e007749. [PMID: 31694410 DOI: 10.1161/CIRCINTERVENTIONS.118.007749] [Reference Citation Analysis]
597 Ferrières J, Lautsch D, Ambegaonkar BM, De Ferrari GM, Vyas A, Baxter CA, Bash LD, Velkovski-rouyer M, Horack M, Almahmeed W, Chiang F, Poh KK, Elisaf M, Brudi P, Gitt AK. Use of guideline-recommended management in established coronary heart disease in the observational DYSIS II study. International Journal of Cardiology 2018;270:21-7. [DOI: 10.1016/j.ijcard.2018.06.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
598 You SC, Rho Y, Bikdeli B, Kim J, Siapos A, Weaver J, Londhe A, Cho J, Park J, Schuemie M, Suchard MA, Madigan D, Hripcsak G, Gupta A, Reich CG, Ryan PB, Park RW, Krumholz HM. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA 2020;324:1640-50. [PMID: 33107944 DOI: 10.1001/jama.2020.16167] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 16.0] [Reference Citation Analysis]
599 Costa F, Brugaletta S. Antithrombotic Therapy in Acute Coronary Syndrome: Striking a Happy Medium. Rev Esp Cardiol (Engl Ed) 2018;71:782-6. [PMID: 29705073 DOI: 10.1016/j.rec.2018.03.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
600 Kim HK, Ahn Y, Chang K, Jeong YH, Hahn JY, Choo EH, Kim MC, Kim HS, Kim W, Cho MC, Jang Y, Kim CJ, Jeong MH, Chae SC; Task Force on Expert Consensus Document of the Korean Society of Myocardial Infarction (KSMI). 2020 Korean Society of Myocardial Infarction Expert Consensus Document on Pharmacotherapy for Acute Myocardial Infarction. Korean Circ J 2020;50:845-66. [PMID: 32969206 DOI: 10.4070/kcj.2020.0196] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
601 Stone GW, Généreux P, Harrington RA, White HD, Gibson CM, Steg PG, Hamm CW, Mahaffey KW, Price MJ, Prats J, Deliargyris EN, Bhatt DL. Impact of lesion complexity on peri-procedural adverse events and the benefit of potent intravenous platelet adenosine diphosphate receptor inhibition after percutaneous coronary intervention: core laboratory analysis from 10 854 patients from the CHAMPION PHOENIX trial. Eur Heart J 2018;39:4112-21. [PMID: 30203006 DOI: 10.1093/eurheartj/ehy562] [Cited by in Crossref: 30] [Cited by in F6Publishing: 17] [Article Influence: 15.0] [Reference Citation Analysis]
602 Marquis-gravel G, Dalgaard F, Jones AD, Lokhnygina Y, James SK, Harrington RA, Wallentin L, Steg PG, Lopes RD, Storey RF, Goodman SG, Mahaffey KW, Tricoci P, White HD, Armstrong PW, Ohman EM, Alexander JH, Roe MT. Post-Discharge Bleeding and Mortality Following Acute Coronary Syndromes With or Without PCI. Journal of the American College of Cardiology 2020;76:162-71. [DOI: 10.1016/j.jacc.2020.05.031] [Cited by in Crossref: 16] [Cited by in F6Publishing: 9] [Article Influence: 16.0] [Reference Citation Analysis]
603 Gimbel ME, Tavenier AH, Bor W, Hermanides RS, de Vrey E, Heestermans T, Gin MTJ, Waalewijn R, Hofma S, den Hartog F, Jukema W, von Birgelen C, Voskuil M, Kelder J, Deneer V, Ten Berg JM. Ticagrelor Versus Clopidogrel in Older Patients with NSTE-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. J Clin Med 2020;9:E3249. [PMID: 33053622 DOI: 10.3390/jcm9103249] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
604 Ying L, Wang F, Zhang J, Yang L, Gong X, Fan Y, Xu K, Li J, Lu Y, Mei L, Zhou Z, Li C. Impact of hepatitis B virus (HBV) infection on platelet response to clopidogrel in patients undergoing coronary stent implantation. Thromb Res 2018;167:119-24. [PMID: 29807287 DOI: 10.1016/j.thromres.2018.04.017] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
605 Milder DA, Kam PC. Perioperative implications of newer generation drug-eluting coronary stents: A narrative review. Anaesth Intensive Care 2021;:310057X20984792. [PMID: 34134534 DOI: 10.1177/0310057X20984792] [Reference Citation Analysis]
606 De Luca L, Piscione F, Colivicchi F, Lucci D, Mascia F, Marinoni B, Cirillo P, Grosseto D, Mauro C, Calabrò P, Nardi F, Rossini R, Geraci G, Gabrielli D, Di Lenarda A, Gulizia MM. Contemporary management of patients referring to cardiologists one to three years from a myocardial infarction: The EYESHOT Post-MI study. International Journal of Cardiology 2018;273:8-14. [DOI: 10.1016/j.ijcard.2018.08.055] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 5.0] [Reference Citation Analysis]
607 Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, Cannon CP, Tanguay J, Granger CB, Mauri L, Holmes DR, Gibson CM, Faxon DP. Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective–2018 Update. Circulation 2018;138:527-36. [DOI: 10.1161/circulationaha.118.034722] [Cited by in Crossref: 148] [Cited by in F6Publishing: 24] [Article Influence: 49.3] [Reference Citation Analysis]
608 Kuno T, Ueyama H, Ando T, Briasoulis A, Takagi H. Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome undergoing percutaneous coronary intervention; insights from a meta-analysis. Coron Artery Dis 2021;32:31-5. [PMID: 32310855 DOI: 10.1097/MCA.0000000000000900] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
609 Mukherjee D. Coronary lesion complexity and the benefit of potent platelet inhibition after percutaneous coronary intervention. Eur Heart J 2018;39:4122-4. [PMID: 30202874 DOI: 10.1093/eurheartj/ehy506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
610 Saito Y, Nazif T, Baumbach A, Tchétché D, Latib A, Kaple R, Forrest J, Prendergast B, Lansky A. Adjunctive Antithrombotic Therapy for Patients With Aortic Stenosis Undergoing Transcatheter Aortic Valve Replacement. JAMA Cardiol 2020;5:92-101. [PMID: 31721980 DOI: 10.1001/jamacardio.2019.4367] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
611 Syed S, Wąsowicz M. Anti-platelet therapy and the anaesthesiologist: controversies and unresolved clinical dilemmas continue. Br J Anaesth 2019;123:e1-2. [PMID: 30954240 DOI: 10.1016/j.bja.2019.03.009] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
612 Lee SH, Choi KH, Song YB, Jeong DS, Yang JH, Kim WS, Lee YT. Comprehensive assessment of heart failure in patients with preserved ejection fraction undergoing coronary bypass grafting. J Thorac Cardiovasc Surg 2021:S0022-5223(21)00980-6. [PMID: 34217536 DOI: 10.1016/j.jtcvs.2021.06.026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
613 Woo HG, Lee HA, Ryu DR, Song TJ. Association of Mortality with Antiplatelet Treatment in Patients with Stent Placement or Angioplasty: A Population-Based Nested Case-Control Study. Yonsei Med J 2021;62:75-85. [PMID: 33381937 DOI: 10.3349/ymj.2021.62.1.75] [Reference Citation Analysis]
614 Fernando H, McFadyen JD, Palasubramaniam J, Shaw J, Wang X, Stub D, Peter K. Antithrombotic Therapy in Myocardial Infarction: Historic Perils and Current Challenges-A 70-Year Journey. Thromb Haemost 2020;120:1352-6. [PMID: 32707594 DOI: 10.1055/s-0040-1714212] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
615 Faridi KF, Garratt KN, Kennedy KF, Maddox TM, Secemsky EA, Butala NM, Yeh RW. Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment–Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative. Circ: Cardiovascular Quality and Outcomes 2020;13. [DOI: 10.1161/circoutcomes.119.006275] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
616 Verma S, Goodman SG, Tan MK, Daneault B, Lubelsky BJ, Mansour S, Lam AS, Laflamme D, Tymchak WJ, Welsh RC, Rose RC, Chetty RM, Constance CM, Cieza T, Potter BJ, Hartleib MC, Khan R, Choi RF, Keeble W, Dery JP, Shukla D, Chua GL, Bainey KR. Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. Int J Clin Pract 2021;:e14597. [PMID: 34228865 DOI: 10.1111/ijcp.14597] [Reference Citation Analysis]
617 Bulluck H, Paradies V, Barbato E, Baumbach A, Bøtker HE, Capodanno D, De Caterina R, Cavallini C, Davidson SM, Feldman DN, Ferdinandy P, Gili S, Gyöngyösi M, Kunadian V, Ooi SY, Madonna R, Marber M, Mehran R, Ndrepepa G, Perrino C, Schüpke S, Silvain J, Sluijter JPG, Tarantini G, Toth GG, Van Laake LW, von Birgelen C, Zeitouni M, Jaffe AS, Thygesen K, Hausenloy DJ. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2021;42:2630-42. [PMID: 34059914 DOI: 10.1093/eurheartj/ehab271] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
618 Fujisaki T, Kuno T, Ando T, Briasoulis A, Takagi H, Bangalore S. Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis. Am Heart J 2021;237:34-44. [PMID: 33737060 DOI: 10.1016/j.ahj.2021.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
619 Tarantini G, Mojoli M, Varbella F, Caporale R, Rigattieri S, Andò G, Cirillo P, Pierini S, Santarelli A, Sganzerla P, De Cesare N, Limbruno U, Lupi A, Ricci R, Cernetti C, Favero L, Saia F, Roncon L, Gasparetto V, Ferlini M, Ronco F, Ferri L, Trabattoni D, Russo A, Guiducci V, Penzo C, Tarantino F, Mauro C, Marchese A, Castiglioni B, La Manna A, Martinato M, Gregori D, Angiolillo DJ, Musumeci G. Downstream or upstream administration of P2Y12 receptor blockers in non-ST elevated acute coronary syndromes: study protocol for a randomized controlled trial. Trials 2020;21:966. [PMID: 33234137 DOI: 10.1186/s13063-020-04859-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
620 Cammisotto V, Biondi-Zoccai G, Frati G, Giordano A. Prasugrel and Ticagrelor: the Romulus and Remus of Antiplatelet Therapy? Am J Cardiovasc Drugs 2019;19:377-9. [PMID: 31030412 DOI: 10.1007/s40256-019-00340-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
621 Sinnaeve PR, Adriaenssens T. Dual Antiplatelet Therapy De-escalation Strategies. Am J Cardiol 2021;144 Suppl 1:S23-31. [PMID: 33706987 DOI: 10.1016/j.amjcard.2020.12.020] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
622 Wang HY, Mo R, Guan CD, Wang Y, Zhao YY, Xie LH, Zhang R, Cai ZX, Xu B, Dou KF. Establishing the optimal duration of DAPT following PCI in high-risk TWILIGHT-like patients with acute coronary syndrome. Catheter Cardiovasc Interv 2021. [PMID: 33909311 DOI: 10.1002/ccd.29741] [Reference Citation Analysis]
623 Kim C, Hong S, Shin D, Kim B, Ahn C, Kim J, Ko Y, Choi D, Hong M, Jang Y. Randomized evaluation of ticagrelor monotherapy after 3-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with new-generation sirolimus-eluting stents: TICO trial rationale and design. American Heart Journal 2019;212:45-52. [DOI: 10.1016/j.ahj.2019.02.015] [Cited by in Crossref: 18] [Cited by in F6Publishing: 11] [Article Influence: 9.0] [Reference Citation Analysis]
624 Martín-Asenjo R, Gregson J, Rossello X, Van de Werf F, Medina J, Danchin N, Pocock S, Bueno H. Number of Antithrombotic Drugs Used Early and In-hospital Outcomes in Acute Coronary Syndromes. J Cardiovasc Transl Res 2021;14:790-8. [PMID: 33420682 DOI: 10.1007/s12265-020-10094-5] [Reference Citation Analysis]
625 Ozaki Y, Katagiri Y, Onuma Y, Amano T, Muramatsu T, Kozuma K, Otsuji S, Ueno T, Shiode N, Kawai K, Tanaka N, Ueda K, Akasaka T, Hanaoka KI, Uemura S, Oda H, Katahira Y, Kadota K, Kyo E, Sato K, Sato T, Shite J, Nakao K, Nishino M, Hikichi Y, Honye J, Matsubara T, Mizuno S, Muramatsu T, Inohara T, Kohsaka S, Michishita I, Yokoi H, Serruys PW, Ikari Y, Nakamura M; Task Force on Primary Percutaneous Coronary Intervention (PCI) of the Japanese Cardiovascular Interventional Therapeutics (CVIT). CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) in 2018. Cardiovasc Interv Ther 2018;33:178-203. [PMID: 29594964 DOI: 10.1007/s12928-018-0516-y] [Cited by in Crossref: 50] [Cited by in F6Publishing: 26] [Article Influence: 16.7] [Reference Citation Analysis]
626 Shokry KA, Farag EM, Salem AM, Ibrahim IM, Abel-Aziz M, El Zayat A. Original Article--Value of Pathological Q Waves and Angiographic Collateral Grade in Patients Undergoing Coronary Chronic Total Occlusion Recanalization: Cardiac Magnetic Resonance Study. J Saudi Heart Assoc 2021;33:41-50. [PMID: 33880327 DOI: 10.37616/2212-5043.1239] [Reference Citation Analysis]
627 Bencivenga L, Komici K, Corbi G, Cittadini A, Ferrara N, Rengo G. The Management of Combined Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Particularly Complex Challenge, Especially in the Elderly. Front Physiol 2018;9:876. [PMID: 30038586 DOI: 10.3389/fphys.2018.00876] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
628 Casula M, Fortuni F, Fabris F, Leonardi S, Gnecchi M, Sanzo A, Greco A, Rordorf R. Direct oral Xa inhibitors versus warfarin in patients with cancer and atrial fibrillation: a meta-analysis. Journal of Cardiovascular Medicine 2020;21:570-6. [DOI: 10.2459/jcm.0000000000001041] [Cited by in Crossref: 3] [Article Influence: 3.0] [Reference Citation Analysis]
629 Söderberg M, Holm M, Gupta A. Assessment of platelet function after discontinuation of ticagrelor. Acta Anaesthesiol Scand 2020;64:526-31. [PMID: 31828756 DOI: 10.1111/aas.13524] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
630 Zhu P, Gao Z, Tang XF, Xu JJ, Zhang Y, Gao LJ, Chen J, Qiao SB, Yang YJ, Gao RL, Xu B, Yuan JQ. Impact of Proton-pump Inhibitors on the Pharmacodynamic Effect and Clinical Outcomes in Patients Receiving Dual Antiplatelet Therapy after Percutaneous Coronary Intervention: A Propensity Score Analysis. Chin Med J (Engl) 2017;130:2899-905. [PMID: 29237921 DOI: 10.4103/0366-6999.220304] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 2.7] [Reference Citation Analysis]
631 Cicci JD, Iyer P, Clarke MM, Mazzella AJ. Aspirin for the Primary Prevention of Cardiovascular Disease: A Review of the Literature and Considerations for Clinical Practice. Cardiology in Review 2020;28:98-106. [DOI: 10.1097/crd.0000000000000297] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
632 Ando T, Nakazato K, Kimishima Y, Kiko T, Shimizu T, Misaka T, Yamada S, Kaneshiro T, Yoshihisa A, Yamaki T, Kunii H, Takeishi Y. The clinical value of the PRECISE-DAPT score in predicting long-term prognosis in patients with acute myocardial infarction. Int J Cardiol Heart Vasc 2020;29:100552. [PMID: 32551359 DOI: 10.1016/j.ijcha.2020.100552] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
633 Bainey KR, Morais J, Zeymer U, Welsh RC. Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. Atherosclerosis 2019;289:118-25. [PMID: 31494384 DOI: 10.1016/j.atherosclerosis.2019.08.021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
634 Liu Y, Zhang WL, Bu JQ, Gu JJ, Sun YQ, Cui HZ, Wang DW, Chen ZY. Using Thromboelastography to Predict Blood Loss After Off-Pump Coronary Artery Bypass Grafting. Int J Gen Med 2021;14:949-56. [PMID: 33776473 DOI: 10.2147/IJGM.S291864] [Reference Citation Analysis]
635 De Luca L, Valgimigli M. Unravelling the puzzle of antithrombotic therapies for complex percutaneous coronary intervention. Eur Heart J Cardiovasc Pharmacother 2021;7:352-9. [PMID: 33175148 DOI: 10.1093/ehjcvp/pvaa107] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
636 Capodanno D, Morice M, Angiolillo DJ, Bhatt DL, Byrne RA, Colleran R, Cuisset T, Cutlip D, Eerdmans P, Eikelboom J, Farb A, Gibson CM, Gregson J, Haude M, James SK, Kim H, Kimura T, Konishi A, Leon MB, Magee PA, Mitsutake Y, Mylotte D, Pocock SJ, Rao SV, Spitzer E, Stockbridge N, Valgimigli M, Varenne O, Windhovel U, Krucoff MW, Urban P, Mehran R. Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology 2020;76:1468-83. [DOI: 10.1016/j.jacc.2020.06.085] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 15.0] [Reference Citation Analysis]
637 Li J, Fan Y, Zhu T, Chen J, Kong D, Meng H, Zhang J, Xu K, Ye S, Ji Y, Li C. Clinical pharmacodynamics and long-term efficacy of Talcom vs. Plavix in patients undergoing coronary stent implantation: a randomized study with 5-year follow-up. Eur J Clin Pharmacol 2018;74:1397-403. [PMID: 30128705 DOI: 10.1007/s00228-018-2532-3] [Reference Citation Analysis]
638 Tantry US, Hartmann J, Neal MD, Schöechl H, Bliden KP, Agarwal S, Mason D, Dias JD, Mahla E, Gurbel PA. The role of viscoelastic testing in assessing peri-interventional platelet function and coagulation. Platelets 2021;:1-11. [PMID: 34369848 DOI: 10.1080/09537104.2021.1961709] [Reference Citation Analysis]
639 Burlacu A, Covic A. Longer or shorter dual antiplatelet therapy in dialysis patients receiving a coronary drug-eluting stent? A rope game still ongoing. Clin Kidney J 2020;13:749-52. [PMID: 33125001 DOI: 10.1093/ckj/sfaa040] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
640 Inohara T, Endo A, Melloni C. Unmet Needs in Managing Myocardial Infarction in Patients With Malignancy. Front Cardiovasc Med 2019;6:57. [PMID: 31157239 DOI: 10.3389/fcvm.2019.00057] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
641 Jovin DG, Katlaps GJ, Sumption KF. Coronary artery bypass graft markers: history, usage, and effects. Gen Thorac Cardiovasc Surg 2020;68:453-8. [DOI: 10.1007/s11748-020-01325-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
642 Santoro C, Capone V, Canonico ME, Gargiulo G, Esposito R, Sanna GD, Parodi G, Esposito G. Single, Dual, and Triple Antithrombotic Therapy in Cancer Patients with Coronary Artery Disease: Searching for Evidence and Personalized Approaches. Semin Thromb Hemost 2021. [PMID: 34261150 DOI: 10.1055/s-0041-1726298] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
643 Witberg G, Zusman O, Yahav D, Perl L, Vaknin-Assa H, Kornowski R. Meta-analysis of studies examining the external validity of the dual antiplatelet therapy score. Eur Heart J Cardiovasc Pharmacother 2020;6:285-91. [PMID: 31794022 DOI: 10.1093/ehjcvp/pvz075] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 9.0] [Reference Citation Analysis]
644 Larson EA, German DM, Shatzel J, DeLoughery TG. Anticoagulation in the cardiac patient: A concise review. Eur J Haematol 2019;102:3-19. [PMID: 30203452 DOI: 10.1111/ejh.13171] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
645 Schunkert H, Boening A, von Scheidt M, Lanig C, Gusmini F, de Waha A, Kuna C, Fach A, Grothusen C, Oberhoffer M, Knosalla C, Walther T, Danner BC, Misfeld M, Zeymer U, Wimmer-greinecker G, Siepe M, Grubitzsch H, Joost A, Schaefer A, Conradi L, Cremer J, Hamm C, Lange R, Radke PW, Schulz R, Laufer G, Grieshaber P, Pader P, Attmann T, Schmoeckel M, Meyer A, Ziegelhöffer T, Hambrecht R, Kastrati A, Sandner SE. Randomized trial of ticagrelor vs. aspirin in patients after coronary artery bypass grafting: the TiCAB trial. European Heart Journal 2019;40:2432-40. [DOI: 10.1093/eurheartj/ehz185] [Cited by in Crossref: 26] [Cited by in F6Publishing: 11] [Article Influence: 13.0] [Reference Citation Analysis]
646 Yun KH, Cho JY, Lee SY, Rhee SJ, Kim BK, Hong MK, Jang Y, Oh SK; TICO Investigators. Ischemic and Bleeding Events of Ticagrelor Monotherapy in Korean Patients With and Without Diabetes Mellitus: Insights From the TICO Trial. Front Pharmacol 2020;11:620906. [PMID: 33519487 DOI: 10.3389/fphar.2020.620906] [Reference Citation Analysis]
647 Wernly B, Rezar R, Gurbel P, Jung C. Short-term dual antiplatelet therapy (DAPT) followed by P2Y12 monotherapy versus traditional DAPT in patients undergoing percutaneous coronary intervention: meta-analysis and viewpoint. J Thromb Thrombolysis 2020;49:173-6. [PMID: 31686298 DOI: 10.1007/s11239-019-01985-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 6.0] [Reference Citation Analysis]
648 Colombo A, Chandrasekhar J, Aquino M, Ong TK, Sartori S, Baber U, Lee M, Iniguez A, Hajek P, Borisov B, Atzev B, Den Heijer P, Coufal Z, Hudec M, Mates M, Snyder C, Moalem K, Morrell D, Elmore F, Rowland S, Mehran R. Safety and efficacy of the COMBO bio-engineered stent in an all-comer PCI cohort: 1-Year final clinical outcomes from the MASCOT post-marketing registry. International Journal of Cardiology 2019;283:67-72. [DOI: 10.1016/j.ijcard.2019.01.053] [Cited by in Crossref: 13] [Cited by in F6Publishing: 6] [Article Influence: 6.5] [Reference Citation Analysis]
649 Sharma R, Kumar P, Prashanth SP, Belagali Y. Dual Antiplatelet Therapy in Coronary Artery Disease. Cardiol Ther 2020;9:349-61. [PMID: 32804330 DOI: 10.1007/s40119-020-00197-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
650 Roberto M, Radovanovic D, Buttà C, Tersalvi G, Krüll J, Erne P, Rickli H, Pedrazzini GB, Moccetti M. Dual antiplatelet therapy is under-prescribed in patients with surgically treated acute myocardial infarction. Interact Cardiovasc Thorac Surg 2021:ivab159. [PMID: 34171919 DOI: 10.1093/icvts/ivab159] [Reference Citation Analysis]
651 Abtan J, Ducrocq G, Steg PG, Stone GW, Mahaffey KW, Gibson CM, Hamm CW, Price MJ, Prats J, Deliargyris EN, White HD, Harrington RA, Bhatt DL. Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y12 Inhibitor Pretreatment. Circ Cardiovasc Interv 2019;12:e007445. [PMID: 30871355 DOI: 10.1161/CIRCINTERVENTIONS.118.007445] [Reference Citation Analysis]
652 Mohamed MO, Van Spall HGC, Kontopantelis E, Alkhouli M, Barac A, Elgendy IY, Khan SU, Kwok CS, Shoaib A, Bhatt DL, Mamas MA. Effect of primary percutaneous coronary intervention on in-hospital outcomes among active cancer patients presenting with ST-elevation myocardial infarction: a propensity score matching analysis. Eur Heart J Acute Cardiovasc Care 2021:zuaa032. [PMID: 33587752 DOI: 10.1093/ehjacc/zuaa032] [Reference Citation Analysis]
653 Chiarito M, Sanz-Sánchez J, Cannata F, Cao D, Sturla M, Panico C, Godino C, Regazzoli D, Reimers B, De Caterina R, Condorelli G, Ferrante G, Stefanini GG. Monotherapy with a P2Y12 inhibitor or aspirin for secondary prevention in patients with established atherosclerosis: a systematic review and meta-analysis. Lancet 2020;395:1487-95. [PMID: 32386592 DOI: 10.1016/S0140-6736(20)30315-9] [Cited by in Crossref: 34] [Cited by in F6Publishing: 6] [Article Influence: 34.0] [Reference Citation Analysis]
654 Schoenrath F, Just IA, Falk V, Emmert MY. Antiplatelet and direct oral anticoagulation management after coronary artery bypass graft surgery: the Cinderella of current cardiovascular trials, please show me (some) evidence. Eur Heart J 2021;42:2145-8. [PMID: 33615338 DOI: 10.1093/eurheartj/ehab033] [Reference Citation Analysis]
655 Salsano A, Dominici C, Nenna A, Olivieri GM, Miette A, Barbato R, Sportelli E, Natali R, Maestri F, Chello M, Mariscalco G, Santini F. Predictive scores for major bleeding after coronary artery bypass surgery in low operative risk patients. J Cardiovasc Surg (Torino) 2020;61:234-42. [PMID: 31937080 DOI: 10.23736/S0021-9509.20.11048-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
656 Mishra A, Singh M, Acker WW, Kamboj S, Sporn D, Stapleton D, Kaluski E. Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease Undergoing Percutaneous Coronary Intervention. J Cardiovasc Pharmacol 2019;74:82-90. [PMID: 31306367 DOI: 10.1097/FJC.0000000000000697] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
657 Franchin L, Piroli F, D'Ascenzo F, Nuñez-Gil I, Wojakowski W, Imori Y, Trabattoni D, Huczek Z, Venuti G, Muscoli S, Montabone A, Rognoni A, Parma R, Figini F, Mitomo S, Quadri G, Wańha W, Cortese B, De Filippo O, Ryan N, Varbella F, Sheiban I, Helft G, De Ferrari GM. Impact of stent thickness on clinical outcomes in small vessel and bifurcation lesions: a RAIN-CARDIOGROUP VII sub-study. J Cardiovasc Med (Hagerstown) 2021;22:20-5. [PMID: 32740419 DOI: 10.2459/JCM.0000000000001037] [Reference Citation Analysis]
658 Velders MA, Hagström E, James SK. Temporal Trends in the Prevalence of Cancer and Its Impact on Outcome in Patients With First Myocardial Infarction: A Nationwide Study. J Am Heart Assoc 2020;9:e014383. [PMID: 32067596 DOI: 10.1161/JAHA.119.014383] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 5.0] [Reference Citation Analysis]
659 Ullrich H, Münzel T, Gori T. Coronary Stent Thrombosis- Predictors and Prevention. Dtsch Arztebl Int 2020;117:320-6. [PMID: 32605709 DOI: 10.3238/arztebl.2020.0320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
660 Jeong YH, Oh JH, Yoon HJ, Park Y, Suh J, Lee SW, Lee K, Kim JS, Chun WJ, Park YH, Nam CW, Kim JH, Ahn JH, Hwang SJ, Hwang JY, Tantry US, Gurbel PA, Shin ES. Pharmacodynamic Profile and Prevalence of Bleeding Episode in East Asian Patients with Acute Coronary Syndromes Treated with Prasugrel Standard-Dose versus De-escalation Strategy: A Randomized A-MATCH Trial. Thromb Haemost 2021. [PMID: 33401330 DOI: 10.1055/a-1346-3300] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
661 Cakal S, Cakal B, Güven Z, Tosu AR, Kalyoncuoglu M, Biter HI, Apaydın Z, Karaca IO, Belen E, Can MM. Switching Ticagrelor to 600 mg or 300 mg Clopidogrel Loading Bridge in Patients with Unstable Angina. J Clin Med 2021;10:2463. [PMID: 34199404 DOI: 10.3390/jcm10112463] [Reference Citation Analysis]
662 Essebag V, Healey JS, Joza J, Nery PB, Kalfon E, Leiria TLL, Verma A, Ayala-Paredes F, Coutu B, Sumner GL, Becker G, Philippon F, Eikelboom J, Sandhu RK, Sapp J, Leather R, Yung D, Thibault B, Simpson CS, Ahmad K, Toal S, Sturmer M, Kavanagh K, Crystal E, Wells GA, Krahn AD, Birnie DH. Effect of Direct Oral Anticoagulants, Warfarin, and Antiplatelet Agents on Risk of Device Pocket Hematoma: Combined Analysis of BRUISE CONTROL 1 and 2. Circ Arrhythm Electrophysiol 2019;12:e007545. [PMID: 31610718 DOI: 10.1161/CIRCEP.119.007545] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
663 Reiss AB, Grossfeld D, Kasselman LJ, Renna HA, Vernice NA, Drewes W, Konig J, Carsons SE, DeLeon J. Adenosine and the Cardiovascular System. Am J Cardiovasc Drugs 2019;19:449-64. [PMID: 30972618 DOI: 10.1007/s40256-019-00345-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 18.0] [Reference Citation Analysis]
664 Duerschmied D, Brachmann J, Darius H, Frey N, Katus HA, Rottbauer W, Schäfer A, Thiele H, Bode C, Zeymer U. Antithrombotic therapy in patients with non-valvular atrial fibrillation undergoing percutaneous coronary intervention: should we change our practice after the PIONEER AF-PCI and RE-DUAL PCI trials? Clin Res Cardiol 2018;107:533-8. [PMID: 29679144 DOI: 10.1007/s00392-018-1242-2] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 3.7] [Reference Citation Analysis]
665 Lagoutte-Renosi J, Allemand F, Ramseyer C, Rabani V, Davani S. Influence of Antiplatelet Agents on the Lipid Composition of Platelet Plasma Membrane: A Lipidomics Approach with Ticagrelor and Its Active Metabolite. Int J Mol Sci 2021;22:1432. [PMID: 33572690 DOI: 10.3390/ijms22031432] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
666 Delluc A, Lacut K, Rodger MA. Arterial and venous thrombosis: What's the link? A narrative review. Thromb Res 2020;191:97-102. [PMID: 32416310 DOI: 10.1016/j.thromres.2020.04.035] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
667 Thuijs DJFM, Milojevic M, Head SJ. Doubling up on antiplatelet therapy after CABG: changing practice ASAP after DACAB? J Thorac Dis 2018;10:S3095-9. [PMID: 30370088 DOI: 10.21037/jtd.2018.07.37] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
668 Hein L, Wille H. Antithrombotika und Antihämorrhagika. In: Schwabe U, Paffrath D, Ludwig W, Klauber J, editors. Arzneiverordnungs-Report 2019. Berlin: Springer Berlin Heidelberg; 2019. pp. 531-55. [DOI: 10.1007/978-3-662-59046-1_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
669 Nakashima CAK, Dallan LAO, Lisboa LAF, Jatene FB, Hajjar LA, Soeiro AM, Furtado RHM, Dalçoquio TF, Baracioli LM, Lima FG, Giraldez RRCV, Silva BA, Costa MSS, Strunz CMC, Dallan LRP, Barbosa CJDG, Britto FAB, Farkouh ME, Gurbel PA, Nicolau JC. Platelet Reactivity in Patients With Acute Coronary Syndromes Awaiting Surgical Revascularization. J Am Coll Cardiol 2021;77:1277-86. [PMID: 33706868 DOI: 10.1016/j.jacc.2021.01.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
670 Costa F, Van Klaveren D, Feres F, James S, Räber L, Pilgrim T, Hong MK, Kim HS, Colombo A, Steg PG, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M; PRECISE-DAPT Study Investigators. Dual Antiplatelet Therapy Duration Based on Ischemic and Bleeding Risks After Coronary Stenting. J Am Coll Cardiol 2019;73:741-54. [PMID: 30784667 DOI: 10.1016/j.jacc.2018.11.048] [Cited by in Crossref: 107] [Cited by in F6Publishing: 49] [Article Influence: 107.0] [Reference Citation Analysis]
671 Solo K, Lavi S, Kabali C, Levine GN, Kulik A, John-Baptiste AA, Fremes SE, Martin J, Eikelboom JW, Ruel M, Huitema AA, Choudhury T, Bhatt DL, Tzemos N, Mamas MA, Bagur R. Antithrombotic treatment after coronary artery bypass graft surgery: systematic review and network meta-analysis. BMJ 2019;367:l5476. [PMID: 31601578 DOI: 10.1136/bmj.l5476] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 12.5] [Reference Citation Analysis]
672 Kwok CS, Wong CW, Kontopantelis E, Barac A, Brown SA, Velagapudi P, Hilliard AA, Bharadwaj AS, Chadi Alraies M, Mohamed M, Bhatt DL, Mamas MA. Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA. Eur Heart J 2021;42:1019-34. [PMID: 33681960 DOI: 10.1093/eurheartj/ehaa1032] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 9.0] [Reference Citation Analysis]
673 Kook H, Kim HD, Shim J, Kim YH, Kim JS, Pak HN, Lee HJ, Choi RK, Kang WC, Shin ES, Park JW, Yu CW, Lim DS. Comparison of clinical outcomes between multiple antithrombotic therapy versus left atrial appendage occlusion with dual antiplatelet therapy in patients with atrial fibrillation undergoing drug-eluting stent implantation. PLoS One 2021;16:e0244723. [PMID: 33411816 DOI: 10.1371/journal.pone.0244723] [Reference Citation Analysis]
674 Lee DH, de la Torre Hernandez JM. The Newest Generation of Drug-eluting Stents and Beyond. Eur Cardiol 2018;13:54-9. [PMID: